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Abstract:  
 
Chorismate mutase is one of the essential enzymes in the shikimate pathway and is key to 
the survival of the organism Mycobacterium tuberculosis. The x-ray crystal structure of this 
enzyme from Mycobacterium tuberculosis was manipulated to prepare an initial set of in 
silico protein models of the active site. Known inhibitors of the enzyme were docked into the 
active site using the flexible ligand / flexible active site side chains approach implemented in 
CAChe Worksystem (Fujitsu Ltd). The resulting complexes were refined by molecular 
dynamics studies in explicit water using Amber 9. This yielded a further set of protein models 
that were used for additional rounds of ligand docking. A binding hypothesis was established 
for the enzyme and this was used to screen a database of commercially available drug-like 
compounds. From these results new potential ligands were designed that fitted appropriately 
into the active site and matched the functional groups and binding motifs founds therein. 
Some of these compounds and close analogues were then synthesized and submitted for 
biological evaluation.  
 
As a separate part of this thesis, analogues of very active anti-tuberculosis 
pyridylcarboxamidrazone were also prepared. This was carried out by the addition and the 
deletion of the substitutions from the lead compound thereby preparing heteroaryl 
carboxamidrazone derivatives and related compounds. All these compounds were initially 
evaluated for biological activity against various gram positive organisms and then sent to the 
TAACF (USA) for screening against Mycobacterium tuberculosis. Some of the new 
compounds proved to be at least as potent as the original lead compound but less toxic. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1  Introduction to Tuberculosis: 
Tuberculosis (TB) is one of the infectious diseases caused by Mycobacterium tuberculosis 
and is the leading cause of death in the recent world. More than 25% of the death during the 
early 19th century was reported from tuberculosis. Although the death rates fall down until the 
late 20th century with the development of new anti-TB drugs, drug resistant TB became 
another important issue in most of the TB epidemic countries. Today about one third of the 
world’s population is infected, of these almost 15 million have the active disease at all times. 
In the 21st century about 9.2 million people have been estimated with TB cases. Of these 
about 3 millions were reported from the African and South East Asia and about 2 million from 
the West Pacific region. India and China has been reported the most affected region (TB 
epidemic region). In US, the cases have declined by 10 fold since 1953. In 2007 about 
13,299 cases were reported, half of these cases were reported from foreign-born people 
born outside US. Blacks accounted for 45% of the cases among the US-born people (Merck 
Manual 2010). 
 
 
 
Figure 1.1: Showing the distribution of TB cases worldwide. The scale indicates TB cases 
per 100,000 populations. (WHO, 2010) 
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1.1.1 Background:  
Tuberculosis has been known under a variety of names in the past. The term ‘Tuberculosis’ 
is only known from during the first half of the 19th Century. The disease has been known by 
other names such as the phthisis, scrofula, tabes, bronchitis, inflammation of lungs, hectic 
fever, gastric fever and lupus. It was also known as the great white plague and consumption. 
Although it is still under research, how this organism originated, the current study shows that 
TB was detected 18,000 years ago (Rothschild. et al., 2001). Perhaps this organism 
originated from cattle and then was transferred into the humans (Pearce-Duvet. 2006).  That 
this organism has evolved gradually and has mutated is clear. It was only in 1882, Dr Robert 
Koch isolated the tubercle bacillus and established TB as an infectious disease. It has 
descended from another organism called Mycobacterium bovis (Ernst. et al., 2007). This 
organism was responsible in causing infection in human being and perhaps it was only after 
1930 when cow milk was regularly pasteurised before they were used by human being. Later 
with the development of the live attenuated strain of Mycobacterium bovis, which is 
commonly known today as the BCG vaccine, the spread of TB went down. The first child to 
be immunised with this vaccine was in 1921, whose mother died of TB and today this 
vaccine is used to immunise many children worldwide.  
 
1.1.2 Signs and symptoms in tuberculosis: 
Tuberculosis is a pulmonary disease and therefore the symptoms will not appear until the 
infection reaches the lungs. Unlike the other bacteria this organism is very slow growing and 
symptoms precipitate years after the individual was affected by the disease. Pulmonary 
tuberculosis is the condition when the pulmonary system is affected by this disease and this 
result in persistent cough which may be associated with bloody phlegm, breathlessness, 
weight loss, lack of appetite and fever.  Sometimes the infection can spread from lungs into 
the other organs such as lymph glands, bones, digestive system, reproductive system and 
finally into the central nervous system. Lymph nodes being closer to the lungs are usually 
affected first causing lymph node swelling, pain around the neck region and fluid discharge. 
Skeletal tuberculosis is associated with pain in bone and joints followed by fracture thereby 
resulting in loss of movement. T.B in the digestive systems may cause abdominal pain, 
diarrhoea and rectal bleeding. If the genitourinary tract is affected it may result in blood in 
urine, burning sensation during urination, groin pain and frequent urge to pass urine during 
night. Finally if the central nervous system is affected, it may result in vomiting, stiff neck, 
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changes in mental states, confusion and seizures. Extra-pulmonary tuberculosis is often 
common with patients associated with HIV or immune-deficient diseases. (NHS) 
 
1.1.3 Aetiology: 
TB is caused by the inhalation of the air borne particles or droplets containing 
Mycobacterium tuberculosis. These aerosolized infectious particles are released through 
coughing or sneezing by an infected candidate who has active pulmonary tuberculosis. 
Droplets can remain suspended in the air for several hours, thereby increasing the chance of 
spreading the disease. Patients with pulmonary TB infect about 7 close contacts on average. 
Inhabitants of the same poverty or institutions are at risk where a single patient is affected 
with active pulmonary TB. Medical practitioners and laboratory scientists who are in close 
contacts with the organism are also at high risk. Patients with HIV are at high risk of getting 
affected by this disease because cell-mediated immune system is essential for defence 
against TB. Other immune suppressive illness includes diabetes, anti-cancer therapy, etc. 
Elderly people are more susceptible to TB and this is partly due to the weaker immune 
system.  
 
 
1.1.4 Pathophysiology: 
The tubercle bacilli, once inside the host body, trigger a series of events from the primary 
infection that gradually progress into the latent stage. The primary infection develops once 
the organism in the form of droplets from air enters into the respiratory tract. In the lung the 
bacteria are engulfed by the macrophages which trigger an inflammatory response and enter 
into the blood stream (Figure 1.2). These cells are the building blocks for the tubercle that 
defines the disease. The tubercule or the granuloma consists of a kernel of infected 
macrophages, surrounded by the foamy giant cells and macrophages. At this stage the host 
does not transmit the infection, however if the immune system changes or if the host is 
affected with HIV-co-infection, the centre of the granuloma undergoes caseation and the 
infectious bacilli go into the airways. This leads to development of a productive cough where 
the aerosol spreads out infectious bacilli (Russell. D, 2001). 
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Figure 1.2 : The mechanism of TB infection within the host (Russell. D, 2001).  
 
 
In the latent stage the organism can spread to any part of the body infecting the organs. 50-
80% of the people who develop active TB reactivate within 1-2 years. TB damages tissues 
through Type IV hypersensitivity reaction producing necrosis of the organs.  
 
 
1.1.5 Diagnosis and Treatment:  
1.1.5.1 Diagnosis of TB: 
TB is diagnosed with chest X-ray, showing an abnormality in the mid and lower lung region; 
sometimes this is accompanied by enlarged lymph gland. A Sputum test to detect the bacilli 
is the only test that confirms TB infection. TB can be diagnosed by the analysis of interferon 
(INF) gamma in the blood sample from a TB infected patient. In an affected patient the IFN-
gamma production takes place in response to the organism in the blood. Other pathological 
test includes tuberculin test. This is often done in patients who have no other symptoms.   
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Until the first half of the 20th century no effective treatment for TB was available. People were 
terrified by the disease.  The first antibiotic to fight against TB became available only in 1946. 
Later in 1952 isoniazid (INH) was discovered as another potential anti-TB drug. Still today 
Isoniazid (INH), Ethambutol (EMB), Pyrazinamide (PZA), Rifampacin (RMP) and 
streptomycin (STM) are considered as a first line drug of treatment for TB. There are five 
classes of other second line drugs used for the treatment of tuberculosis (Table 1.1). The 
second line drugs are less potent and more toxic and therefore are only used either in 
conjunction with the first line drugs or when the first line drugs fail to treat the infection. 
However with the spreading of the drug resistant TB, tuberculosis is a concern to the current 
world.  Also with the increase in the growth of the HIV and AIDS, treatment for TB infection is 
getting more complicated and difficult.  
 
 
 
 
Table 1.1:  The first line and the second line anti TB drugs.  
 
 
 
 All these drugs act on the bacilli through different pathways. Based on the mechanism of 
action these drugs were classified as the drugs which act by inhibiting the cell wall synthesis 
of the organism (TB), drugs which act by inhibiting the ATP synthesis and drugs which inhibit 
the RNA synthesis as shown in the figure 1.3  
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Figure 1.3: The mechanism by which the drugs act on the bacilli.  (Image obtained from 
www3.niaid.nih.gov/topics/tuberculosis/WhatIsTB/ScientificIllustrations) 
  
 
1.1.5.2 Isoniazid (INH): 
Isoniazid or isonicotinylhydrazine (INH) acid was one of the first anti-TB drugs used to treat 
the infection. This drug was discovered in 1912, and was only used to combat against TB 
infection in 1951. Isoniazid was found to have carcinogenic property; however it was very 
useful against TB. The mechanism by which the drug acts is still under debate. It was 
thought that this drug acts by inhibiting the cell wall synthesis (Figure 1.3). Isoniazid is a 
prodrug and is converted into the active form by the bacterial Kat G catalase-peroxidase 
enzyme (Suarez J, et al. 2009). This activated form of INH binds with the NADH to form a 
complex thus inhibiting the fatty acid synthesis, which is essential for the bacterial cell wall 
synthesis. The bacteria tend to develop resistance against INH and for this reason; it is 
always used in combination to other anti-TB drugs.  
 
1.1.5.3 Ethambutol (EMB): 
Similar to INH, ethambutol acts by inhibiting the cell wall synthesis by obstructing the building 
of the arabino residues. These arabino residues are an important element as they bind to the 
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peptidoglycan via the galactan providing support to the cell wall. Inhibiting the binding of 
arabino residues to the peptidoglycan stops the formation of the cell wall thereby increasing 
permeability of the cell wall.  
 
1.1.5.4 Pyrazinamide (PZA): 
Pyrazinamide was discovered in 1951. Interestingly this drug was found to work well when 
used in combination with other anti-TB drugs. Perhaps it accelerates the activity of INH and 
RMP. The drug is only active in acidic conditions (Zhang. Y, et al., 2003) and is converted 
into the active form, pyrazinoic acid by the enzyme pyrazinamidase. The accumulation of this 
pyrazinoic acid disrupts the membrane potential thereby causing cell lysis. This drug was 
also reported to act by inhibiting the fatty acid synthase I, which is required for the synthesis 
of fatty acid in bacteria (Zimhony. et al., 2000).    
 
1.1.5.5 Rifampacin (RMP): 
Rifampicin is a semi synthetic antibiotic which was discovered in 1957 and became clinically 
available in 1966. This drug inhibits the synthesis of the DNA-dependant RNA polymerase by 
binding to the beta subunits in the bacterial cell. As a result it prevents the transcription of 
RNA and subsequent translation of protein. Human RNA polymerase does not bind to 
rifampicin and therefore is not inhibited. Resistance to rifampicin results due to the 
glycosylation and phosphorylation of it by the host cell.  
 
1.1.5.6 Streptomycin (STM): 
Streptomycin was discovered in 1943 and was first used clinically in 1947. Steptomycin 
belongs to the class of the Aminoglycosides. This drug binds to the 30S subunit of the 
bacterial ribosome (Sharma. D, et al., 2007) and thereby interferes with the binding of the 
formyl-methionyl-tRNA which is essential for protein synthesis leading to the death of the 
organism. This drug was however found to produce ototoxicity in human beings. The 
organism also tends to develop resistance very quickly to this drug. This led to the 
development of new generation aminoglycosides to combat against the resistant species. 
There are various aminoglycosides which are currently available such as amikacin, 
kanamycin, vancomycin, etc.    
 
1.1.5.7 Polypeptides:  
The polypeptides which are commonly used in the treatment of TB are viomycin and 
capreomycin. As the name suggests, these agents are members of the nonribosomal peptide 
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antibiotics exhibiting anti-tubercular activity. These groups are called as the 
tuberactinomycin. Viomycin is the first member of the tuberactinomycin family to be identified 
as a potential anti-TB drug. This drug targets the bacterial ribosomes by binding to the RNA 
and causing disruption to the bacterial protein biosynthesis. Viomycin was found to be toxic 
and later it was replaced by a less toxic antibiotic of the same class called capreomycin.  
 
1.1.5.8 Fluoroquinolones: 
The first generation of fluoroquinolones were introduced in 1962 for the treatment of urinary 
tract infection. Today fluoroquinolones are used as broad spectrum antibiotics. These agents 
act by inhibiting bacterial DNA gyrase and topoisomerase IV enzyme, thereby inhibiting DNA 
replication and transcription. Temafloxacin, an analogue of ciprofloxacin is widely used in TB 
infection. Levofloxacin is equally effective as ethambutol, against the organism but lower 
than INH and RMP (King. J, et al. 1999). Other drugs which are used in TB infections are 
Ciprofloxacin, Moxifloxacin, etc. 
 
1.1.5.9 Thioamides  
Thioamides are used in both pulmonary and extrapulmonary TB infections. The commonly 
used thioamides are the ethionamide (ETA) and prothionamide. Ethionamide is structurally 
similar to pyrazinamide and INH. It is thought that this drug is a prodrug and undergoes 
intracellular modification in a similar fashion as in INH (Tommaso. A., et al 2002). This 
inhibits the synthesis of mycolic acid, which is essential for the cell wall synthesis. Similar to 
INH, ethionamide also inhibits the enzyme enoyl-aryl carrier protein reductase inhA 
(Banerjee. eta al, 1994).    
 
1.1.5.10. Para amino salicylic acid class of drugs.  
Para amino salicylic acid as oral drugs to treat TB were first introduced in 1944. This drug is 
used to treat multiple drug resistance tuberculosis and is always used in combinations with 
other anti-TB drugs. This drug acts by inhibiting the nucleic acid synthesis in the organism.  
Para amino salicylic acid was also used in the treatment of anti-inflammatory bowel 
diseases, particularly in ulcerative colitis and Crohn’s disease.  
   
1.1.6 Newer Drugs: 
Although currently there are third line treatments available in TB infections, none of these 
drugs were as potent as the first line treatment and at the same time these drugs were also 
observed with some toxicity. Thus there is an urgent need to develop a new class of anti-TB 
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drug. In the current decades research in TB is getting more attention and this is mainly due 
to the gradual increase in the number of TB cases, particularly for the multi-drug resistance 
TB. Within the last six decades another new class of TB drugs which are unrelated to INH or 
RMP has emerged into research. These new agents belong to the new class of anti TB drugs 
called the amidrazones; these compounds are in active stage of development and have 
shown some high level of toxicity. These compounds have emerged from a group of 
hydrazines which were found to have some anti-tubercular activity (Bertrand et al. 1956). 
Later further investigations were implemented to develop the new class of compounds called 
carboxamidrazone (Mamalo et al., 1992, 1993, 1996).  This compound was thought to have 
a wide range of activity from antibacterial to antifungal (Vio, et al., 1989). Research into this 
new class of compounds was also carried in the Aston University laboratory and several N1-
benzylideneheteroaryl-carboxamidrazones have shown significant anti-microbial activity 
(Billington et al, 1998, 1998, 2000). Some were found to be effective against some strains of 
Mycobacterium tuberculosis which were resistant to isoniazid and rifampicin. Further work to 
develop these compounds was carried out in this thesis and is discussed in the chapter 5.   
 
1.1.7 Treatment regimen:  
The treatment regiment is very important in treating the TB affected patients. Patients with 
TB positive should initiate first line treatment (INH, RMP, PZA, EMB) for the first two months. 
If the smear culture is still positive, the treatment is continued with RMP and INH daily for 4 
months to complete a 6 month regimen. If the chest X-ray shows the cavity, the treatment is 
continued for further 3 months; this completes a total of 9 months regimen. The flow diagram 
below shows the treatment regimen in TB patient with concomitant HIV condition.  
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Figure 1.4: The treatment regimen in TB patients.  
 
 
Unlike other anti-bacterial treatment, anti-TB drug treatments are far more complicated. This 
attempt causes many patients to stop the treatment without consulting with the health 
professionals as soon as they start feeling better. To overcome this complication directly 
observed therapy short course (DOTS) was introduced. While DOTS involves health workers 
watching their patients take their medication, FDC (Fixed-Dose Drug Combinations) became 
more useful in TB treatment. FDC became more beneficial in decreasing the risk of multi 
drug resistant tuberculosis. FDC involves an advanced method of drug delivery where two to 
four anti-TB drugs were administered in a fixed dose in a tablet.   
 
 
1.1.8 Drug resistance: 
Despite innovative ideas to improve the treatment procedure, patients on anti-TB treatment 
regimens still develop resistance to the drug. Drug resistance due to drug happens due to 
inappropriate treatment or inadequate treatment, frequent inadvertently skipping the course 
of treatment and very often due to the underlying HIV infection followed by neglect in 
treatment (Zignol, et al., 2006).   As a result the bacterium undergoes mutation and develops 
resistant strains which fail to respond to the treatment. Resistance to INH is brought about by 
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the inactivation of the enzyme KatG which is essential for the activation of the INH when 
administered to the TB infected patients. Since the INH is not activated, the drug fails to exert 
its toxic effect in the organism. The chance of resistance is higher particularly to the less 
effective or the second line drugs, medium chances are for the INH and EMB and less in 
case of RMP (Shimao. 1987; Crofton.1970). The probability of resistance is directly 
proportional to the bacterial load. A bacillary load of 109 will contain several mutants resistant 
to one tubercular drug (Grange. et al., 1990). When the organisms containing both the 
resistant strain and non-resistant strains are exposed to the drugs, the non-resistant stains 
are killed and the drug resistant strains flourish.  When these forms of the strains are 
exposed to the second line treatment, mutants resistant to the new drugs develop. This form 
of TB does not respond to the standard 6 month treatment with the first line drugs and may 
take up to two years with the second line treatments which are less potent to the organism, 
more toxic and more susceptible to resistance.  
 
1.2 Biosynthetic pathway in bacteria.  
1.2.1 Shikimic acid pathway: 
Unlike animals, bacteria do not derive their amino acids from other sources, rather all the 
amino acids are synthesised by the bacteria. The shikimic acid pathway (shikimate pathway) 
is one of the bio-synthetic routes in microorganisms to synthesise these aromatic amino 
acids such as L-phenylalanine, L-tryptophan, L-tyrosine and other essential amino acids. 
These amino acids are essential for the synthesis of folic acid in microorganisms which is 
necessary for their survival. This pathway is only found in plants, bacteria, fungi and some 
parasites but is absent in vertebrates or mammals (Haslam. et al., 1993).  The absence of 
these pathways in mammals has revealed a potential area in drug discovery.   
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Scheme 1.1:   Showing the shikimic acid pathway (Nissen. S, et al., 2005)  
 
The Shikimic acid pathway is an important area of research to discover antibacterial agents. 
Although several enzymes have been established as potential targets, perhaps the most 
interesting one of them was the chorismate mutase. Chorismate mutase catalyse the 
conversion of the chorismate to prephenate and this is a key step for the biosynthesis of 
several amino acids, alkaloids, etc (Scheme 1.1) 
 
1.2.2 Chorismate mutase: 
Chorismate mutase is one of the important targets to block the metabolism in bacteria, fungi 
or plants. It sits as a branch point enzyme in shikimic acid pathway. As mentioned this 
enzyme is important for the microorganism and is involved in the first step of the biosynthesis 
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of tyrosine and phenylalanine. Therefore blocking of such enzyme will ultimately block the 
metabolism in the micro organism thereby resulting in the death of micro-organism. This 
enyme is however absent in humans; for these reason chorismate mutase has become a 
vital target in discovery of antibiotics, fungicides and herbicides. The conversion of the 
chorismate to prephenate takes place by Claisen rearrangement with the formation of a chair 
shaped intermediate. This intermediate and its conformation are of particular interest and 
several analogues to this intermediate have been designed as a potential target to develop 
anti bacterial agents.  
 
1.2.3 Transition State Analogue (TSA):  
 
O
OH
CO2
O2C
O
OH
CO2
CO2-
-
-
-
 
   A      B 
Figure1.5:  Showing the transitional state conformation (A) and the transitional state 
analogue (B).  
 
The figure above shows the transitional state conformation during the conversion of 
chorismate to prephenate. Although several inhibitors have been designed to block the 
conversion of chorismate to prephenate, the transitional state analogue (the endo-oxabicyclic 
dicarboxylic acid) was found the best inhibitor for the enzyme. (Mandal. et al., 2003). TSA is 
a bicyclic structure and the chair form of the TSA is vital for its inhibitory activity and that the 
rearrangement of the chorismate to prephenate proceeds via chair like conformation (figure1) 
has been confirmed with various analogues of the bicarboxylic acid analogue (Andrews, P. 
R, et al. 1977).  
 
1.3. Drug design methods:  
The term drug design refers to the design of a chemical compound that would bind to the 
biological target generating the desired biological outcome. It is therefore essential that the 
drugs are designed based on the knowledge of the biological targets (Madsen. 2002).  There 
are two different approaches for drug design; it can be either ligand based drug design or 
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structure based drug design. Ligand based drug design involves the preparation of a 
pharmacophore model of the binding site such that the structural characteristic would 
facilitate the binding of the ligand (Osman F. 2000). Structure based drug design on the other 
hand utilises the information from the biological active site to design ligand that would fit 
appropriately into the active site (Leach. A, 2007). This method thus relies on the protein 
crystal structures of the biological targets.   
 
1.3.1 Protein: 
Proteins are the polymers of amino acid. Again as the name suggests amino acids are the 
units of protein which contains an amino group and an acid group connected to an alpha 
carbon to which is attached a side chain R group. All amino acids have distinct R groups 
(Figure 1.6).   
 
Figure  1.6: Peptide bond between two amino acids.  
 
As shown in the figure 1.6 above, peptide bonds are the linkage between the carbonyl 
carbon of one amino acid to the amino nitrogen of the other. The amino acids are referred to 
by either a three letter code or a single letter code. The peptide bond has double bond 
characteristic (40%) due to resonance. The peptide bonds are therefore generally planar and 
this reduces the degree of freedom of the polypeptide during folding (Figure 1.7). 
 
C
N
O
H
C
N
H
O
 
Figure 1.7  Showing the resonance within a peptide unit. 
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The amino acid sequence of a protein is called the primary structure. The different structure 
of a protein structure is illustrated in figure 1.8 below. The secondary structures in protein 
structure are the α-helices, β-sheets and the β-turns. The secondary structure is the regular 
arrangement of amino acid residues in a segment of the protein structure where each 
residue is spatially related to its neighbour in the same way. The secondary structures are 
formed by the non-covalent interactions in protein such as hydrogen bonding. The tertiary 
structure of a protein is folded into a compacity using a variety of loops and turns. The 
tertiary structure of a protein is characterised by weak bonding interactions and sometimes 
by covalent bonds such as disulphide cross-links. The quaternary structure is formed by the 
non-covalent interactions between subunits of multi-subunit proteins or large protein 
assembles (eg: haemoglobin contains four polypeptide chains held by non-covalent bonds).   
 
 
Figure  1.8:  Illustrates the different structure of a protein structure.  (Image obtained from 
commons.wikimedia.org/wiki/File:Main_protein_structure_levels_en) 
 
1.3.2. Protein crystal structures 
The three dimensional co-ordinates of protein structures can be obtained following x-ray 
diffraction on the crystal form or NMR spectroscopy or if the experimental structure of the 
target is not available it can be created using homology model. A crystallographer can study 
the angle and the intensity of diffracted beams and can determine the arrangement of the 
atoms within the crystal as well as the chemical bonding and various other informations. The 
higher is the resolution of these x-ray diffracted beams, the better is the information about the 
structure.  
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Figure 1.9:  Crystal structure of an enzyme 2FP2.pdb. (chorismate mutase from M. 
tuberculosis)  
 
 
The functional information of a crystal structure can be represented in the form of Cartesian 
coordinates (as in x,y,z) of all the atoms present are in the form of internal coordinates. 
Within the internal coordinates the positions of the atoms are described as relative to the 
other atoms in the system. The internal coordinates are useful for a small and single 
molecule whereas the Cartesian coordinates are useful in defining a collection of discrete 
molecules. The localization of the hydrogen atoms within the protein structure are difficult to 
observe by x-ray crystallography. This is because the x-rays are scattered by the electron 
density around the atom. Each hydrogen atom contains only one electron and their influence 
on x-ray scattering is low and they are normally disregarded. Therefore the hydrogen 
positions are appointed on the basis of collected knowledge on standard bond length and 
angles. It is important to note that the crystalline state geometry of a molecule is based on 
the influence of the crystal packing force and therefore bond lengths and bond angles can 
differ from theoretical standard values. The energy level of the structure is thus affected by 
the neighbouring molecules in the crystal unit and sometimes by the solvent units. Therefore 
study of the global energy minima of the crystal structure is essential while using the x-ray 
crystal structure.  
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           Atom   
            type    Chain      Temperature factor
                  Cartesian  
            Atom      Amino Residue       coordinates   Occupancy 
            number       acids   number               (X,Y,Z)           fraction         Atom 
   
ATOM   1335   N      ALA   A  199       3.998   39.167  67.156 1.00    9.78        N   
ATOM   1336   CA    ALA   A  199       4.227   40.459  67.781 1.00   10.65       C   
ATOM   1337   C      ALA   A  199       4.962   40.208  69.084 1.00   11.31       C   
ATOM   1338   O      ALA   A  199       5.320   39.040  69.330 1.00   10.72       O   
ATOM   1339   CB    ALA   A  199       2.877   41.180  68.055 1.00   12.02       C    
TER       
ATOM   1342   N     SER   B   37     4.895   18.474   7.161   1.00   22.20      N 
ATOM   1343   CA   SER   B  37        4.977   16.974   7.049   1.00   19.97      C 
ATOM   1344   C     SER   B   37        3.604   16.323   6.927   1.00   18.26      C 
ATOM   1345   O     SER   B   37        2.605   16.742   7.521   1.00   17.61      O 
TER 
HETATM 2663  C1  TSA    X  500      -4.796   5.651  29.633   1.00   11.71      C   
HETATM 2664  C2  TSA    X  500      -5.652   4.433  29.982   1.00   13.22      C 
 
Figure 1.10:  Explaining the crystal structure data from protein data bank file.   
 
 
The figure 1.10 above represents a sample how the information from the amino acids are 
coded in a protein crystal structure file. The crystal structure of the protein may have more 
than one strand and this is usually defined as A,B,C etc. The amino acids from the proteins 
are coded with ‘ATOM’ and the ligands are coded with ‘HETATM’. The amino acids are 
encoded as 3 letter code and termination of each strand is represented as TER. The atom 
number is the number of the atom in the whole protein. The atom type represents the atom 
type of the residue (N=amide, CA= alpha carbon, C= carbonyl C, O=carbonyl O). The amino 
acids are represented as a three letter code. The occupancy fraction represents the unit cells 
that contain the atom in this particular location and is usually 1.00. The temperature factor is 
an indication of uncertainty in this atom’s position due to disorder or thermal vibration.  The 
protein files of the crystal structure may also contains useful information such as missing 
residues within the data, disulphide linkage and these are added while using such crystal 
structure.  
 
Strand A 
Termination 
of strand A 
Strand B 
Ligand 
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1.4 Introduction to Molecular Modelling: 
Molecular modelling is a modern technique widely used in chemistry and biology to design 
experiments and evaluate experimental results. Research on molecular models drew more 
attention after 1953 when Watson and Crick described the structure of DNA. Today 
molecular modelling utilises computers as a powerful tool and it requires sophisticated 
software and more skills to operate. Molecular modelling is used to visualise the x-ray crystal 
data of protein, simulate the protein and ligands, refine protein structure using molecular 
dynamics, evaluate the protein structure models and dock the potential structure into the 
enzyme active sites thereby calculating their binding affinities. Therefore the study of the 
potential energy in a molecular system is important while performing molecular modelling 
studies. Generally molecular modelling can be categorised into molecular mechanics and 
quantum mechanics.  
 
1.5 Molecular Mechanics: 
Molecular mechanics is based on the simple empirical interaction of the atoms and 
molecules using classical Newton’s Law. Molecular mechanics consider atoms as spheres 
and bonds as springs; a brief overview is shown below (Figure 1.11). These methods are 
used to calculate the forces acting on the atoms in molecular system and these forces are 
used to calculate the potential energy of the molecular system.  
 
 
 
Figure 1.11: Showing the distribution of the potential energy in a molecule. 
(http://en.wikipedia.org/wiki/File:MM_PEF.png) 
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The potential energy of a molecular system in molecular mechanics is calculated using force 
fields. The four main components on which force field depends are the bond stretching, 
angle-bending, bond rotation (torsion) and the non-bonded interactions which are the van der 
Waals and electrostatic. The total energy of the system can be represented by the following 
equation: 
 
   Equation 1.1   
 
Where Etot is the total energy of the molecule, Estr is the bond stretching energy, Ebend is the 
energy due to bond bending, Etors is the torsional energy term, Evdw is the van der waals 
energy and Eelec is the electrostatic energy. Molecular mechanics thus enables the 
calculation of the total change in the energy system from the reference or initial energy level. 
This therefore involves the measurement of the energies from bond stretching, angle 
bending, bond rotation, and the other non-bonded interactions which is known as force fields.  
 
1.5.1 Bond stretching:  
Since molecular mechanics typically treats atoms as spheres, and bonds as springs, the 
mathematical expression from Hooke's Law can be used to describe the ability of bonds to 
stretch, bend, and twist. According to Hooke’s Law:   
 
       Equation 1.2 
 
Where, E stands for the potential energy of a deformation, x is the displacement of the 
spheres and k is the force constant. The same applies to all the bonded interaction as 
discussed earlier. The bond stretching can be represented as.  
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Graph 1.1: An example of energy change due to bond stretching variation 
.  
 
      Equation 1.3  
 
Where kb is the bond stretching force constant, b is the actual bond length and bo is the 
unstrained bond length.  
 
 
1.5.2 Bond bending:  
The energy due to angle bending Ebend is the energy required to bend the angle to and away 
from the actual angle. It can be represented as:  
 
      Equation 1.4 
 
Where K
θ
 is the angle-bending force constant that is determined empirically, θo is the 
equilibrium value, in other words the natural bond angle for θ is the actual bond angle in the 
molecule.  
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Graph 1.2: The change of energy due to bond bending.  
 
If the optimal bond angle for H-Csp2-Csp3 is 122°, then any change in angle (θ-θ0), either 
wider or narrower, will increase the energy of the molecule.  
 
1.5.3 Torsional energy:  
The torsional energy represents the amount of energy that must be added to or subtracted 
from the Stretching Energy + Bending Energy + Non-Bonded Interaction Energy terms to 
make the total energy agree with experiment or rigorous quantum mechanical calculation for 
a model dihedral angle.  
 
 
Figure 1.12: The variation of energy due to torsion angle variation.  
θo 
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The energy due to torsional angle can be represented as  
   
      Equation 1.5 
 
Where k  is the torsional barrier,  is the actual torsional angle; n is the periodicity or the 
number of energy minima within one full cycle. o is the reference torsional angle.  
 
1.5.4 Non bonded interactions:  
The non-bonded energy accounts for repulsion, van der Waals attraction, and electrostatic 
interactions.  
1.5.4.1 Van der Waals interactions:  
The Van der Waals interactions are modelled using the Leonard-Jones potential. Van der 
Waals attraction occurs at short range, and rapidly dies off as the interacting atoms move 
apart by a few Angstroms. Repulsion occurs when the distance between interacting atoms 
becomes even slightly less than the sum of their contact radii. The Van der Waals 
interactions can be represented as:  
 
       Equation 1.6 
 
Where A
 ij is the repulsive term coefficient, B ij is the attractive term coefficient and rij is the 
distance between the atoms i and j.  
  
Graph 1.3: The change of energy due to van der Waals interaction. 
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1.5.4.2. Electrostatic interactions:  
The electrostatic energy is a function of the charge on the non-bonded atoms, their inter-
atomic distance, and a molecular dielectric expression that accounts for the attenuation of 
electrostatic interaction by the environment. The electrostatic contribution is modelled using a 
Coulombic potential. It is represented as. 
 
         Equation 1.7  
 
Where ε is the dielectric constant, Qi and Qj are the atomic charges of interacting atoms and 
r is the inter-atomic distance.  
 
In summary the potential energy in the force fields can therefore be represented as  
 
         Equation 1.8 
 
Where V(r) is the potential energy, which is the function of the position (r) of the atoms 
(Ponder. J, et al., 2003).  Force field thus can be defined as an energy system of a molecular 
system which changes as the bonds are rotated and it also depends on the non-bonded 
interactions of the molecular system. Force fields are empirical, that is there is no correct 
form for a force field. If one form is shown to perform better than another, it is likely that form 
will be favoured. The functional form employed in molecular mechanics is often a 
compromise between the accuracy and computational efficiency. As the performance of the 
computers increase the models became more sophisticated.  
 
In case of proteins the number of the non-bonded interactions increases with the square of 
the interacting sites, thus the number of the interacting sites can be reduced by considering 
the group as an atom (pseudo-atom) e.g. methyl group can be considered as a single atom. 
This is what referred to as united atom force field (Yang. et al, 2006) and it saves a 
significant computational effort in carrying out calculation.  
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1.6 Quantum mechanics: 
Quantum mechanical calculation of a molecular system involves the molecular orbital 
calculation and offers the in-depth description of the molecule’s chemical behaviour. 
Quantum mechanical simulation is based on the law of quantum mechanics. Quantum 
mechanics states that energy and other related properties of molecules can be solved by 
using Schrodinger equation.  
 
       Equation 1.9 
Where,  
  is the square of the reduced Planck constant . 
 m is the mass of the particle 
  is the particle’s wave function 
 X,Y,Z are the co-ordinates (3 dimensional variables) 
  is the second derivative with respect to dimension X.  
 V is the potential of the particle at X,Y,Z co-ordinates.  
 E is the energy of the particle. 
 
In the above equation a single particle of mass m is moving through a space given by a 
position vector r and time t under the influence of an external field V.  is the wave function 
of the particle and it is from this function the properties of the particles can be derived. The 
above equation can be written as  
   
H  = E  = (U + K)      Equation 1.10 
Where,  
        Equation 1.11 
       Equation 1.12 
        Equation 1.13 
In the above equation H is the Hamiltonian and  is the wave function representing the 
distribution of the electrons around the molecule. The total energy E, contains the potential 
energy U and Kinetic energy K. The above equation can also be written as  
  
     Equation 1.14 
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Where, N is the number of particles (electron and proton) with r position vector. In an atom 
that contains a single electron, the potential energy depends upon the distance between the 
electron and the nucleus and thus the Hamiltonian equation is as follows.  
 
         Equation 1.15 
 
Where Z is the nuclear charge and r is the distance of the electron from nucleus. 
Unfortunately, the Schrodinger equation can only be used to solve for very small molecules 
such as hydrogen and helium. Therefore approximations must be introduced to make this 
method applicable for the systems containing more than one atom. The first approximation 
attempts to differentiate nuclei and electrons where the nuclei are considered much heavier 
than electrons and move much more slowly so that molecular systems can be viewed as 
electrons moving in a field of fixed nuclei (the Born-Oppenheimer approximation). This allows 
the separation of Hamiltonian into nuclear Hn and electronic parts He.  
 
    Equation 1.16 
 
Where r1are the electronic and R1 are the nuclear coordinate. He depends on the nuclear 
coordinates.   
   Equation 1.17 
 
The separation of the Hamiltonian allows the separation of the Schrödinger equation.The 
Hartree-Fock method finds its application in the solution to the Schrödinger equation. The 
Hartree-Fock method is also known as the self-consistent field method (SCF). The ab initio 
method utilises Hartree-Fock (HF) method in which the calculations are simplified by 
considering the electrons in an average field. This results in the calculation of the 
Hamiltonian for each electron independently using a new term for its interaction with the 
other electrons. Thus in order to search the global minima by conformational search, it 
requires large computer time and this method is limited to compounds containing between 
ten to twenty atoms. 
 
1.6.1 Energy calculation using ab initio quantum mechanical methods: 
Ab initio methods do not include any empirical or semi-empirical parameters in their 
equations and derived directly from theoretical principles, with no inclusion of experimental 
data. The ab initio method was introduced to model small molecules, lately this method 
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became available for large molecules (Kenny. B, 1993). The simplest type of ab initio 
electronic calculation is the HF method in which the electron-electron repulsion is not taken 
into account and the average effect is included. The obtained approximate energies are 
expressed in terms of the system’s wave function and are equal or greater than the exact 
energies. Several versions of the ab initio methods are available commercially such as the 
Gaussian series (Pople. J, 1950).  
 
1.6.2 Energy Calculations using semi empirical methods: 
The semi empirical calculations are based on the same or related quantum mechanical 
principles; with certain approximations for the majority of the electron-electron interactions to 
simplify the computations or to include some empirical parameters based on the 
experimental data.There are various types of the semi empirical methods which differ in their 
approach to approximation. This can be categorised based on the two research groups, the 
Zero Differential Overlap (ZDO) approach, the Complete Neglect Differential Overlap 
(CNDO) approach (Pople et al. 1965), intermediate neglect of differential overlap approach 
(INDO) and the Neglect of Diatomic Differential Overlap approach (NDDO) was carried out 
by John Pople and co-workers. These methods are rarely used and are modified by Michael 
Dewar and co-workers to make the calculation more realistic and requiring significantly less 
amount of time. This includes the modified neglect differential approach (MNDO), Modified 
Intermediate Neglect Differential Overlap approach (MINDO), (AMI), (PM3) and (SAM1). 
These calculations are widely used in MOPAC and AMPAC packages.  
 
While the semi empirical methods require less computer resources when compared to the ab 
initio methods, they still are computer intensive. The major drawback of this method is that its 
application is limited to systems for which appropriate parameters have been developed.  
 
1.7 Geometry optimization:  
The geometry of a molecule determines its physical and chemical properties. It is therefore 
important to have the correct geometry of the molecule before performing any computation 
experiments. The arrangement of the atoms in the molecules, perhaps the electrons around 
the atoms determines the energy level of the molecule. Therefore the geometry of the 
molecular system has direct impact on the energy system of the molecule. One way to 
observe the effect of potential energy surface is to calculate the potential energy surface 
(PES).  
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Graph 1.4 : Showing the flow of energy (potential energy) level during simulation.  
 
As shown in the graph above, the global maximum is the point on the potential energy 
surface where the molecule is at its highest value. At local maxima the potential energy of 
the molecule is at its highest value at that particular conformation. The local minimum is the 
point on the PES where the energy of the molecule is at its lowest value at that particular 
conformation. At global minima the molecule is at its lowest energy level in the entire PES. 
The saddle point is the point on the PES where the potential energy is maximum in one 
direction and minimum on the other. This is of particular interest to the chemist as they 
sometimes produce transitional states.  The geometry generated from the saddle point may 
produce a structure similiar to transitional state when the geometry is optimized. At each and 
every point on this PES the molecule has its own conformation; it is the purpose of the 
geometry optimization to locate the minima based on the geometry of the molecule.  This can 
be performed by:  
 
1.7.1 Geometry optimization by molecular mechanic methods. 
The molecular mechanical approach to optimize the geometry is carried out by minimization 
and molecular dynamics simulation method.  
Global maximum 
Global minima 
Local minima 
Local maximum 
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1.7.1.1 Minimisation: 
In molecular modelling and drug designing every NMR or crystal structure downloaded are 
just the snapshots of one conformation. Minimisation is carried out to identify the 
corresponding local minimum on the potential energy surfaces that describes the relative 
energies of the conformations and geometries of molecules within a particular system. In this 
investigation the system is carried through a series of steps until it is no longer possible to 
decrease the energy gradient any further within the specified criteria. The end point yields a 
snapshot representing the most energetically favourable state. It is important to note that the 
minimisation of the system depends on the starting conformation of the system. This can be 
resolved by the additonal use of Molecular dynamics (MD).  
  
1.7.1.2 Molecular dynamics:  
Molecular dynamics (MD) involves the study of the motion of the atoms in the complex 
protein. In drug designing molecular dynamics studies are used to refine the geometry of the 
proteins and to study their motions. A good molecular dynamics study for a system depends 
on the time length chosen for its simulation; this is because during these simulations the 
molecules inherit various conformations. The final result is the best possible conformation 
and invariably depends on how many best conformations did the molecules pass through 
with minimum energetic values. Molecular dynamics follows the classical Newton’s Law:  
Fi = mi ai       Equation 1.18 
Where F is the force, m, is the mass and a, is the acceleration. The force can also be 
expressed as the gradient of potential energy,  
        Equation 1.19 
Combining these two equation gives:  
        Equation 1.20 
Where, V is the potential energy of the system, t is the time and r represents the Cartesian 
coordinates of the atom. In more pictorial term the atoms will move, bumping into each other 
and if the system is fluid it will oscillate in waves in concert with their neighbours, perhaps 
evaporating away from the surface if there is free surface, in other words it will do everything 
what atoms in real substance would do. In molecular dynamics the atoms interact with each 
other creating a force, which once again acts on the neighbouring atoms and the atoms 
move further because of such interaction; as these atoms move their relative position and 
force changes as well (Ercolessi. 1997). Thus the velocity and position of a new atom is 
updated to a new velocity and position. These simulations are the representation of the 
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potential energy function of the molecule from its atomic co-ordinates, which can be 
represented as,  
 
Fi = -׏ri V(r1,……rN)     Equation 1.21 
 
As mentioned earlier; F is the force and V(r1,……rN) represent the pairwise interaction. The 
lower energy states of the potential energy function are populated at thermal equilibrium and 
forces on the individual atoms are related to the gradient of this function; such functions are 
commonly referred to as force fields.  
 
1.7.2 Geometry optimization by semi-empirical methods.  
MOPAC (Molecular orbital Package) was used in this thesis as a semi-empirical method of 
optimization. MOPAC follows the Schrödinger equation 1.10. It finds the minimum-energy 
geometries which are near to the stationary geometries. Stationary geometries are those for 
which the energy does not change and the net force on each atom is zero. The minimum 
geometry is obtained by calculating the forces acting on the system, changing the geometry 
so as to lower the total energy. (Cache 2002).  The default geometry optimizer in MOPAC 
uses Baker's EigenFollowing method. If this is not wanted, for example, if there is a need to 
reduce memory demands, then the Broyden Fletcher Goldfarb Shanno (BFGS) method can 
be used.   
 
MOZYME is copyrighted software by Fujitsu. The geometry optimization carried out in this 
thesis was performed in MOZYME which was build on MOPAC methods. The methods in 
MOZYME were similar to MOPAC with the advantage of its use to study larger systems. This 
happens because the calculation time in MOPAC increases as the cube of the number of 
atoms, MOZYME alters the way in which the electronic structures are calculated and uses 
the localised molecular orbital. Therefore big molecules like proteins require MOZYME for its 
geometry optimisation and calculation of polarizability. However the calculations that need 
high precision were not possible to perform in MOZYME (Cache 2002).  
 
1.7.3 Geometry optimization by ab initio methods.  
As discussed (Equation 1.17 and 1.18) the motion of the electron and nuclei can be 
separated using the Born-Oppenheimer approximation. The initial geometry can be 
calculated by performing the single point energy calculation. The forces on the nuclei can be 
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calculated from the wave function using the Hellmann-Feynman theorem (Feynman 
1939).The force on a nucleus I with position RI is:  
          Equation 1.22 
Where, E is the energy. This force can be used to find the ground state position of the atoms. 
As the force move toward minima, the motion for the nuclei will move toward equilibrium 
structure (Cheung.D, 2002).  
 
1.8 Background and development of the Amber Force field.  
Although a large number of protein force fields were used over the years based on equation 
1.10, research interest with protein force field has only started after the development of the 
Monte Carlo simulation of proteins. The most popular of them were the ECEPP potentials 
from Scheraga and co-workers (Momaney et al., 1975; Némethy et al., 1983), and the 
consistent force field (CFF) developed by the Lifson group (Lifson and Warshel, 1969; Hagler 
et al., 1974; Hagler and Lifson, 1974; Niketic and Rasmussen, 1977). All these force fields 
provided enough experience to develop more sophisticated force fields and by the 1980 
research for the development of new generation of force field started; this force field is known 
today as the Amber force field.  
 
During the earlier stage of this development, computers which were available had a limited 
power and therefore hydrogen atoms were excluded from the study. Later this hydrogen 
bonding were found important and were included in the force field (Weiner et al., 1984) by 
incorporating the new concept of united atoms where the hydrogen atoms attached to a 
single carbon were considered as a single entity. This force field was incorporated into the 
Amber molecular mechanics package, which was also at the early stage of development 
(Weiner and Kollman et al., 1981). This resulted in significant increase in calculation time. 
Unfortunately it was difficult with united atom models to make comparisons between 
computed and observed vibrational frequencies and therefore an extension of this model was 
published in 1986 (Weiner et al., 1986). With the increase in speed of the computers a new 
force field was developed in 1994 known as ff94 force field (Cornell et al., 1995). Later a 
more serious attempt was made to develop parameters for the molecules other than the 
protein (Fox and Kollman, 1998). This led to the development of a key program in Amber 
called antechamber. The parameters from 1984 and 1986 involved the use of gas phase 
simulation; later the empirical water models were developed such as TIP3P and incorporated 
into the force field.  
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Amber 11 is the latest version of Amber project with some little updates in force fields from 
Amber 10 and Amber 9. The work carried out in the current thesis has used Amber 9. The 
idea on the desire to generate simple “generic” force field models has been utilised widely in 
simulation of protein and nucleic acids, using simpler functions to describe bonds, angles 
and dihedral terms and attempts to employ as few empirical parameters as possible. 
Developing the torsional parameters in the Amber force field was difficult. The 
implementation of restrained ESP-fit method has restricted the use of torsional terms in 
Amber force field. The energy profile for rotation about a bond depends upon the atom types 
of the two atoms that comprise the central bond and not upon the terminal atoms (Leach, A., 
2001). Interestingly ff94 force field has used more than one term to describe the torsional 
terms (Verma, et al., 2001).  Amber force field has improved the reproduction of interaction 
energies and free energies of solvation (Cornwell et al., 1995; Wang et al., 2000). Also 
further implementation of scaling factor for the charges alongside and thereby implementing 
ff02 and ff02EP force fields managed to produce better representation of the H-bond 
interactions.  
 
Another force field developed in 1996 by Halgren and co worker called MMFF94 force field 
was also very popular in the development of force fields (Halgren, 1996abcd; Halgren and 
Nachbar, 1996; Halgren 1999ab). MMFF94 is similiar to MM3 and achieves similar accuracy 
for small drug like ligands although it is applicable for the biological protein complexes. 
Halgren pioneered a novel way to more accurately model van der Waals interactions by 
using buffered formation in developing MMFF94 force field. The force field designed for the 
MMFF approach was restricted to certain types of uses and parameterised accordingly. The 
MMFF94 was designed specifically for MD simulation whereas the MMFF94s (static variant) 
performs better in minimisation. Of all the force fields developed, the most successful force 
fields so far are the MMFF94 and Amber force field.  
 
The Amber project is based on these two force fields used in an overlapping manner. The 
Amber force field developed by Kollman and co-workers (Cornell et al., 1995, Pearlman et 
al., case et al., 2002) and the MMFF94/MMFF94s force field described by Halgren (Halgren, 
1996a; Halgren, 1999a). The Amber model is simpler in functional content than MMFF, but 
requires more computational input if the system carries ligands. The MMFF approach has 
been used to describe the structural geometries and charges derived from quantum-
mechanical calculations on a large set of diverse small molecule species. In this way the 
complexity for this program was increased with distinct advantages when applied to wide 
chemical functionalities and features.  
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1.8.1.  Amber Project:  
Amber (Assisted model building with Energy refinement) is a computer based software 
mainly applied to nucleic acids and proteins and is best for simulating biological systems.  
Amber program is a collective name for a suite of programs to carry out molecular dynamics 
simulation. All these programs are clustered in 3 main areas (i.e preparatory program, 
simulation programs and analysis programs) as shown below.  
 
 
 
 
 
 
 
 
 
Figure 1.13: The Amber program suite (Amber Manual. 2005).   
 
1.9. Selection of Algorithm: 
In molecular dynamics the configuration of the system is obtained by integrating the 
Newton’s law. The result is the trajectory which is obtained by solving the differentiating 
Equation 1.19.  
 
      Equation 1. 23  
  
The equation above shows the motion of a particle of mass mi along one coordinate Xi with 
Fxi is the force on the particle in that direction. Thus the particles move together colliding with 
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each other and thus changing position. The position of the particle  thus changes by i , 
where i is the constant velocity and  is the time between collisions. In more realistic 
models the forces from each particle change as the particle changes its position. Thus the 
acceleration of the particles at time t can be calculated from the force; this can then be used 
to calculate the new position and velocities at time t+δt. Similarly the velocities at time t+δt 
was determined at t+2δt. There are several algorithms for integrating the equation of motion 
which are commonly used in molecular dynamics calculation.  All algorithms can be derived 
by the Taylor series expansion:  
    Equation 1.24 
    Equation 1.25 
 .   Equation 1.26 
 
1.9.1 Verlet algorithm: 
The most widely used of these are the Verlet algorithm (Verlet et al., 1967). The Verlet 
algorithm uses the position and acceleration at time t from the previous steps (t-δt) to 
calculate the new position at t+δt. Knowing . Thus the velocities in Verlet 
algorithm can be represented as:  
    Equation 1.27 
 
Then the new velocities can be calculated from   via force field. Similarly 
the velocities at time , can be determined by the equation 1.27. Unfortunately the lack 
of the explicit velocity term in the equation makes it difficult to obtain the velocities. That is 
the velocities are not available unless the positions are computed at the next step.  
 
1.9.2 Leap-frog algorithm 
The leap-frog algorithm (Hockney. et al., 1970) has the advantages over Verlet algorithm; it 
explicitly includes the velocity and does not require the calculation of the differences of large 
numbers. Knowing . The leap-frog algorithm is expressed as:  
     Equation 1.28 
     Equation 1.29 
 
Then the new velocities can be calculated from   via force field and the 
velocities at time , can be determined by the equation 1.28 and 1. 29. 
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1.9.3 Velocity Verlet method 
The Velocity Verlet method gives position, velocity and acceleration at the same time in three 
steps. Knowing . To calculate the new velocities the positions at t+δt and at 
time t were first calculated using the equation  
 
).   Equation 1.30 
 
The velocities at time t+1/2δt are then determined using: 
 
    Equation 1.31 
 
The new forces are then calculated from the current position giving a(t+ δt).  The velocities at 
time (t+δt) using the equation below.  
 
   Equation 1.32 
 
The velocities at time  thus can be determined by the equation 1.30, 1.31 and 1.32. 
 
 
Figure 1.14: Stepwise view of the verlet integration algorithm and its variants. At each 
algorithm the dark and the light grey cells indicate the initial and calculating variables, 
respectively. The numbers in the cells represent the orders in the calculation procedures. 
The arrows point from the data used in the calculation of the variable that is being calculated 
each step (Becker.O, et al., 2001).  
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1.9.3 Beeman’s algorithm: 
The Beeman’s algorithm (Beeman 1976) is another algorithm which is related to the Verlet 
algorithm. It uses a more accurate expression for the velocity and therefore it produce better 
energy conservation because the kinetic energy is calculated directly from the velocities. 
These expressions are more complex and computationally more expensive to perform.  
 
1.10.  Starting, running, measuring and analysing simulation program:  
1.10.1 Starting:  
In order to start a simulation, it requires Newton’s equation (1.10) of motion with two initial 
values which are typically a set of coordinates (r0) and a set of initial velocities (V0). The initial 
coordinates are usually obtained mainly from the X-ray crystallography and NMR 
experiments. This information is sometimes not enough and therefore it undergoes further 
preparation. The hydrogen atoms in particular are not determined by the X-ray 
Crystallography and therefore they need to be assigned. Sometimes there are missing 
residues within which also need to be added; these often happen when there are loops within 
the structure. These loops are not very well identified during the experiments and thus not 
well captured by NMR or X-ray diffraction. At other times they reflect the part of the 
molecules which were removed intentionally to facilitate the crystallisation process.    
 
The initial velocities were not obtained from the experimental information. The only relevant 
information available about the atomic velocities was the system’s temperature T. The initial 
velocities were randomly assigned taking from the standard Maxwell distribution at a certain 
temperature T as shown below. 
 
     Equation 1.33 
 
      Equation 1.34 
 
Velocities are initially assigned at low temperature which is then gradually increased until the 
system achieves the desired temperature. While doing this the system will have a small 
linear momentum, corresponding to a translational motion of the whole system. This is not 
very appropriate and thus the velocity of each particle was subtracted from this component to 
operate in a zero total momentum condition.  
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1.10.2 Running:  
The first stage of the molecular dynamics simulation is the equilibration phase. This is carried 
out to bring the system to equilibrium. During this stage various parameters are closely 
observed and once the parameters achieve the stable conformation, the production phase is 
started. It is usually desired to run a MD at a specific temperature. Thus the velocity of the 
system is carefully scaled so that the temperature gradually reaches the desired 
temperature. Thus the same applies when the pressure of the system needs to be adjusted 
so as to run the MD at a particular pressure. Once the equilibrium is obtained, the next stage 
is the production phase. During the production stage the simulation of the protein is carried 
for the desired time length. During the production phase thermodynamic parameters are 
calculated and stored; careful monitoring of these properties during the simulation can show 
if the simulation was consistent or whether or not the simulation need to be restarted. The 
positions were also stored in regular time intervals from which other properties can be 
calculated once the simulation is completed.    
 
1.10.3 Measuring and analysing: 
When a protein complex is set for MD, it is important to check the root mean square 
deviation of the back bone of the protein to the initial structure. Too much deviation means 
that the protein has undergone too much change in the amino acid residues orientation 
whereas little deviation suggests the protein requires longer MD. In an ideal condition 
following the MD study the RMSD value should stay around 2 (Oliviero, et al., 2003). The 
other most commonly measured physical properties after a MD study are as follows:   
 
The average potential energy V is required to verify energy conservation during the MD 
study. For the two body interacting.  
  
     Equation 1.35 
  
 The Kinetic energy can be calculated using the equation: 
 
      Equation 1.36 
 
The total energy E is calculated as the sum of the potential energy and the kinetic energy in 
the system.  
 
         Equation 1.37 
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The temperature T, is directly related to kinetic energy (using the Equation 1.40 below) and 
thus can be obtained from the average kinetic energy K.   
     
        Equation 1.38 
 
A calorie curve using all these information after a MD study is helpful in understanding the 
overall change in these parameters throughout the simulation.  
 
1.11. Validation of models using Ramachandran Plot: 
A Ramachandran plot is the graphical representation in which the dihedral angle of rotation 
about the alpha-carbon to carbonyl-carbon bond (Figure 1.15) in polypeptides is plotted 
against the dihedral angle of rotation about the alpha-carbon to nitrogen bond. It is a 2-d plot 
of the φ- ψ torsion angles of the protein back bone.  It shows the possible conformations of φ 
and ψ angles for a polypeptide. Certain combinations of φ and ψ angles are ‘forbidden’ 
because they result in steric clashes between atoms or angle strains. The remaining plot 
corresponds to allowed conformation. Hence Ramachandran plots draw particular attention 
towards the unrealistic conformations in models. A Ramachandran plot is of particular 
importance to study the protein structure after a long molecular dynamics study. The number 
of the unfavourable clashes due to the improper torsion can be identified by the number of 
residues in the unfavourable region on the Ramachandran plot. 
 
 
Figure 1.15:  The phi-angle (φ) and the psi-angle (ψ) in a peptide unit. (Adapted from 
wiki.cmbi.ru.nl/index.php/File:Phipsi.jpg) 
 
As shown in the above figure 1.15, in the polypeptide the main chain N-Cα and Cα-C bonds 
are relatively free to rotate. As mentioned these rotations are represented by the torsion 
angles phi (φ) and psi (ψ), respectively. GN Ramachandran used computer models of small 
polypeptides to systematically vary and with the objective of finding stable conformations 
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(Ramachandran. G., et al.,. 1963). The structures were analysed and the conformations were 
monitored for close contacts between the atoms and the van der Waals interactions were 
studied. Thus the angles which result in the steric hindrance or collisions correspond to 
disallowed conformation of the polypeptide backbone. 
 
 
 
Figure 1.16:  Example of a Ramachandran plot.  
 
The diagram above is a representation of a Ramachandran plot where the white regions 
correspond to the residues with high steric hindrance and therefore are disallowed in a 
protein model. Disallowed regions generally involve steric hindrance between the side chain 
C methylene group and main chain atoms. Glycine residues lack a side chain and therefore 
can adopt phi and psi angles in all four quadrants of the Ramachandran plot. The dark region 
corresponds to the conformations of the residues with no steric clashes and is highly desired 
in a good quality model. The light grey areas shows the conformations of residues with little 
steric hindrance, these conformations are tolerable by the model. 
Procheck is one of the standalone computer packages in addition to the other web based 
packages (PDBSUM and WEBMOL) to calculate the torsional angles in the form of 
Ramachandran plot (Laskowski., et al., 2001). Unlike the other molecular dynamics program, 
Procheck checks the detailed stereochemical quality of the protein structure (Laskowski et 
al., 1993). It utilises the coordinate information of the atoms from a single snapshot of the 
molecular structure in the form of PDB file (Bernstein et al., 1977). The output or the results 
are available in the form of the pdf file readable in the Adobe system.  
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1.12.  Docking studies:  
Docking is a process by which the ligand or the inhibitor binds to the receptor site and they fit 
together appropriately in 3D space. Docking studies involves the posing, ranking and 
scoring. Posing involves the determination of the conformation and orientation of a ligand to 
fit appropriately into the active site. It is often a rough measurement of the ligand into the 
active site. Ranking enables more advanced study to estimate the binding free energy when 
the ligand binds to the active site. Both posing and ranking involve scoring. Scoring is a 
relative term and determined the placement of the ligand towards its ability to bind at the 
active site.  
 G  
Protein  [E]  Ligand [I]  Protein-Ligand complex [EI] 
 
Figure 1.17: Showing the binding of the ligand to the receptor.  
 
 
As shown in the above figure, binding of the ligand into the active site generates binding free 
energy G. The Gibbs free energy is then related to the binding constant. The G is 
calculated using the following equation:  
 
G = -RTLnKA       Equation 1.39 
       Equation 1.40 
 
Prediction of the correct posing do not require the KA information during the binding; this 
information is however important while scoring the ligands (Douglas. et al., 2004). 
 
1.13.1. Docking 
Docking is usually carried out to predict the binding mode of protein inhibitors. There are 
different types of algorithm available which are used to treat ligand flexibility and to some 
extent the protein flexibility.This is carried out using various search techniques. The ligand 
flexibility has been classified into three basic categories (Brooijmans, N, et al., 2003) which 
are systematic search, random search and molecular dynamics search methods.  
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The systematic search method or the incremental method finds the best possible fit of the 
ligand by identifying a set of interactions at the receptor site. This is then followed by 
fragmenting the ligands and then placing them into the active site and finally linking these 
fragments. The software which utilise this algorithms are DOCK and FlexX 
 
Molecular dynamics simulation technique can also be used to search for the best possible fit. 
However, these procedures may not be able to achieve the global minima and there often 
results the conformation in local minima (Brooijmans et al. 2003). Also molecular dynamics 
simulations involve longer time length and therefore often unable to cross high-energy 
barriers within feasible simulation time periods. Thus MD simulations are rarely used as 
stand-alone search techniques. 
 
The random search algorithm operates by producing random changes.  They have been 
classified into two widely used approaches i.e the Monte Carlo and the Genetic algorithm. In 
Monte Carlo algorithm, an initial set of configuration of ligands are created in the active site 
consisting of random conformation, translation and rotation. The initial configuration is then 
scored and a further new generation of conformation is generated and scored again. If the 
new solution scores better they are accepted immediately. If the solution is not a new 
minimum, Boltzmann based probability applies. If the solution passes the probability function 
test, it is accepted otherwise rejected.   
 
    
  
Figure 1.18:  The steps involved in the docking process. The targeted interactions were first 
identified. This is then followed by identifying the best possible fit.   
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Genetic algorithm (GA) is an optimization technique derived from the evolutionary theory 
(Holland, 1975). GA is widely used in finding the global minimum energy conformation of a 
molecule (Goldberg 1989). Today it is widely used in protein-ligand docking, molecular 
design, QSAR mapping and pharmacophore mapping (Cark. et al., 1996; Jones 1998; 
Judson 1997). The first step involved in GA is to create a population of possible solutions. 
This corresponds to the set of randomly generated conformations of the molecule. The initial 
population is most easily obtained by randomly generating the conformation. The torsional 
angle values were then assigned and then the internal energy of the molecules was 
calculated by the molecular mechanics studies. The new population is thus generated and 
this became the starting point for the generation of the new population for the next cycle 
(Leach, A 2001). The software such as Gold, Autodock, Cache etc uses genetic algorithm to 
rank the ligands.    
 
   
Figure 1.19: The traditional genetic algorithm (Goldberg 1989) designed to generate the 
initial population P(t) through a random selection process. (Chromosomes represent the 
conformation of the molecules). The next algorithm cycles through rounds of selection, 
recombination and recombination until the terminal conditions are met. (The terminal 
condition represents the internal energy) 
 
 While considering the [EI] (Figure 1.17) the steric hindrance, electrostatic force, hydrogen 
bonding and the strain on the inhibitor or the enzyme are of particular importance. This is 
accomplished by maximizing favourable interactions and minimizing unfavourable 
interactions between the two molecules. It is important to note that both the structure of the 
receptor and the ligand changes during the binding process in a real biological environment. 
In this investigation we carried out the docking studies under flexible condition of the receptor 
and the ligand. Another important feature about the docking studies is the ligand placement 
algorithm to enumerate and test possible poses for the ligand in the protein's active site. In 
this study we use ‘Project Leader’ that follows genetic algorithm based approach.  
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The genetic algorithm represents the states of the degrees of freedom of the ligand as a 
string of digits, and this string is referred to as a gene. A population of different genes is 
generated at random, and each is scored using the energy function. Genes are selected to 
form the next population based on their score, with better scoring genes more likely to be 
selected. A gene may be selected more than once, and some may not be selected at all. 
Pairs of the selected genes are allowed to cross over with each other. In this process, a 
segment of the gene is selected and the values in this range are exchanged between them. 
Hence the values are expected to be different each time the studies are carried out under 
similar conditions.     
 
1.13.2. Scoring Methods:  
As discussed earlier that algorithm is required to search the conformation of the ligand within 
the active site. It is also important to rank these conformations and this is perhaps the most 
critical side of docking studies. Scoring methods are generally the reflexions between the 
correct and incorrect conformation and therefore designing a reliable scoring function is 
important. Although the free energy simulation method can be used to predict the protein-
ligand interactions (Kollman. P., et al., 199; Simonson, T., et al., 2002), these techniques 
require expensive resources.  The use of entropic effect makes this scoring function simpler 
and hence can be used in evaluation of large number of protein ligand complexes. The 
binding of the ligand to the protein to form the ligand-protein complex takes place in the 
aqueous environment. The transfer from the solute state with complete separation of both 
reactants to the complexed state involves either enthalpic and entropic effects (Bohm, et al., 
1996) that contribute to the Gibbs free energy of binding. Thus the free energy can be written 
as: 
 
      Equation 1.41  
  
In the above equation rG is the free energy left once the ligand binds to the protein. It is 
defined as the mutual compensation of the enthalpy and the entropy.  rH is the enthalpy 
and counts for the hydrogen bonds, polar interaction, van der Waals interaction, etc. rS is 
the entropy and counts for loss of degree of freedom, gain of vibrational modes, and loss of 
solvation / protein structure at the binding site.   
 
Currently three types of scoring functions are in use which are force fields based scoring, 
empirical based and knowledge based scoring.  
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The force field based scorings are carried out by the sum of the internal energies such as the 
energy from the bond, angle, torsional (dihedral) angle, out of plane (improper) torsional, etc 
and the energies due to ligand receptor interactions. These can be represented as shown 
below (Douglas. et al., 2004).  
 
Epot = Ebond + Eangle + Etorsion + Eoop + Eelectrostatics + EvdW + Econstraint  Equation 1.42 
 
The drawback of the method is that this method does not include solvation and entropic 
terms. Also a cut off distance is generally maintained for the treatment of non bonded 
interactions making the calculations even more complicated. The hydrogen bondings are 
often used in different ways depending of the geometry of interactions (Verdonk. et al, 2003).   
 
The empirical scoring functions reproduce experimental data such as bindng energies, 
conformation a sum of several parameterised functions. The binding energies can be 
approximated by a sum of individual uncorrelated terms derived from experimental data (X-
ray structural information) (Douglas.et al. 2004).  Although the complex empirical scoring 
functions can address solvation and desolvation effects, however the terms provide only 
incomplete descriptions of these effects on protein-ligand binding (Wang. R.,et al. 1998)   
 
The knowledge based scoring or the PMF (Potential mean function) scoring of the protein 
ligand complexes are modelled using relatively simple interaction pair potential. The PMF 
scoring is the interaction potential of each atom pair in two molecules (eg. Ligand and 
protein) to approximate the free energy of each pairwise interactions as a function of their 
inter-atomic distance. This structural information is stored in databases of protein-ligand 
complexes to derive quick calculation of the atom pair interaction potentials (Muegge, I,et al., 
2000). The total energy for the protein-ligand complex is calculated by taking the sum of the 
PMF values of all interacting atoms. The major advantage of using the knowledge based 
scoring system is the computational simplicity and therefore it becomes possible to screen a 
large database of compounds (Douglas. B,et al., 2004). Cache workstation (Fujitsu) utilise 
PMF based scoring which has been used in this study. One disadvantage is that it is 
essentially based on the explicitly coded information in a limited set of protein-ligand 
complexes.  
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CHAPTER 2 
OPTIM IZATION OF AN INSILICO MODEL FOR MYCOBACTERIAL CHORISMATE 
MUTASE: THE COMPUTATIONAL APPROACH 
 
 
 
2.1 Aim: 
The aim of this work is to design a protein model for the enzyme mycobacterial chorismate 
mutase (MtCM) that can be used for ligand screening.   
 
2.2 Background:  
The crystal structure of the enzyme chorismate mutase (MtCM) from Mycobacterium 
tuberculosis (encoded by Rv1885c) was isolated and successfully determined at 1.6 Å 
(Okvist, Dey et al. 2006). Apart from the new topology of the dimeric structure of the enzyme, 
it has also revealed the entry of the ligand and its binding at the active site. This enzyme has 
followed simple Michaelis-Menten Kinetics (kcat of 50 s-1 and km of 180 µM) and provided a 
high quality model. This enzyme is involved in the pathogenesis of tuberculosis (Sasso, 
Ramakrishnan et al. 2005). In an assay to estimate the chorismate mutase activity of the 
enzyme from M. tuberculosis, over 15000 compounds were used and screen against the 
MtCM chorismate mutase by docking studies. Only 15 compounds have shown satisfactory 
results in the model and 4 compounds had good inhibitory response when tested against  
MtCM chorismate mutase (Agrawal, Kumar et al. 2007). This crystal structure of MtCM along 
with the known biologically active inhibitors of MtCM has opened an opportunity in designing 
inhibitor molecules against the deadly pathogen.  
 
2.3 Crystal structure of chorismate mutase from Mycobacterium tuberculosis: 
2.3.1 Background of chorismate mutase: 
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Table 2.1: The broad classification of chorismate mutase (Babu. et al., 2004).  
 
 
Chorismate mutase has been classified into three categories, the AroH, the prokaryotic AroQ 
class and the eukaryotic AroQ class. The tertiary structural folds of the AroQ class and the 
AroH class are completely unrelated, whereas the two types of AroQ can be structurally 
superimposed and the topology of the four-helix forming the active site is conserved (Lee, 
Stewart et al. 1995). Size exclusion chromatography revealed that the Mycobacterium 
tuberculosis chorismate mutase is a dimer (figure 2.2), and extensive biochemical and 
biophysical characterisation of the recombinant protein suggest that it is similar to the AroQ 
class of chorismate mutase (Qamra, Prakash et al. 2005). The annotated genome sequence 
of M. tuberculosis shows the presence of two reading frames Rv1885c and Rv0948c. Okvist 
and his co-worker in their investigation chose the secreted mycobacterial chorismate mutase 
encoded by frame Rv1885c in strain H37Rv and determined its crystal structure both in the 
unliganded form and in complex with a transition state analogue (Okvist, Dey et al. 2006). 
The PDB entries for these crystallographic models are 2FP1 and 2FP2.   
 
2.3.2 Structure of Mycobacterium Chorismate Mutase:  
The structure of the mycobacterium chorismate mutase has been revealed from the X-ray 
crystal structure determined at 1.6 Å (Okvist, Dey et al. 2006).  
 
 
AroQr AroH Prephenate Dehydrogenase
Prephenate 
Dehydatase
3-deoxy-D-arabino-
heptulosonate-7-
phosphate synthase
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Figure 2.1:  The X-ray crystal structure of the Chorismate mutase (2FP2.pdb) determined 
at 1.6 Å. 
 
 
The MtCM is a dimeric structure (Figure 2.1) and this is similar to the E. coli chorismate 
mutase (EcCM) and Saccharomyces cerevisiae chorismate mutase (ScCM) and the active 
sites are located at the interface of the two protomers with the formation of an allosteric 
binding site. The interesting feature about the mycobacterium chorismate mutase is that the 
active site is located only in the B-chain of the dimer chain and there is no such allosteric 
regulation associated from the other chain (Okvist, Dey et al. 2006).     
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Figure 2.2: Showing the ligand bound chain B. H1, H2, H3, H4, H5 and H6 represent the 
helices of the chain (2FP2.pdb).   
 
 
The chain consists of 6 α-helices which are arranged in groups of three. There is a disulphide 
bond between Cys160 of helix H5 and Cys193 of helix H6 thereby forming excellent 
hydrophobic packing in this part of the structure. Overall the structure of MtCM resembles the 
EcCM; the only difference is the H1, which is much longer in EcCM and the H3 which is one 
turn longer in MtCM (Okvist, Dey et al. 2006).   
 
 
2.4 Active site analysis:  
The active site of the enzyme was identified by comparing the chorismate mutase from yeast 
and E.coli (Xue, Y et al. 1995). The active site of the mycobacterial chorismate mutase 
(2FP2.pdb) is very similar to the active sites of the other class of the AroQ chorismate 
mutase particularly to EcCM and ScCM (Okvist, Dey et al. 2006).  
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A B 
 
Figure 2.3:  The active site within the TSA-2FP2 complex. The above conformation is the 
snap shot obtained in ‘CAChe’ directly from the crystal structure 2FP2.pdb. The active site 
was defined by selecting the amino acids within the 5 Å region of the TSA.  
 
 
The two Arg134 and Arg49, of EcCM and ScCM, which form a strong interaction with the 
carboxylate group of the ligand, have been observed even for M. tuberculosis chorismate 
mutase. Lys186 in mycobacterial chorismate mutase forms a hydrogen bond with the ether 
oxygen of the ligand. This corresponds to the Lys39 in EcCM and Lys168 in ScCM. Lys186 
also interacts with Glu235 alongside coordinating with the ether oxygen of the ligand (Figure 
2.3). Arg196 of the mycobacterium chorismate mutase coordinates a tightly bound water 
molecule bridging the two carboxylate groups of the ligand which is absent in all classes of 
AroQ chorismate mutase. All these interactions have been cited as crucial for the enzyme 
mechanism (Okvist, Dey et al. 2006). The glutamate residue (Glu235) was under debate for 
its enzymatic reaction. A positively charged residue is essential at the active site which is 
essential for the stabilization of the transitional state of the enzymatic chorismate 
rearrangement (Kast, P et al. 1996). It was also reported that this glutamate residue restricts 
the enzyme activity in acidic conditions (Schnappauf, Strater et al,. 1997). Also an intensive 
study of catalytic efficiency of the mycobacterial chorismate mutase suggests that the kcat 
increases on increasing the pH from 5 to 8, and km increases more dramatically by a factor of 
20 fold in the same range. Hence the catalytic efficiency kcat/km drops between pH 5 and pH 9 
(Sasso, Ramakrishnan et al,. 2005). These suggest that the glutamate residue (Glu235) 
should be protonated for the enzymatic reaction. Another important feature about this active 
site is that the cysteine residues are very close to each other and there is a disulfide bond 
between them. 
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2.5 The Ligands: 
A number of fundamental strategies were developed to design the best inhibitor for 
chorismate mutase; the principal strategy relies on enhancing the binding strength of the 
inhibitor at the binding site (Wolfenden, R 1976). All the previous approaches were based on 
the assumption that the isomerisation of chorismate to prephenate takes place through a 
transitional state or high energy intermediate resembling a bicyclic species and this is the 
structure that should be mimicked (Bartlett et al., 1988).  
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Chorismate        Transitional state species        Prephenate 
 
Figure 2.4:  The conversion of prephenate from chorismate through the transitional state.  
 
A number of the bicyclic diacids (Bartlett et al., 1988), and a series of aza inhibitors (Mark, 
E.et al., 2004) has been designed and screened for the chorismate activity. None of these 
compounds have shown sufficient inhibitory effect when compared to the endo oxabicyclic 
dicarboxylic acid (TSA).  
 
O
OH
O
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Figure 2.5:  The structure of the Transitional state analogue (TSA).  
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TSA has by far been the best mimic of the geometry of the transition state of the chorismate 
mutase catalysed reaction and is currently the best inhibitor for the broad range of 
chorismate mutases (Mandal and Hilvert 2003) including the Mycobacterium tuberculosis 
chorismate mutase (Sasso, Ramakrishnan et al. 2005). Therefore the work in this thesis has 
used TSA as an active ligand throughout the investigation. All the other ligands used in the 
current investigation were following the biological evaluation of the ligands carried out by 
Himanshu et. al (Agrawal, Kumar et al. 2007). Out of all the fifteen compounds tested by 
these authors for the chorismate mutase inhibitory activity against the Mycobacterium 
tuberculosis, four compounds have shown biological activity (Table 2.2).  
 
 
 
Table 2.2:  Published structures of biologically active ligands against MtCM (Agrawal, 
Kumar et al. 2007) 
 
The remaining eleven compounds (Table 2.3) evaluated for biological activities against 
MtCM were found to be inactive. Unfortunately there was not enough information available 
regarding seven of these eleven compounds particularly with regard to the configuration of 
their chiral centre and therefore they have been omitted from the current study.  
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Table 2.3:  List of all the inactive ligands following the biological evaluation by Himanshu 
et al. (Agrawal, Kumar et al. 2007). 
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One active Ligand, Ligand 3 also has three stereo centres and the configurations of the 
asymmetric centres have not been provided. Therefore in the current study to prepare a 
computer model of the X-ray crystal structure (2FP2.pdb) seven compounds have been used 
(Table 2.4).  
 
SL No Structures     Ki (nM) 
 
Ligand 1 
 
NO2H
N
H2NO2S COOHMeO
OMe
 
 
5.7±1.2 
 
Ligand 2 
 
Cl
H
MeO
MeO NO2
O
HO
 
17.71±3.35 
Ligand 4 
MeOOC NO2
NH
 
28.8±4.1 
Ligand 7 N
N
O
S
NH2
COO
 
Inactive 
Ligand 8 
N
N
Ph
H2NO2S COOH 
Inactive 
Ligand 9 
N
N N
N
(CH2)2
N
N
N
N
SMe
SMe
O
Me
O
Me
 
Inactive 
Ligand 13 
N
N N
N
(CH2)5
N
N
N
N
SMe
SMe
O
Me
O
Me
 
Inactive 
Table 2. 4:  The table above shows the list of ligands used in the current study. Ligand 1 
to Ligand 4 denotes the active ligands whereas Ligand 7 to Ligand 13 denotes the inactive 
ligands.   
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2.6 Computational approach:  
The computational approach was carried out by preparing the initial protein structure, 
preparing the ligands, setting up and running molecular dynamics, analyzing the protein 
models and docking studies.   
 
2.6.1 Preparing the initial protein structure: 
In the current investigation the X-ray crystal structure, 2FP2.pdb, of the Mycobacterial 
chorismate mutase (Okvist et al., 2006) was downloaded from the Protein Data Bank through 
the World Wide Web (www.pdb.org). The initial structure was prepared by removing all the 
extra information and the water molecules (HOH). This results in the preparation of a pdb file 
with only Cartesian coordinate’s information of the residues from chain A, Chain B and the 
ligand (TSA).  
 
There were also two disulfide bonds between the cystine residues (CYS) 160 and 193 in 
both Chain A and B. The cystine residues CYS were therefore manipulated to CYX; this was 
to facilitate Amber program to identify the disulfide bonds in this residues. 
 
SSBOND   1 CYS A  160    CYS A  193                          1555   1555  2.05 
SSBOND   2 CYS B  160    CYS B  193                          1555   1555  2.04 
 
The glutamic acid (GLU 109) in the active site was protonated (Okvist et al., 2006), this was 
not identified during the diffraction and therefore it was converted to GLH, to be identified as 
protonated by Amber. The next step in the preparatory step involves the addition of the 
missing residues from both the chain A and B as shown below.  
 
REMARK 465     M RES C SSSEQI                                                      
REMARK 465  ASP  A     34 
REMARK 465      GLY  A    35 
REMARK 465      PRO  A    125 
REMARK 465     GLU A    126 
REMARK 465     ASP  B     34 
REMARK 465      GLY  B     35 
REMARK 465     THR  B     36 
 
This process was carried out in Fujitsu Cache. Once the missing residues were added, the 
protein with the ligand was re-sequenced and saved as pdb file.  
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Scheme 2.1: Schematic representation of the model design.  
 
2.6.2 Preparing the initial Ligand structures: 
All the ligands from table 2.4 were prepared in Fujitsu CAChe workstation by drawing the 
structure and beautifying the ligands. These ligands were then set for conformation search 
using MM2 parameters and the geometry was then optimized using MOPAC PM3 
parameters. The final structures were then saved as pdb files.  
 
2.6.3 Generating the model: 
The model generation step involves various phases of study as shown in Scheme 2.1. A brief 
overview of the entire stages is also outlined in Appendix I. In this step the active site was 
first identified in the protein-ligand complex and this was carried out by identifying the 
neighbouring residues within the 5 Å regions. The ligand (TSA) was then removed and the 
protein was used for docking studies with a series of ligands (Table 2.4) with known 
biological activity.  
 
2.6.4 Phase I Study:  
In the Phase I study as shown in Scheme 2.2, docking studies were performed at least three 
times with the ligands from table 2.4 and the average scores were considered. The active 
Phase 1 
Molecular 
dynamics
Initial Model
Setting up 
Hypothesis
Stage 1
Phase 2 
Molecular 
dynamics
Phase 3 
Molecular 
dynamics
Stage 2
Final Model
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site was further refined by molecular dynamics study carried out at 1120ps on the TSA-
protein complex in Amber 9.  
 
 
 
Scheme 2.2: Schematic representation of the Phase I study. The docking studies were 
performed three times and the average docking scores were calculated.   
 
 
The pdb file (2FP2TSA.pdb) was prepared from the Cache file (2FP2TSA.csf). The ligand 
(TSA.pdb) was copied from the pdb file and the Antechamber program was used to identify 
the TSA.pdb as a ligand using the following command.   
 
$AMBERHOME/exe/antechamber -i TSA.pdb -fi pdb -o TSA.prepin -fo prepi -c bcc -s 
2 -nc -2 
$AMBERHOME/exe/parmchk -i TSA.prepin -f prepi -o TSA.frcmod 
 
 
The Xleap was then loaded, this creates a new sytem or working station for the molecular 
dynamics to run in Amber 9 using the ff99 force field.  
 
$AMBERHOME/exe/xleap -s -f $AMBERHOME/dat/leap/cmd/leaprc.ff99 
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Before loading the protein-ligand complex for the molecular dynamics process, it was 
important to parameterise the ligand and this was carried out by loading the TSA.prepin and 
the TSA.frcmod file using the following commands.   
 
source leaprc.gaff 
loadamberprep TSA.prepin 
loadamberparams TSA.frcmod 
 
 
Finally the protein-ligand complex was loaded using the following command. 
 
B=loadpdb 2FP2TSA.pdb 
 
Where B was the name of the complex. Once everything was loaded, the system was then 
checked with the command ‘check B’ to see if the parameters were correctly loaded. The 
sodium ions and water molecules were then added and the system was then saved using the 
following commands.   
 
addions B Na+ 0 
solvateoct B TIP3PBOX 8.0 
Saveamberparm B wat.prmtop wat.inpcrd 
Output file: wat.prmtop and wat.inpcrd 
 
The water molecules were explicitly used in the system by generating a box of water 
molecules within the 8.0 Å region of the protein (TIP3PBOX 8.0). Once the protein and 
ligands were prepared in the preparatory steps, the next step involves the molecular 
dynamics simulation studies on the protein-ligand complex.  
 
The simulation method was performed in three steps. The initial minimisation method was 
carried out using the following parameters. 
 
$AMBERHOME/exe/sander -O  -i min.in -o wat_min.out -p wat.prmtop -c wat.inpcrd -r 
wat_min.crd & 
 
Minimisation of complex (imin) 
 &cntrl 
  imin=1, maxcyc=2000, ncyc=1000, 
  cut=16, ntb=1, igb=0, ntr=0 
 / 
END 
END 
 
Input file: imin.in, wat.prmtop, wat.inpcrd 
Output file: wat_min.out, wat_min.crd 
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This performed (imin=1) 2000 steps (maxcyc), using a nonbonded cut off at 16 Å (cut), a 
generalised Born solvent model (igb=0), no periodic boundaries (ntb=1) and no position 
restrain (ntr=0).  
 
The next step was the molecular dynamics (MD1) study in constant volume which was 
carried out by gradually increasing the temperature to 300K over 20ps. This was carried out 
using the following command.  
 
 
nohup mpirun -np 2 $AMBERHOME/exe/sander.MPI -O -i md1.in -o wat_md1.out -p 
wat.prmtop -c wat_min.crd -r wat_md1.restrt -x wat_md1.mdcrd & 
 
MD heating 0 to 300K over 20 ps at CONSTANT VOLUME, no shake 
 &cntrl 
  imin    = 0,  (minimisation turned off) 
  irest   = 0, (we are not restarting out MD) 
  ntx     = 1, (first stage of MD), 
  ntb     = 1, (constant volume periodic boundaries), 
  cut     = 16, (use cutoff at 16 Å) 
  ntr     = 0, (no positional restraints), 
  ntc     = 1, (no shake), 
  ntf     = 1, (no shake), 
  igb     = 0 (generalised Born solvent model) 
  tempi   = 0.0,  (start temp), 
  temp0 = 300.0, (end temp), 
  ntt    = 3, 
  gamma_ln = 1.0, (langevin dynamic should be used to control temp), 
  nstlim = 20000, dt = 0.001 
  ntpr = 500, ntwx = 500, ntwr = 1000 (restart job after 1000 step) 
/ 
END 
END 
 
Input file : md1.in, wat.prmtop,  
Output file : wat_md1.out, wat_min.crd, wat_md1.restrt, wat_md1.mdcrd 
 
 
 
Once the molecular dynamics trajectory was achieved at 300K and the system reached 
equilibrium, the next molecular dynamics simulation (MD2) was carried out at constant 
pressure for initial 100ps and thereafter the step was repeated until the system achieved the 
desired conformations. The following commands were used for MD2 simulation. 
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nohup $AMBERHOME/exe/sander -O -i md2.in -o wat_md2.out -p wat.prmtop -c 
wat_md1.restrt -r wat_md2.restrt -x wat_md2.mdcrd & 
 
MD run const pressure (md2.in) 
 &cntrl 
  imin   = 0, 
  irest  = 1, 
  ntx    = 7, 
  ntb    = 2, 
  cut    = 16, 
  ntr    = 0, 
  ntc    = 1, 
  ntf    = 1, 
  igb    = 0 
  ntp    = 1 
  tempi  = 300.0, 
  temp0  = 300.0, 
  ntt    = 3, 
  gamma_ln = 1.0, 
  nstlim =100000, dt = 0.001 
  ntpr = 1000, ntwx = 1000, ntwr = 1000 
/ 
END 
END 
 
Input file:  md2.in, wat.prmtop, md1.restrt 
Output file: wat_md2.out, wat_md2.restrt, wat_md2.mdcrd 
  
 
The MD2 was carried out for initial 100ps and then for another 1000ps. Finally the protein-
ligand simulated complex at 1120ps was minimised and the output file (wat_md2_min.crd) 
was converted to the wat_md2_min.pdb.pdb file using the following commands 
 
 
Minimisation of the structure  
nohup mpirun -np 2 $AMBERHOME/exe/sander.MPI -O -i min2.in -o 
wat_md2_min.out -p wat.prmtop -c wat_md2.restrt -r wat_md2_min.crd & 
  
covnert the output file (wat_md2_min.crd) into pdb. 
$AMBERHOME/exe/ambpdb -p wat.prmtop < wat_md2_min.crd > wat_md2_min.pdb 
 
 
 The final pdb structure was then tailored by removing the water molecules and then 
visualised in Cache workstation. The active site was once again identified and the protein 
was used for docking studies (Scheme 2.2).  
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2.6.5 Phase II study: 
The schematic representation of the Phase II is given in Scheme 2.3. The TSA-ligand 
complex model following the Phase I molecular dynamics study at 1220 ps in Amber9 was 
set for docking with the inactive and active inhibitors in Phase II. The docked complexes 
were then set for further molecular dynamics in Amber 9 at 1220 ps. These complexes were 
then rescored in CAChe.   
 
 
 
Scheme 2.3:  Schematic representation of the Phase II study 
 
2.6.6 Phase III study: 
The schematic representation of the Phase III has been illustrated in the Scheme 2.4. Phase 
III study was also performed as an extension from Phase I study. The ligand docked 
complexes were set for geometry optimization studies in ‘CAChe Workstation Pro’. The 
geometry of the docked complexes was optimised in MOPAC using PM3 parameters. To 
obtain reasonable geometry optimization results in reasonable time, the optimization was 
controlled by gradually decreasing the gradient norm (GNORM). The GNORM was first set to 
100 (very crude optimization), and then to 10 (precise optimization) and 1 until a very precise 
optimization was achieved. Unfortunately GNORM 1 was not possible to obtain and therefore 
all the complexes were optimized at GNORM 10. These complexes were then re-scored.  
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Scheme 2. 4: The schematic representation of the Phase III study.  
 
The rHf (heat of formation) of the complexes and the independent enzyme and receptor 
were calculated and rHf of the binding was calculated using the following equation (2.1).  
  
rHf (binding) = rHf (complex) - rHf (enzyme) - rHf (ligand).   Equation 2.43 
 
Ligands Score GNORM 
10 Kcal/mol 
rHf 
(complex) 
Kcal/mol 
rHf (ligand) 
Kcal/mol 
rHf 
(enzyme) 
Kcal/mol 
rHf 
(binding) 
Kcal/mol 
      
Ligand 1 -435 -23344.70 -225.38 -22909.79 -209.53 
Ligand 2 -385.61 -23185.8 -109.25 -22909.79 -166.76 
Ligand 4 -303 -23131.2 -69.16 -22909.79 -152.25 
Ligand 7 -367 -23104.5 -48.08 -22909.79 -146.63 
Ligand 8 -437.23 -23151.9 -91.867 -22909.79 -150.243 
Ligand 9 -556.29 -23120.6 28.25 -22909.79 -239.06 
 
Table 2.5: Showing the calculation of the binding free energy when the ligand binds to the 
protein. The more negative is the energy, the more stable is the predicted binding.  
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2.7 Analyzing the models: 
The protein models following the molecular dynamics simulations were analyzed by plotting 
the changes in the temperature, pressure, kinetic energy,etc. This information was obtained 
by extracting the data from the trajectory ‘out’ files.  
 
The protein models were validated using a Ramachandran plot. This was carried out using 
the windows based software called Procheck (Ramachandran et al., 1963). The pdb files 
were used directly into the software to get the output files readable in Adobe Reader.   
 
2.7.1 Validation of models:   
To understand whether the models had withstood the rigorous condition during the molecular 
dynamics studies, validations of the models are essential. Validations of these models were 
carried out using Ramachandran plot (Ramachandran, G.R 1963). Essentially the errors that 
can be introduced in a protein model during their development and refinement may vary 
tremendously and these produce a significant change in the final model. (Kleywegt, G. et al. 
1995 and Brändén, C. et al. 1990). Therefore it was important to study the topology of the 
final protein structure with the help of Ramachandran plots before proceeding for further 
investigation. 
 
2.7.2 Ramachandran plot: 
Ramachandran plot is a two dimensional plot of the φ-ψ torsion angles of the polypeptides 
(Ramachandran, G.R 1963). The shading region on the plot represents the various φ-ψ 
torsional combinations (Morris et al. 1992) the dark region corresponds to the ‘Core’ region 
and represents the most favourable combinations. In an ideal situation and in a good protein 
model these regions should cover 90% of the residues. The proteins which were subjected to 
molecular dynamics studies were probed with Ramachandran plot with the help of the 
software ‘Procheck’ (Ramachandran, G.R 1963). The Figure 2.6 below shows the 
Ramachandran plot obtained at various intervals of the targeted model. The Figure 2.7 
shows the Ramchandran plot of the various Ligand-protein complexes following a MD study 
as shown in Scheme 2.3.  
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A. Plot of the x-ray crystal structure B. Plot after 1120ps 
 
 
C. Plot after 2120ps D. Plot after 12330ps 
 
Figure 2.6:  Ramachandran plots of the TSA-Protein complexes, where A is the plot from 
X-ray crystal structure, B is the plot following a MD study at 1120ps, C is the plot after a MD 
study at 2120ps and D is the plot after 12330ps.   
 
 
While it is important to know the percentage of the residues in the favoured region, it is also 
important to analyse the number of residues in the dis-allowed region in the Ramachandran 
plot.  
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Time interval in 
(ps) 
Resdues in 
most allowed 
region (%) 
Residues in 
additional 
allowed region. 
(%) 
Residues in 
generously 
allowed region 
(%) 
Residues in 
disallowed 
region. (%) 
     
0 95.9 4.1 0 0 
1120 93.2 6.8 0 0 
2120 90.9 9.1 0 0 
12330 91.6 8.0 0.4 0 
 
Table 2.6: Showing the distribution of the % of residues in Ramachandran plot of TSA-
Protein complex.   
 
At various time intervals during the molecular dynamics study the Ramachandran plots were 
carried out to identify any unwanted interactions within the model. In an attempt to carry out 
the dynamics study beyond 2120 ps, the Ramachandran plot has shown some residues in 
the unwanted regions.   
 
 
The protein-ligand complexes obtained following the MD studies from Phase 2 studies were 
also validated using the Ramachandran plot and each of these plots were shown in the table 
below.  
 
 
 
Ligand 1 – protein complex Ligand 2 – protein complex 
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Ligand 4 – protein complex Ligand 7 – protein complex 
 
 
 
 
 
Ligand 8 – protein complex Ligand 9 – protein complex 
 
Figure 2.7: Showing the Ramachandran plot of the ligand protein complex following the MD 
from Phase 2 studies.  
 
MD of Protein 
complexes at 
2240 ps  
Resdues in 
most allowed 
region (%) 
Residues in 
additional 
allowed region. 
(%) 
Residues in 
generously 
allowed region 
(%) 
Residues in 
disallowed 
region. (%) 
     
Ligand1-Protein 87.8 12.2 0 0 
Ligand2-Protein 91.6 8.4 0 0 
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MD of Protein 
complexes at 
2240 ps  
Resdues in 
most allowed 
region (%) 
Residues in 
additional 
allowed region. 
(%) 
Residues in 
generously 
allowed region 
(%) 
Residues in 
disallowed 
region. (%) 
     
Ligand4-Protein 86.5 13.5 0 0 
Ligand7-Protein 85.8 14.2 0 0 
Ligand8-Protein 88.5 11.5 0 0 
Ligand9-Protein 86.1 13.2 0.7 0 
 
Table 2.7: Showing the distribution of the residues in Ramachandran plot of the protein 
ligand complexes obtained in the Phase 2 studies at 2240ps. 
 
2.7.3 Analysis of the parameters.  
While the Ramachandran plot provides information on a particular conformational snapshot 
following the molecular dynamics studies, it is also important to get a clear picture of the 
protein model during the entire period of the molecular dynamics studies within the specified 
conditions; the changes in the model in presence of the various parameters need to be 
studied. The Graphs 2.1 to 2.4 below shows that the temperature, pressure, total kinetic 
energy (EKTOT) and total potential energy (EPTOT) from 0 to 2120 ps of the study 
maintained consistency and there was no unusual behaviour of the residues during the 
study.   
 
 
 
Graph 2.1: Variation in temperature through the MD simulation performed on the TSA-protein 
complex over 123300ps. 
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Graph 2.2: Variation in pressure through the MD simulation performed on the TSA-protein 
complex over 123300ps 
 
 
 
 
 
Graph 2.3: Variation in total potential energy (EPTOT) and total kinetic energy (EKTOT) 
through the MD simulation performed on the TSA-protein complex over 123300ps. 
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Graph 2. 4: Variation in total potential energy (EPTOT) and total kinetic energy (EKTOT) 
through the MD simulation performed on the TSA-protein complex over1120ps. 
 
 
 
 
 
 
Graph 2.5: Variation in EPTOT and EKTOT through the MD simulation performed on the 
ligand1-protein complex over 1120ps. 
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Graph 2.6: Variation in pressure through the MD simulation performed on the Ligand1-
protein complex over 1120ps. 
 
 
 
 
 
Graph 2.7: Variation in temperature through the MD simulation performed on the Ligand1-
protein complex over 1120ps. 
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Graph 2.8: Variation in EPTOT and EKTOT through the MD simulation performed on the 
Ligand2-protein complex at 1120ps. 
 
 
 
 
 
 
 
Graph 2.9: Variation in temperature through the MD simulation performed on the Ligand 2 -
protein complex over 1120ps. 
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Graph 2.10: Variation in pressure through the MD simulation performed on the Ligand2-
protein complex over 1120ps. 
 
 
 
 
 
 
 
 
Graph 2.11: Variation in EPTOT and EKTOT through the MD simulation performed on the 
Ligand4-protein complex at 1120ps. 
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Graph 2.12: Variation in pressure through the MD simulation performed on the Ligand 4-
protein complex over 1120ps. 
 
 
 
 
 
 
 
 
Graph 2.13: Variation in temperature through the MD simulation performed on the Ligand 4 -
protein complex over 1120ps. 
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Graph 2.14: Variation in EPTOT and EKTOT through the MD simulation performed on the on 
the Ligand7-protein complex at 1120ps. 
 
 
 
 
 
 
 
Graph 2.15: Variation in temperature through the MD simulation performed on the Ligand 7 -
protein complex over 1120ps. 
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Graph 2.16: Variation in pressure through the MD simulation performed on the Ligand 7-
protein complex over 1120ps. 
 
 
 
 
 
 
 
 
Graph 2.17: Variation in EPTOT and EKTOT through the MD simulation performed on the on 
the Ligand 8-protein complex at 1120ps. 
 
 
-1000
-500
0
500
0 200 400 600 800 1000
At
m
Time (ps)
Variation in pressure during the MD simulation 
of the Ligand 7-Protein complex
-300000
-250000
-200000
-150000
-100000
-50000
0
50000
100000
0 200 400 600 800 1000
K
ca
l/m
o
l
Time (ps)
Variation in energy parameters during MD 
study of the Ligand8-Protein complex
EKTOT EPTOT
The Computational approach.   2010 
 
P a g e  | 98  
 
 
 
 
 
 
Graph 2.18: Variation in pressure through the MD simulation performed on the Ligand 8-
protein complex over 1120ps. 
 
 
 
 
 
 
 
 
Graph 2.19: Variation in temperature through the MD simulation performed on the Ligand 8 -
protein complex over 1120ps. 
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Graph 2.20: Variation in EPTOT and EKTOT through the MD simulation performed on the on 
the Ligand 9-protein complex at 1120ps. 
 
 
 
 
 
 
Graph 2.21: Variation in pressure through the MD simulation performed on the Ligand 9-
protein complex over 1120ps. 
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Graph 2.22: Variation in temperature through the MD simulation performed on the Ligand 9 -
protein complex over 1120ps. 
 
2.7.4  RMSD analysis: 
Another key estimator of the structural similarity is the RSMD (Root mean square distance) 
calculation (Carugo, O et al., 2003). The RMSD of the final conformation in the model was 
also calculated from the zero-th conformation of the model structure and the average 
distance between the atoms was calculated. Since the initial crystal structure was 
determined at a very high resolution of 1.6 Å, it should have smaller RMSD value (Carugo, 
O. et al, 2003). It was observed that the RMSD values were increased when the molecular 
dynamics studies were performed at more than 1120ps (Graph 2.2.)       
 
 
Graph 2.23: RMSD changes of the TSA-protein complex during MD study at 12330ps.   
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Graph 2.24: RMSD changes of the Ligand1-protein complex during MD study at 1120ps 
during the Phase I study.   
 
 
 
 
 
 
 
 
Graph 2.25: RMSD changes of the Ligand2-protein complex during MD study at 1120ps 
during the Phase II study 
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Graph 2.26: RMSD changes of the Ligand4-protein complex during MD study at 1120ps 
during the Phase II study 
 
 
 
 
 
 
Graph 2.27: RMSD changes of the Ligand7-protein complex during MD study at 1120ps 
during the Phase II study 
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Graph 2.28: RMSD changes of the Ligand8-protein complex during MD study at 1120ps 
during the Phase II study 
 
  
 
Graph 2.29: RMSD changes of the Ligand9-protein complex during MD study at 1120ps 
during the Phase II study.  
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The docking studies carried out in this investigation were performed using the active site 
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the docking studies were carried out at least three times and the average scores were 
considered.  
 
Following a series of molecular modelling studies as shown in Scheme 2.2 of the Phase 1 
study, the ligands from table 2.4 were docked into the active site of the protein model 
obtained following a MD study on the TSA-protein complex at 1120ps. A brief overview of the 
steps employed to establish the targeted model using a flow diagram is shown in Appendix I. 
In the aim to establish the target model, attempts have also been made to perform MD study 
on the other biologically active ligand-protein complexes. These docking scores were laid out 
in Appendix II. Docking studies in the active site of the target model with each of the ligands 
were carried out at least three times and the docking scores collected were shown in Table 
2.8.  
 
Ligands        Ki (nM) PMF Score1 (Kcal/mol) 
PMF Score 2 
(Kcal/mol) 
PMF Score 3 
(Kcal/mol) 
Average score 
(Kcal/mol) 
Ligand 1 5.7±1.2 -330.19 -496.8 -413 -413.33 
Ligand 2 17.71±3.35 -257.73 -415.12 -402.35 -358.4 
Ligand 4 28.8±4.1 -215.41 -384.65 -332.08 -310.71 
Ligand 7 Inactive -422.8 -358 -405 -395 
Ligand 8 Inactive -330.45 -262.77 -195.86 -263.02 
Ligand 9 Inactive 120.60 -20.90 -10.5 29.73 
Ligand 13 Inactive -309.553 -296.49 -263.79 -289.94 
TSA 
 
-398.4 -386.2 -374.08 -386.2 
 
Table 2.8:  Showing the docking score of the ligands.   
 
2.8.1 Docking scores results:  
Scoring was carried out to rank the placement of the ligands to one another. In an ideal 
situation the most active ligand would score most negative while the less active would score 
more positive. The overall idea for the computer model was to produce docking scores that 
will reflect the possibility of the biological activity of the ligands used in the docking study to 
the maximum extent.  All the ligands were designed by studying the interactions within the 
active site. 
 
Okvist, et al., in the earlier research have successfully illustrated the entry of the TSA 
(Transitional state analogue) into the active site and also have determined the interaction of 
the TSA within the active site. As shown in Figure 2.3, within the active site Lys60, Arg49, 
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Arg 72 Glu106 and Glu109 were involved in the most interactions with the ligands. Ligand 1 
has been so far reported to be the most active compound against the MtCM (Agrawal, Kumar 
et al. 2007) after TSA. In the current model, Ligand 1 has also successfully produced 
docking scores which were much negative than other active ligands including TSA. 
Therefore in the current investigation Ligand 1 was manipulated with several substituent 
(Figure 2.8) depending on the availability of space within the active sites.      
 
N
H
NO2
O
OH
O
O
S
NH2 O
O
A C B
 
 
Figure 2.8:  Showing the Ligand 1 and A, B and C points to the targets where the variations 
have been made to design various ligands.  
 
In the aim to design inhibitors for the model the A, B and C part of the Ligand 1 was modified, 
as shown in Figure 2.5. The nitro and nitroso groups can serve as close analogues of 
carboxylic substrates for enzymes and also that the nitro group is more electronegative than 
the carboxylic group may serve as a better analogue of Ligand 1( Alston, T. 1983). Therefore 
in this study the carboxylic group was modified with a nitro group. The sulphonamide group is 
an electron withdrawing species and therefore was also attempted to substitute with the nitro 
group. Interestingly S-(-)-dinitrobiphenic acid has shown interesting chorismate mutase 
activity from E.coli, B.subtilis and S.cerevisiea (Husain, A 1999). Therefore in this work the 
ligand was modified with two nitro groups. The sulphonamide chain was also increased by 
incorporating some methyl groups, such as N-methyl sulphonamide. The linkage between 
the two chains was also modified by substituting with amino or amide groups, however the 
distance between the two rings was left untouched. Since the methoxy groups have shown 
good intermolecular and intramolecular hydrogen bonding, in this work the ring B of ligand 1 
(Figure 2.8) was also substituted with hydroxyl groups. At the same time these fragments 
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were also used separately and docked into the active site. These new ligands were docked 
at least three times, scored and their orientations at the active sites were studied. 
 
R10
"
R5
R1 R2
R4
R3
R6
R7
R8
R9
 
Ligands R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 
Ligand 16 NO2 NO2 OCH3 OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 17 CO2 NO2 OH OH SO2NH2 H CH2 CH2 H NH 
Ligand 18 CO2 NO2 CH2OH CH2OH SO2NH2 H CH2 CH2 H NH 
Ligand 19 CO2 NO2 OCH3 CH2OH SO2NH2 H CH2 CH2 H NH 
Ligand 20 CO2 NO2 OCH3 OCH3 CO2NH2 H CH2 CH2 H NH 
Ligand 21 CO2 CO2 OCH3 OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 22 CO2 NO2 OH OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 23 CO2 NO2 H OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 24 CO2 NO2 H OCH3 SO2NH2 OH CH2 CH2 H NH 
Ligand 25 CO2 NO2 H OCH3 SO2NH2 NH2 CH2 CH2 H NH 
Ligand 26 CO2 NO2 H OCH3 SO2NH2 OCH3 CH2 CH2 H NH 
Ligand 27 NO2 NO2 H OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 28 CO2 NO2 OCH2CH3 H SO2NH2 OCH2CH3 CH2 CH2 H NH 
Ligand 29 NO2 NO2 OH OH SO2NH2 H CH2 CH2 H NH 
Ligand 30 CO2 NO2 OCH3 OCH3 SO2NH2 OCH3 CH2 CH2 H NH 
Ligand 31 CO2 CO2CH3 OCH3 OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 32 CO2 CH2NO2 OCH3 OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 33 CO2 CO2CH3 OCH3 OCH3 SO2NH2 H CH2 CH2 H NH 
Ligand 34 CO2 NO2 OCH3 OCH3 SO2NHCH3 H CH2 CH2 H NH 
Ligand 35 CO2 NO2 OCH3 OCH3 SO2NH2 H CH2  H NH 
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Ligands R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 
Ligand 36 CO2 NO2 OH H SO2NH2 OH CH2 CH2 H NH 
Ligand 37 CO2 NO2 OCH3 OCH3 SO2NH2 H CH2 CH2 H NCH3 
Ligand 38 CO2 NO2 OCH3 OCH3 SO2NH2 H N CH2 H NH 
Ligand 39 CO2 NO2 OH OH SO2NH2 H N CH2 H NH 
Ligand 40 CO2 NO2 H H SO2NH2 OCH3 N CH2 OCH3 NH 
Ligand 41 NO2 CO2 OH OCH3 SO2NH2 H N CH2 H NH 
Ligand 42 CO2 NO2 H OCH3 SO2NH2 OCH3 CH2 CH2 H NH 
Ligand 43 CO2 NO2 OH OH SO2NH2 OH CH2 CH2 H NH 
Ligand 44 CO2 NO2 OCH3 OCH3 SO2NH2 OCH3 CH2 CH2 H NH 
Ligand 45 CO2 NO2 OH OH NO2 H CH2 CH2 H NH 
Ligand 46 CO2 NO2 OH OH SO2NH2 H CO CH2 H NH 
Ligand 47 CO2 NO2 OH OH SO2NH2 H N CO H NH 
Ligand 48 CO2 NO2 OH OH SO2NH2 H CO CH2 H NH 
Ligand 49 NO2 NO2 OH OH SO2NH2 H CO CH2 H NH 
Ligand 50 CO2 NO2 OH OH NO2 H CH2 CH2 H NH 
Ligand 51 CO2 NO2 OCH3 OCH3 NO2 H CH2 CH2 H NH 
Ligand 52 CO2 NO2 OH H NO2 H CH2 CH2 H NH 
Ligand 53 CO2 NO2 OH OH NO2 OH CH2 CH2 H NH 
Ligand 54 CO2 NO2 OH OH NO2 H CH2 CH2 OH NH 
Ligand 55 CO2 NO2 H OCH3 NO2 H CH2 CH2 H NH 
Ligand 56 CO2 NO2 OH OH NO2 H CH2 CH2 OH NH 
Ligand 57 CO2 NO2 H OCH3 NO2 OCH3 CO CH2 H NH 
Ligand 58 CO2 NO2 OCH3 OCH3 SO2NH2 H CO CH2 H NH 
Ligand 59 CO2 NO2 OH OH SO2NH2 H N CO H NH 
Ligand 60 CO2 NO2 OH OH NO2 H N CO H NH 
Ligand 61 CO2 NO2 OCH3 OCH3 NO2 H N CO H NH 
Ligand 62 CO2 NO2 OCH3 OCH3 SO2NH2 H N CO H NH 
Ligand 63 CO2 NO2 OCH3 OCH3 SO2NH2 H N CH2 H NH 
Ligand 64 CO2 NO2 OCH3 OCH3 NO2 H N CH2 H NH 
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Ligands R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 
Ligand 65 CO2 NO2 OH OH SO2NH2 H N CH2 H NH 
Ligand 66 CO2 NO2 OH OH NO2 H N CH2 H NH 
Ligand 67 CO2 NO2 H OCH3 NO2 H N CH2 H NH 
Ligand 68 CO2 NO2 H OCH3 SO2NH2 H N CH2 H NH 
Ligand 69 CO2 NO2 H OCH3 NO2 H N CO H NH 
Ligand 70 CO2 NO2 H OCH3 SO2NH2 H N CO H NH 
Ligand 71 CO2 NO2 OH OH NO2 H N CO H NH 
Ligand 72 CO2 NO2 H OCH3 NO2 H CO CH2 H NH 
Ligand 73 CO2 NO2 H OCH3 SO2NH2 H CO CH2 H NH 
Ligand 74 CO2 NO2 OH OH SO2NH2 H CO CH2 H NH 
Ligand 75 CO2 NO2 H H SO2NH2 H CH2 CH2 H NH 
 
Table 2.9:  Ligands designed as analogue of Ligand 1.  
  
N
SO2NH2
NO2HOOC
R1
R2R3
R4
R5
 
Ligands R1 R2 R3 R4 R5 
Ligand 76 CH N CH OCH3 H 
Ligand 77 N CH CH OCH3 H 
Ligand 78 CH N CH OCH3 OCH3 
Ligand 79 CH CH N H OCH3 
Ligand 80 CH N CH H H 
 
Table 2. 10:  Analogues of ligand 1 containing a pyridyl moiety.  
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Ligand 2 was the next potentially active mycobacterial chorismate mutase inhibitor. 
Interestingly the ligand carries structural similarity to ligand 1. This ligand was also modified 
and some of the analogues designed were illustrated in the table below.  
 
O
O
O2N
HOOC R1
R2
 
Ligands R1 R2 
Ligand 81 H H 
Ligand 82 H tert-butyl 
Ligand 83 tert-butyl H 
 
Table 2.11: Showing the various ligands designed as analogue of Ligand 2. 
 
 Ligand 1 contains two ring systems and therefore it was also essential to study the 
interactions of the substituents more closely.  The ligand was fragmented and the fragments 
were also modified (Table 2.12) to study the interactions more closely.  
O2N
MeO
COOH
SO2NH2
 
NO2
CH2OCH3
SO2NH2
 
SO2NH2
NHCH3
CH2COCH3
HOOC
 
Ligand 86 
 
Ligand 85 
 
Ligand 87 
 
NH2
OMe
OMe
 OMe
NO2
SO2NH2
 
NH2
SO2NH2
NO2HOOC
 
Ligand 89 Ligand 84 Ligand 88 
   
Table 2.12: Showing the list of the fragments used to study the interactions within the active 
site.   
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The ligand 1 when docked into the active site was observed in a folding fashion. Thus to 
facilitate the interactions within the active site, the folded pattern of the ligand was locked and 
the following ligands were produced.  
  
SO2NH2
HOOC NO2
N
O
CH2OH
OH
 
SO2NH2
HOOC NO2
N
O
OMe
OMe
 
Ligand 90 Ligand 91 
N
NO2
SO2NH2
CH2
C
H2O
O
O
O
CH2
 
N
NO2
SO2NH2
CH2
C
H2O
O
O
O
CH2
CH2
 
Ligand 93 Ligand 92 
 
Table 2.13: Showing the list of analogues of Ligand 1 where the folding pattern of the ligands 
was fixed.  
 
All the ligands shown in the table 2.9, 2.10, 2.11, 2.12 and 2.13 were docked into the active 
site and the docking scores were obtained as shown in the table 2.14 below.  
 
Compounds Dock 1 Kcal/mol 
Dock 2 
Kcal/mol 
Dock 3 
Kcal/mol 
Average Score 
Kcal/mol 
     
TSA -402 -367 -385 -385 
Ligand 1 -533 -336 -501 -456 
Ligand 2 -464 -450 -348 -421 
Ligand 4 -407 -422 -405 -411 
Ligand 7 -347 -367 -348 -354 
Ligand 8 -350 -455 -384 -396 
Ligand 9 -303 -164 -432 -299 
Ligand 16 -438 -472 -328 -413 
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Compounds Dock 1 Kcal/mol 
Dock 2 
Kcal/mol 
Dock 3 
Kcal/mol 
Average Score 
Kcal/mol 
     
Ligand 17 -456 -496 -494 -482 
Ligand 18 -478 -400 -205 -361 
Ligand 19 -361 -428 -359 -383 
Ligand 20 -298 -483 -523 -435 
Ligand 21 -429 -405 -381 -405 
Ligand 22 -512 -423 -502 -479 
Ligand 23 -507 -248 -531 -429 
Ligand 24 -384 -539 -486 -470 
Ligand 25 -477 -358 -490 -442 
Ligand 26 -570 -390 -356 -439 
Ligand 27 -420 -349 -495 -421 
Ligand 28 -469 64 -266 -224 
Ligand 29 -337 -458 -499 -431 
Ligand 30 -276 -509 42 -248 
Ligand 31 0 -432 -450 -294 
Ligand 32 -409 -390 -453 -417 
Ligand 33 -409 -394 -316 -373 
Ligand 34 -403 -459 -331 -398 
Ligand 35 -376 -345 -384 -368 
Ligand 36 -437 -437 -287 -387 
Ligand 37 -412 -412 -412 -412 
Ligand 38 -461 -552 -476 -496 
Ligand 39 -454 -222 -492 -389 
Ligand 40 -508 -302 -484 -431 
Ligand 41 -537 -458 -390 -462 
Ligand 42 -263 -472 -471 -402 
Ligand 43 -538 -293 -469 -433 
Ligand 44 -391 -414 -452 -419 
Ligand 45 -275 -359 -431 -355 
Ligand 46 -396 -224 -431 -350 
Ligand 47 -439 -481 -417 -446 
Ligand 48 -439 -447 -414 -433 
Ligand 49 -442 -464 -423 -443 
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Compounds Dock 1 Kcal/mol 
Dock 2 
Kcal/mol 
Dock 3 
Kcal/mol 
Average Score 
Kcal/mol 
     
Ligand 50 -507 -422 -486 -472 
Ligand 51 -498 -91 -496 -362 
Ligand 52 -485 -486 -437 -469 
Ligand 53 -407 -497 -498 -467 
Ligand 54 -435 -408 -448 -430 
Ligand 55 -307 -340 -445 -364 
Ligand 56 -478 -445 -525 -483 
Ligand 57 -523 -380 -285 -396 
Ligand 58 -223 -446 -409 -359 
Ligand 59 -469 -436 -416 -440 
Ligand 60 -406 -395 -491 -431 
Ligand 61 -513 -129 -452 -365 
Ligand 62 -420 -371 -410 -400 
Ligand 63 -440 -412 -474 -442 
Ligand 64 -488 -384 -512 -461 
Ligand 65 -256 -425 -392 -358 
Ligand 66 -301 -400 -432 -378 
Ligand 67 -456 -446 -345 -416 
Ligand 68 -267 -401 -397 -355 
Ligand 69 -347 -502 -474 -441 
Ligand 70 -492 -475 -452 -473 
Ligand 71 -498 -442 -448 -463 
Ligand 72 -370 -280 -446 -365 
Ligand 73 -428 -436 -461 -442 
Ligand 74 -455 -473 -474 -467 
Ligand 75  -439 -447 -461 -449 
Ligand 76 -305 -422 -429 -385 
Ligand 77 -447 -515 -392 -451 
Ligand 78 -334 -457 -488 -426 
Ligand 79 -440 -226 -369 -345 
Ligand 80 -437 -437 -287 -387 
Ligand 81 -427 -431 -424 -427 
Ligand 82 -233 -413 -432 -359 
The Computational approach.   2010 
 
P a g e  | 113  
 
Compounds Dock 1 Kcal/mol 
Dock 2 
Kcal/mol 
Dock 3 
Kcal/mol 
Average Score 
Kcal/mol 
     
Ligand 83 -438 -492 -497 -476 
Ligand 84 -502 -479 -484 -488 
Ligand 85 -247 -403 -361 -337 
Ligand 86 -445 -444 -396 -428 
Ligand 87 -431 -194 -437 -354 
Ligand 88 -194 -354 -336 -295 
Ligand 89 -263 -472 -471 -402 
Ligand 90 -420 -347 -392 -386 
Ligand 91 -403 -382 -396 -394 
Ligand 92 -380 -314 -242 -312 
Ligand 93 -415 -351 -390 -385 
 
Table 2.14:  The docking scores of the designed ligands carried out on the target protein 
model.   
 
A set of the original 56,000 Maybridge compounds was selected using a pharmacophore 
diversity based approach (Rathbone, personal communication). All these 260 ligands were 
isolated which had diverse structures and were used for docking studies within the active site 
of the model. The average score of three consecutive docking scores were shown in the 
Table 2.15 below.  
  
Compound PMF score Kcal/mol Compound 
PMF score 
Kcal/mol 
    
Ligand 94 903.809 Ligand 211 -503.106 
Ligand 95 -289.859 Ligand 212 -432.588 
Ligand 96 -370.758 Ligand 213 -387.079 
Ligand 97 -404.065 Ligand 214 -211.099 
Ligand 98 -423.719 Ligand 215 -217.48 
Ligand 99 -352.42 Ligand 216 -275.017 
Ligand 100 -433.188 Ligand 218 -313.248 
Ligand 101 -366.871 Ligand 219 -66.191 
Ligand 102 -368.085 Ligand 220 -250.647 
Ligand 103 -388.601 Ligand 221 -234.052 
Ligand 104 103.283 Ligand 222 346.73 
Ligand 105 -188.97 Ligand 223 -207.314 
The Computational approach.   2010 
 
P a g e  | 114  
 
Compound PMF score Kcal/mol Compound 
PMF score 
Kcal/mol 
    
Ligand 106 -333.87 Ligand 224 -216.269 
Ligand 107 5885.056 Ligand 225 59.399 
Ligand 108 -264.047 Ligand 226 -247.22 
Ligand 109 -307.483 Ligand 227 -453.834 
Ligand 110 4856.811 Ligand 229 -273.724 
Ligand 111 -300.456 Ligand 230 456.214 
Ligand 112 -382.258 Ligand 231 -328.143 
Ligand 113 -646.085 Ligand 232 -332.942 
Ligand 114 -426.009 Ligand 233 -480.885 
Ligand 115 -442.108 Ligand 234 -297.012 
Ligand 116 -413.204 Ligand 235 -189.643 
Ligand 117 -237.543 Ligand 236 -405.088 
Ligand 118 -349.447 Ligand 237 -170.258 
Ligand 119 -264.683 Ligand 238 -396.21 
Ligand 120 517.59 Ligand 239 -353.808 
Ligand 121 -450.52 Ligand 240 -110.18 
Ligand 122 -303.779 Ligand 241 -317.626 
Ligand 123 -527.327 Ligand 242 -330.445 
Ligand 124 -631.255 Ligand 243 -206.029 
Ligand 125 -546.48 Ligand 244 -341.858 
Ligand 126 -230.249 Ligand 245 -462.645 
Ligand 127 -488.645 Ligand 246 -157.58 
Ligand 128 -296.453 Ligand 247 -264.888 
Ligand 129 -162.865 Ligand 248 -384.475 
Ligand 130 120.337 Ligand 249 -396.179 
Ligand 131 -377.085 Ligand 250 60.086 
Ligand 133 -464.22 Ligand 251 -411.724 
Ligand 134 233.1 Ligand 252 -293.691 
Ligand 135 -276.439 Ligand 254 -471.139 
Ligand 136 -53.831 Ligand 255 -534.7 
Ligand 137 -451.355 Ligand 256 -307.348 
Ligand 138 -246.807 Ligand 257 -162.041 
Ligand 139 -108.349 Ligand 258 -339.091 
Ligand 140 -211.143 Ligand 259 -199.996 
Ligand 141 -262.27 Ligand 260 -139.407 
Ligand 142 -577.53 Ligand 261 -399.476 
Ligand 143 -410.703 Ligand 262 -407.999 
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Compound PMF score Kcal/mol Compound 
PMF score 
Kcal/mol 
    
Ligand 144 -367.269 Ligand 263 -357.301 
Ligand 145 -337.978 Ligand 264 -425.224 
Ligand 146 -262.69 Ligand 265 -147.716 
Ligand 147 -236.638 Ligand 266 -518.084 
Ligand 148 -318.823 Ligand 267 -200.616 
Ligand 149 89.489 Ligand 268 -153.544 
Ligand 150 -399.989 Ligand 269 -189.727 
Ligand 151 -508.814 Ligand 271 -217.007 
Ligand 152 -448.471 Ligand 272 -446.237 
Ligand 153 -315.915 Ligand 273 -453.142 
Ligand 154 -262.519 Ligand 274 -266.539 
Ligand 155 -316.276 Ligand 276 384.478 
Ligand 157 -256.367 Ligand 277 -484.746 
Ligand 158 -353.222 Ligand 278 -247.428 
Ligand 159 -402.188 Ligand 279 -172.754 
Ligand 160 -501.993 Ligand 280 -230.871 
Ligand 162 -485.757 Ligand 281 -217.327 
Ligand 163 -270.047 Ligand 282 -308.769 
Ligand 164 -415.77 Ligand 283 -202.429 
Ligand 165 -465.685 Ligand 284 -339.646 
Ligand 166 -291.715 Ligand 285 -351.383 
Ligand 167 -423.912 Ligand 286 -326.243 
Ligand 168 -393.311 Ligand 287 -276.71 
Ligand 169 -441.17 Ligand 289 -434.703 
Ligand 171 -243.313 Ligand 290 -186.222 
Ligand 172 -401.559 Ligand 291 -252.54 
Ligand 173 -234.007 Ligand 292 -406.386 
Ligand 174 -374.444 Ligand 293 -333.132 
Ligand 175 2057.602 Ligand 295 -300.264 
Ligand 176 -234.631 Ligand 296 -438.455 
Ligand 177 -289.372 Ligand 297 -391.53 
Ligand 178 -295.651 Ligand 298 -238.05 
Ligand 179 -331.766 Ligand 299 -380.009 
Ligand 180 -342.5 Ligand 300 -339.46 
Ligand 181 -346.86 Ligand 301 -356.298 
Ligand 183 -530.58 Ligand 302 -394.023 
Ligand 184 -246.405 Ligand 303 -408.315 
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Compound PMF score Kcal/mol Compound 
PMF score 
Kcal/mol 
    
Ligand 185 874.544 Ligand 304 -284.57 
Ligand 186 -107.315 Ligand 305 -290.941 
Ligand 187 -163.381 Ligand 306 -238.199 
Ligand 188 -375.039 Ligand 309 -240.694 
Ligand 189 -460.787 Ligand 310 -183.745 
Ligand 190 -462.195 Ligand 313 -320.875 
Ligand 191 339.762 Ligand 314 -282.372 
Ligand 192 -318.697 Ligand 315 -166.965 
Ligand 193 -292.64 Ligand 316 -184.27 
Ligand 194 -508.736 Ligand 317 -261.56 
Ligand 195 -279.02 Ligand 318 -285.319 
Ligand 196 -312.582 Ligand 319 -268.762 
Ligand 197 -510.686 Ligand 320 -228.665 
Ligand 198 -279.421 Ligand 321 -352.863 
Ligand 199 -378.74 Ligand 322 -287.753 
Ligand 200 -398.113 Ligand 323 -273.305 
Ligand 201 -631.172 Ligand 324 3373.438 
Ligand 202 -183.187 Ligand 325 -287.861 
Ligand 204 -467.787 Ligand 326 -455.688 
Ligand 205 -526.051 Ligand 327 -365.032 
Ligand 206 -387.601 Ligand 328 Not found 
Ligand 207 -232.137 Ligand 329 -373.639 
Ligand 208 -500.701 Ligand 330 -455.089 
Ligand 209 -323.651 Ligand 331 -361.732 
Ligand 210 -371.257 Ligand 332 -347.454 
 
Table 2.15: The docking scores following the docking studies carried out with the Maybridge 
compounds using the target protein model.  
 
2.9 Identifying the interactions:  
The orientation of the ligand within the active site was carefully studied and it was observed 
that in majority of the docking studies particularly the target model (obtained at 1120ps 
following the MD study on the TSA-protein complex) Arg 260, Lys 186 and Glu 235 
interacted with the ligand in a similar fashion forming a triangular space within the receptor 
site (Figure 2.10a-d). TSA, when docked within this protein model, exhibited a similar pattern 
of orientation as found initially within the X-ray crystal structure (Figure 2.9). Lys 186 
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undergoes a hydrogen bonding with all of the active ligands. This interaction was also found 
within the X-ray crystal structure containing the TSA (Lys60 as in Figure 2.3). Therefore 
hydrogen bonding with Lys186 was deemed essential in the active site. 
 
   
 
TSA-protein  Ligand1-protein 
 
 
Ligand2-protein Ligand4-protein 
 
 
Ligand7-protein Ligand8-protein 
 
 
Ligand9-protein Ligand13-protein 
  
Figure 2.9: Two dimensional view (using the software ‘Ligand Scout’ )of the ligand interacting 
with the residues within the active site model obtained at 1120ps following a MD study of the 
TSA-protein complex (scheme 2.2). 
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(a)         TSA (b)          Ligand 1 
  
(c)        Ligand 2 (d)        Ligand 4 
  
(e)           Ligand 7 (f)            Ligand 8 
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(g)       Ligand 9 (h)              Ligand 13 
Figure 2.10:  The 3D view using ‘DS visualiser 2’, of the ligand interacting with the residues 
within the active site of the target model obtained at 1120ps following a MD study of the TSA-
protein complex (scheme 2.2). 
 
No analogues of TSA exhibited equivalent interactions as observed with TSA (Hediger, M. et 
al,. 2004). In contrast Ligand 1 in this study exhibited interactions with the protein of a similar 
nature to that seen with TSA. Ligand 1 is an open chain ligand and has shown interaction 
within the active site of this model through a folding pattern. This pattern of folding followed 
by the interactions was mediated by Arg 175 with the nitro and the oxygen of methoxy group 
of Ligand 1 (Figure 2.10b).  
 
An exception to this was the Ligand 2. This ligand had a chlorine atom attached to the phenyl 
ring and this ligand remained unfolded upon docking. On repeated docking of this ligand, it 
was observed that 2 out of three times the chlorine stayed within the active site leaving the 
methoxy benzyl part of the molecule toward the surface. The chlorine part of the molecule 
tended to stay within the active site forming a straight conformation as shown in Figure 
2.10c. The chlorine within the active site interacted with Glu235 and Thr231 whereas the 
nitro formed hydrogen bonds with Arg260.  
 
Most of the inactive ligands had shown less negative docking scores in comparison to the 
active ligands. Also the interactions with Arg 260, Lys 186 and Glu 235 which were 
preserved in the active ligands were found absent with the inactive ligands. Hydrogen 
bonding with Lys186 was absent in most of the inactive ligands (Figure 2.7e-h). Also the 
folding pattern was absent with these ligands although the ligands has more than one ring 
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system. One exception to these is the Ligand 13. It was difficult to fit this ligand into this 
model as the ligand was a large molecule with a large interacting surface and plenty of 
interacting groups. Therefore in the current investigation Ligand 13 was excluded from the 
study. In fact the study has rejected any large molecule. Ligands which are small in size 
including ligands containing more than one ring system were included in the study.     
 
2.10 Discussion:  
Chorismate mutase is known to act as a dimer (Figure 2.1) (Okvist et al, 2003) and perhaps 
the surface binding of one monomer to another has some influence on the three dimensional 
shape of the monomer and this may affect the three dimensional geometry of the active site. 
Thus despite the presence of the active site in the Chain B, both the chains were 
incorporated in the entire study on this protein structure. The target protein model (MtCM) 
was prepared through molecular dynamics studies carried out with the protein TSA complex 
over 1120ps as shown in Scheme 2.1 and Scheme 2.2 (Appendix I). This particular model 
has retained all the interesting interactions of the TSA (ligand) with the neighbouring 
residues, which were essential in the active site (Okvist et al, 2003). This model was 
therefore docked with some active and inactive ligands to set up a series of hypotheses for 
the model, these hypotheses were then used to design further ligands with possible 
biological activity against the organism.   
2.10.1 Model Hypothesis: 
v The ligand should interact with the residues Arg 260, Lys 186 and Glu 235, forming a 
triangular space.  
v Lys 186 hydrogen bonds with the carbonyl oxygen atom of the ligand. 
v Thr 231 hydrogen bonds to the nitro group as in Ac1, suggesting that the Thr 231 
may be an essential residue for drug design. 
v Lys 186 and Glu 235 should form a hydrogen bond together and interact with the 
ligand’s functional groups.  
v The distance between Lys186 and Arg260 should not be more than 4 Å.  
v A ligand with more than two ring systems connected by a chain should fold in upon 
itself and this is mainly mediated by Arg 175, thereby resembling the structure of 
TSA. 
v The connection between the two rings of the ligand should have 3 atom systems.  
v If Cl Is attached to an active ligand having two ring systems, it is unlikely that the 
ligand will fold, and the Cl tends to remain inside the receptor site thereby producing 
a triangular sitting pattern with Arg260, Lys186 and Glu235.  
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2.10.2 Molecular modelling results and discussions:  
The protein crystal structures obtained as a pdb file from the Protein Data Bank were simple 
snapshots and contain co-ordinate information of only one conformation of the protein 
structure which may or may not be in the lowest energy conformation. Molecular dynamics 
was therefore essential to study the global minima or the local minima of the protein 
structure. When MD study was performed at 1120ps on the protein structure (2FP2.pdb) the 
active site shrank; this resulted in interfering with the entrance of the ligands into the active 
site during docking study. Thus when MD was performed directly on the downloaded protein-
TSA complex, at 1120ps, the space available within the active site even became smaller. 
This has also prevented the entrance of the ligands (shown in table 2.4) into the active site 
during docking studies. This was because; TSA is bicyclic structure and was packed within 
the active site, running a MD simulation on this construction shrank the active site. However 
docking the ligand (TSA) into the active site enabled the active site to open up, following a 
MD simulation on this complex produced a model which successfully facilitated the entry of 
the ligands (Table 2.4) into the active site. Thus the ligands were docked into the active site 
of the protein (Scheme 2.2). Although the inactive ligands have shown more negative 
docking scores, these ligands were unable to interact appropriately with the target residues 
in a similar pattern as observed by the TSA in the active site. Thus the protein structure 
together with the TSA docked complex was set for molecular dynamics studies at 1120ps to 
obtain the lowest energy conformation of the active site in the protein complex. This model 
was then docked with the ligands shown in Table 2.4 and the interactions produced by the 
individual ligands were studied carefully. The docking scores obtained from Ligand 1, Ligand 
2 and Ligand 4 were more negative than the inactive ligands (scheme 2.2). The interactions 
produced by the TSA with the active site residues, were also similar to the biologically active 
ligands (Ligand 1, Ligand 2 and Ligand 4) as shown in Figure 2.11 and Figure 2.12. Although 
the model generated by the TSA-protein complex through the molecular dynamics studies at 
1120ps has created a stable and sensible model which has preserved the essential 
interactions when ligands were docked into the active site, it was difficult to establish the 
model as a final protein model which can screen possible biologically active ligands.   
 
Therefore further investigations were carried out with molecular dynamics study for another 
1120ps on the ligand-protein complexes of the active ligands (Scheme 2.3) to get the most 
stable conformation of these ligands within the active site. These were performed essentially 
to study the kind of interactions produced by these ligands within the active site. Each of 
these models was then re-scored and the interactions at this stage were studied (scheme 
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2.3). The conformations of the biologically active ligands in the active site were found to have 
the similar interactions and conformation as was observed in Scheme 2.2. This suggests that 
the model produced in Scheme 2.2 generated stable conformation of these ligands.  
 
Another key aspect that was considered while developing the model was the bond lengths. In 
an ideal condition within the active site Lys186 should hydrogen bond to Arg235 while 
interacting with the ligand. The distance between the Glu260 and the Lys186 should be 
around 2 Å and the distance between the Arg235 and the Lys186 should be less than 5 Å 
(Kameda, T et al. 2003). This pattern of the interaction was observed within the active site of 
the crystal structure (Figure 2.3a) containing the TSA.  Interestingly when the molecular 
dynamics studies on the protein-ligand complexes of the Ligand 1, Ligand 2 and Ligand 4 
were carried out for 1120ps (Scheme 2.3), distance between the Glu235, Lys186 and Arg260 
in the active site of the protein was lost. This could be due to the large size of the ligand 
producing steric hindrance within the active site destroying the wanted interactions. Ligand 4 
on the other hand although was smaller in size. Because it was even smaller than the TSA, it 
could preserve the interactions within the active site.  
 
 
 
TSA      Ligand 1  
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` Ligand 2     Ligand 4 
 
Figure 2.11: Showing the interaction of the ligands in the active site of the target model 
(obtained at 1120ps following the MD study using the TSA-protein complex (scheme 2.2)).   
 
The RMSD value evaluation was another important aspect in identifying the correct model. 
The RMSD values of the ligand-protein complexes with respect to the x-ray crystal structure 
following the molecular dynamics studies carried out at 1120ps (table 2.16) were also 
investigated. The RMSD value of TSA-protein from the initial crystal structure at zero-th 
conformation to the final conformation at 1120 ps was found to be 2.5 Å. This was the least 
when compared with the other ligand bound protein complexes. Similarly when the RMSD of 
the most biologically active compound, Ligand 1 was calculated, it was found to be 3.1 Å. 
Molecular dynamics studies on the Ligand 1- protein complex has resulted in significant 
opening of the active site (Figure 2.12), interfering with the key interacting residues. 
Therefore TSA-protein complex following the molecular dynamics studies at 1120ps was 
designated as the final model for evaluating biological active ligands.  
 
Ligand protein complex RMSD from the x-ray crystal structure 
 
TSA - protein complex 
 
2.5 Å 
Ligand 1- protein complex 3.1 Å 
Ligand 2- protein complex 2.7 Å 
Ligand 4- protein complex 3.4 Å 
 
Table 2.16: The RMSD values of the ligand-protein complexes from the X-ray crystal 
structure 2FP2.pdb.  
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TSA-Protein Complex    Ligand 1-Protein Complex 
 
Figure 2.12: Showing the opening of the active site following the MD studies at 1120ps with 
the ligand-protein complexes.  
 
The RMSD evaluation was also carried out on the MD study of the protein-TSA complex 
carried out at 12330ps. The RMSD was compared with the conformation obtained at 1ps as 
well as to the final structure as shown in graph 2.10 and was observed that the RMSD stays 
below 2 Å during the 1120ps of the MD study. The RMSD then gradually rises above 4 Å 
until the MD was performed to 8000ps after which the RMSD falls down below 3 Å. A close 
observation of the RMSD plot obtained after a MD study at 1120ps suggests that the RMSD 
was below 2 Å. The docking scores of all the ligands obtained in the phase 1 study were in 
accordance with the biological activity of the compounds in the organism, except ligand 7. 
This ligand has shown a more negative score; however when the RMSD of this ligand protein 
complex was evaluated (phase 2), it was found that the RMSD gradually increased beyond 3 
Å and the key interactions were lost in the final confirmation.  
 
Another interesting observation within the active site following the MD studies of the Ligand 
1-protein complex was that the Ligand 1 took up a folded conformation, and this perhaps is 
the lowest energy conformation of the Ligand 1. When the ligand1-protein complex from 
phase I was set for MD study at 1120ps (scheme 2.3;  Appendices I), the final structure was 
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found to have the similar interactions.  To have a clear picture of this study the bond lengths 
of the key interactions were identified and the change of these bonds was observed during 
the MD study at 1120ps of the Ligand1-protein complex carried out in phase II study as 
shown in graph 2.30.  
 
The interactions produced by the GLU 235, LYS 186 and ARG 260 were important in this 
model and therefore these residues were closely monitored throughout the studies. The 
distances between these residues and the interacting groups of the ligands (Figure 9 and 
Figure 2.10) were also closely monitored and the closest distance between the residues was 
graphically studied (Graph 2.16). The consistency over the folding pattern of the Ligand 1 
(Figure 2.10 b) was also observed by monitoring the methoxy-carbonyl bond distance.  
 
 
Graph 2.30: The variation of the bond length throughout the molecular dynamics studies of 
Ligand 1-protein complex at further 2120ps (Phase2).  
 
It was observed that the ligand maintains the folded conformation consistently throughout the 
molecular dynamic studies while it maintains the interactions with the interacting residues of 
the model. This observation supports the fact that this folding pattern was the stable 
conformation of the ligand within the active site and this is mediated by the interaction of the 
residues caused therein.  
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Figure 2.13: The folding pattern following a long MD of the docked Ligand 1-protein complex.  
 
Similarly the TSA-protein complex was also set for molecular dynamics studies and the bond 
lengths between the interacting residues were observed closely (Graph 2.31). 
 
 
Graph 2.31: Showing the variation of the bond length throughout the molecular dynamics 
studies of the TSA-protein complex at further 2120ps (Phase 2).  
 
It was observed that the distance between the LYS186 and ARG260 was unchanging while 
TSA interact with the LYS186 and GLU235 when the TSA-protein complex was set for 
molecular dynamics studies.  
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2.10.3 Selecting the targeted model:  
Following the MD studies of the TSA-protein complex, various frames were collected at 
various time intervals. The plot of the total kinetic energy and the total potential energy vs 
time interval (Graph 2.1) has shown no significant difference, however a close analysis of the 
plot at 1120ps (Graph 2.2) shows that there is a increase in the kinetic energy after 1120ps 
of the MD study. The Ramachandran plot showing the residues in the most allowed region 
went down from 93.5% (1120ps) to 90% (2120ps) and even less. In the frame selected at 
4750ps the Ramachandran plot has shown 88.6% of the residues in the most favoured 
region. In an ideal model 90% or more residues should be in the most favoured region within 
the Ramachandran plot (Ramachandran et al. 1963). The orientation of the residues within 
the active site after MD at 1120 ps (Figure 2.11a) was also studied and compared with the 
orientation of the active site residues as obtained from the crystal structure (Figure 2.3). It 
was observed that the residues retained all interactions as observed by Okvist et al., within 
the crystal structure of the protein, suggesting that the protein model obtained following a MD 
studies at 1120ps is the closest biological representation of the enzyme. Also the distances 
between the LYS-GLH residues and the LYS-ARG residues were altered when MD was 
performed at beyond 1120ps (Graph 2.31). When the active sites, obtained from the 
molecular dynamics studies at 2120ps and 4790ps, were carefully observed, it was found 
that the active sites were condensed. Although the interactions of the residues with the TSA 
were improved, it has significantly condensed the active site. These have interfered with the 
entrance of the ligands into the active site during the docking studies. It was observed that 
most of these ligands remained outside the active site. The frames obtained beyond 1120 ps 
following MD studies were excluded from the model. The model obtained from frame 1120ps 
of the MD studies has preserved all the key interactions within the active site (Okvist, M., R., 
et al. 2006). All these in together supported the frame obtained at 1120ps following the MD 
studies of the TSA-protein complex as a target model to design inhibitor compounds. A flow 
diagram illustrating the development of the model is shown in Appendix 1.   
2.10.4 Docking results and discussion: 
Using the targeted model obtained following a MD study on the TSA protein complex at 
1120ps (Scheme 2.2) docking studies were carried out using the ligand (Table 2.4) with 
known biological activity (Table 2.8). The active sites were designed in accordance with the 
important interactions produced by the TSA (Okvist et al., 2006). The ligands were docked 
into the active site and the docking scores were recorded (Table 2.10, Table 2.11, Table 
2.12, Table 2.13 and Table 2.14). In an ideal situation the most potent ligand should score 
more negative and the less potent should have less negative or positive scores. Interestingly 
the docking score on its own was difficult to judge the possible biological activity of the ligand 
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due to the diversity on the ligand structures. TSA was a small bicyclic structure ligand and all 
other ligands were structurally different to TSA. Also only three biologically active ligands 
were available in this study and this was too few to calibrate the model, which were also very 
different from each other. Therefore in this study much emphasis has been given on the 
interactions produced by the key residues. Hence a series of hypotheses were established 
for the model and these hypotheses were used along with the docking scores to screen 
possible biologically active ligands. Ligand 1 has been the most active inhibitor against MtCM 
reported so far. Therefore in this work much effort has been given to manipulate the Ligand 1 
with various substitutions to design inhibitor ligands that however consider the model 
hypotheses.  
2.10.5 Structural activity studies of Ligand 1: 
N
H
S
O
OH
O
O NH2 O
O
NO2
 
Figure 2.14: The structure of the Ligand 1 
 
On changing the sulphonamide group to an amide group as in Ligand 20 the interaction of 
the ligand to form a hydrogen bonding with the Lys 186 was lost. The interaction with the Arg 
260 and Glu 236 was also changed. Again on changing the carboxylic group into nitro group 
as in Ligand 16, 27 and 29 the folding pattern of the ligand was hindered and the docking 
score went less negative. Changing the nitro group into carboxyl group as in Ligand 21, apart 
from losing the folding pattern, the hydrogen bonding with the Lys 186 was also lost.  On 
changing the methoxy group into hydroxyl Ligand 17, the ligand still maintained interactions 
with the residues thereby folding up. The distance between the Lys186 and the 
sulphonamide moiety increased. Perhaps the presence of a bulky group such as the 
methoxy groups facilitate the ligand to move toward the Lys186 forming a hydrogen bonding. 
The nitro groups permit the rational design of numerous potent and selective inhibitors of 
enzyme and are good analogues of the carbonyl groups (Alston, T. 1983). Thus on replacing 
the Sulphonamide part of the ligand with the nitro as in Ligand 45, 50 – 57, 60, 61, 64, 66, 
67, 69, 71 and 72 preserves all the desirable interactions within the active site. This is 
perhaps due to the fact that although the Sulphonamide group was large compared to the 
nitro, both of them had similar electronic effect. On replacing the methoxy group with the 
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hydrogen, the ligand still followed the model hypothesis and preserved the important 
interactions. Incorporating one more methoxy group into the benzyl ring as in Ligand 30, 
prevents the moiety to completely get within the active site. Substitution of nitro group to the 
carboxylic group reduces the inhibitory property of the ligand, however with the methoxy 
group in 3rd and 5th position on the ring B (Figure 2.8) as in Ligand 26 and the hydroxyl group 
on the 3rd and 4th position as in Ligand 29 moderately retains the inhibitory property of the 
ligand. This is probably due to the intra-molecular hydrogen bonding facilitating the folding 
fashion of the ligand. Another interesting observation was Ligand 75. This ligand was devoid 
of any substitution on ring B (Figure 2.8), and however this ligand had folded within the active 
site. Replacing the ethylamine linkage with a methyl hydrazinyl linkage as in Ligand 37-40 
and Ligand 64-69, some of the ligands particularly the one with di-methoxy substitution 
(Ligand 38) had a good docking score and was also successful in preserving some 
interaction within the active site. This ligand was also observed in adopting a partially folded 
conformation within the active site. Also substituting a -N–N-C=O group in place of the ethyl 
amine linkage as in Ligand 62, this led to the adoption of a partially folded conformation and 
a less negative docking score.  
 
Based on the docking score (Table 2.14) and the hypothesis as framed in section 2.10, all 
the ligands laid out in Table 2.9, Table 2.10, Table 2.11, Table 2.12 and Table 2.13,  were 
ranked as shown in the table below.   
 
Ligand Ranking Ligand Ranking Ligand Ranking 
      
Ligand 17 A Ligand 62 A Ligand 83 B 
Ligand 23 A Ligand 63 A Ligand 81 B 
Ligand 24 A Ligand 64 A Ligand 82 B 
Ligand 27 A Ligand 65 A Ligand 86 C 
Ligand 34 A Ligand 66 A Ligand 87 C 
Ligand 43 A Ligand 67 A Ligand 88 C 
Ligand 44 A Ligand 68 A Ligand 89 C 
Ligand 45 A Ligand 69 A Ligand 80 C 
Ligand 50 A Ligand 70 A Ligand 76 C 
Ligand 51 A Ligand 71 A Ligand 77 C 
Ligand 52 A Ligand 72 A Ligand 90 C 
Ligand 53 A Ligand 73 A Ligand 91 C 
Ligand 54 A Ligand 74 A Ligand 92 C 
Ligand 55 A Ligand 75 A Ligand 93 C 
Ligand 56 A Ligand 61 A Ligand 84 C 
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Ligand Ranking Ligand Ranking Ligand Ranking 
      
Ligand 57 A Ligand 78 B Ligand 85 C 
Ligand 59 A Ligand 79 B 
  
Ligand 60 A Ligand 58 B 
  
Table 2.17: Showing the ranking order of the ligands as determined by the model. A denotes 
that the ligands follow the model hypothesis in all aspects, B denotes that the ligands 
requires further modification and Ligands ranking C are rejected  
 
2.10.6 Fragment based approach for Ligand 1:  
In an attempt to study the interactions of the Ligand 1 within the active site a fragment based 
approach was also employed. The fragments of Ligand 1 were docked separately and then 
the orientation and interactions of the fragments (Ligand 88 and Ligand 89) were studied at 
the active site.  
 
   
   
Ligand 88     Ligand89 
Figure 2.15: The interactions produced when the Ligand 1 was fragmented and docked into 
the active site and the fragments were docked separately as Ligand 88 and Ligand 89.  
 
It was observed that 5-nitro-3-sulphomoyl-4-amino benzoic acid (Ligand 88) exhibited the 
most interactions within the active site, forming hydrogen bonds with Arg 175, Arg 260, Lys 
186 and Glu 235. When Ligand 88 and 89 were used for docking study, the scores were 
found more negative than the TSA. Both the ligands however left plenty of space within the 
active site pocket. An attempt was also made to design various analogues of ligand 88 by 
modifying the side chains of the ligand (Ligand 84, 85, 86 and 87) as shown in Table 2.12 
This was essentially to increase the interaction with the neighbouring residues. On increasing 
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the side chains as in Ligand 87, the ligand tried to adopt a folded conformation. The methoxy 
groups in Ligand 1 have shown good interaction within the active site (Figure 2.10.b), thus in 
an approach to incorporate the methoxy group in the Ligand 88, Ligand 86 was used in the 
study.  These ligands have tried to take up a folding conformation and therefore to increase 
the flexibility saturated ring systems, containing the key interacting groups were used as in 
Ligand 84. This ligand took up a highly strained conformation within the active site. In all the 
ligands used in this investigation the nitro and the sulphonamide groups produced interesting 
interaction with the Arg, Lys and Glu residues at the active site. Ligand 88 has shown the 
most successful docking score and the best interaction with the residues when compared 
with the other analogues of Ligand 88 shown in Table 2.12. These therefore have shown that 
modification in this fragment of the ligand was limited and the sulphonamide, nitro and the 
carboxylic in those positions of the ring were important for the ligand within the active site.    
 
Ligand 89 did not show any interesting interaction with the residues in the active site (Figure 
2.15). Neither dimethoxy phenethylamine part of Ligand 1 has shown any key interaction with 
the active site residues of the target model, apart from facilitating the folding conformation of 
Ligand 1. Therefore the 5-nitro-3-sulphomoyl benzoic acid probably forms the lipophilic part 
of the Ligand 1 creating lipophilic contact with the Arg 260, Lys 175 and Glu 235 whereas the 
dimethoxy phenethylamine makes the hydrophobic contacts with the residues (Figure 2.14). 
Hence dimethoxy phenethylamine is essential in designing analogues of Ligand 1 and 
therefore in this model attempt has been made to create various substitution on the 
dimethoxyphenyl part of the Ligand 1; these had produced ligands which were similar in 
properties.    
 
2.10.7 Structural activity studies of Ligand 2: 
CH3O
CH3O H
O
OH
NO2
Cl
 
 
Figure 2.16: The structure of Ligand 2 
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Agrawal et al., in their research have observed that chlorophenyl part of the moiety of the 
Ligand 2 remained outside the active site, on docking this ligand into their model (Agrawal, 
Kumar et al. 2007). In the attempt to dock Ligand 2 in the active site, three out of five times 
the chlorophenyl part of the moiety remained within the active site. The nitro group of the 
ligand interacts with the Arg 260 in a similar fashion as was observed by Agarwal et al. The 
chlorine within the active site has shown some interaction with Thr 231 and Glu 235 as 
shown in the Figure 2.10(c).  On docking the Ligand 2 into the active site, the ligand did not 
fold within the active site, however on removing the benzyl chloride part of the ligand, it has 
shown some folding pattern within the active site resembling the TSA like structure (Figure 
2.18).  
 
Ligand 81     Ligand 82 
Figure 2.17: Showing the orientation of the Ligand 81 (fragment of Ligand 2) and Ligand 82 
(a modification of Ligand 84) within the active site.  
 
Introducing a bulky group into the moiety the ligand (Ligand 81, 82 and 83) has facilitated the 
folding pattern of the small ligand to lean the carboxylic group toward the ring (Figure 2.17). 
 
2.10.8 Docking studies of the commercially available ligands from Maybridge:  
A library of ligands from the Maybridge Company was screened; a set of 260 ligands were 
selected for docking studies in this investigation. All these ligands have been docked three 
times and the average score have been shown in Table 2.15. The docked complexes were 
then investigated for interesting interactions. Of all the ligands used, the following ligands 
shown in Table 2.18 have shown good score (more negative). However, only Ligand 113 and 
Ligand 124 were ranked well by the model hypothesis.  
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SL No Ligands 
PMF Score 
Kcal/mole 
Rank 
    
Ligand 113 
O
N N
N OO
 
-646.08 A 
Ligand 124 O
N N
NH
N
N
NH2
 
-631.25 A 
Ligand 201 
O
N N
H
N
S
N
 
-631.72 A 
Ligand 142 
N
H
Cl
HN
N
 
-577.53 A 
Ligand 125 
N
NH
O
N
NH
HN N
O
 
-546.48 
 
C 
Ligand 183 N
N
H
NH
N
O
 
-530.58 C 
Ligand 123 
N
H
OH
NH2
Cl
 
-543.32 C 
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SL No Ligands 
PMF Score 
Kcal/mole 
Rank 
    
Ligand 160 N N
HN
HO
NH
OH
 
-501.99 C 
Ligand 194 
N
N
O
HN
NH2
 
 
-508.73 C 
Ligand 197 
HN
HN
NS N
N
 
 
-510.68 C 
Ligand 204 N
N
Cl
S O
HN
NH2
 
 
-462 C 
 
Table 2.18:  Showing the list of the Maybridge compounds with rank 
 
While screening these databases of ligands, the ligands were first ranked by docking scores 
and then the ligands were observed for their ability to get into the active site. Despite the 
more negative docking score some of these ligands were found to be on the surface of the 
active site. This is due to the presence of plenty of interacting groups on these ligands 
producing more negative score. These ligands were also excluded from the study. The final 
set of 11 ligands (Table 2.18) was screened using the model hypothesis and ranked 
accordingly. Only Ligand 113 and 124 were ranked well by the model apart from the docking 
scores, these ligands have shown good interactions with the Lys186, Arg260 and Glu235. 
These ligands have produced more negative scores and had also shown good interaction 
with the Lys186, Arg260 and Glu235 in a similar fashion as TSA and Ligand 1 (Figure 2.4).  
These ligands were also observed with folding up toward itself within the active site. This 
suggests that the folding property of the ligands within the active site of the model is not just 
a feature observed with the ligands designed in the study (Table 2.9, 2.10, 2.11, 2.12 and 
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2.13). Perhaps it is a key feature that should not be ruled out while considering this model to 
design inhibitor compounds.   
 
 
 
 
Ligand 113 Ligand 124 
 
 
Ligand 201 Ligand 142 
 
Figure 2.18: The interactions produced by some of the commercially available compounds 
when docked into the active site of the model obtained following MD study of the TSA-protein 
complex at 1120ps (Scheme 2.2). 
 
Most of these ligands (Table 2.18) have more than one ring system with the saturated 
heterocyclic ring system. These ligands were relatively large, when compared to the 
structure of TSA, and therefore have a large surface area in general. However when these 
ligands were docked within the active site, they folded themselves to form a highly strained 
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boat conformation within the active site. This pattern of orientation favoured the interaction of 
the ligands within the active site (figure 2.18). The ligand 125, 183, 123, 120, 194, 197 and 
204, all went successfully into the active site on docking studies. However these ligands 
were unable to interact with the key residues in the active site.  
 
2.11 Conclusions:  
A protein model of the enzyme chorismate mutase from Mycobacterium tuberculosis was 
prepared through a combination of molecular modelling and docking studies. A range of 
ligands with known biologically activities were used to study the interactions and a final set of 
hypotheses were established specific to the model. A library of ligands was designed which 
were then screened and ranked based on the model hypothesis. The ligands which were 
ranked as good ligands were then considered for synthesis and biological screening. This 
model was also used to screen a database of commercially available ligands represented by 
a smaller set chosen by a pharmacophore based diversity analysis. Ligands 113 and 124 in 
particular showed interesting interactions within the active site and therefore these scaffolds 
represent important areas for future research to discover inhibitor compounds against the 
mycobacterium chorismate mutase.   
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CHAPTER 3 
SUBSTITUTED 3-NITRO 5-SULPHAMOYLBENZOIC ACIDS: 
 DERIVATIVES AND RELATED CHEMISTRY 
 
 
 
3.1 Aim: 
The aim of this work is to prepare a selection of the compounds which have ranked well 
following the docking studies in chapter 2 and to screen for biological activity particularly 
against Mycobacterium tuberculosis.  
 
3.2 Background:  
The protein model appropriate for the enzyme from chorismate mutase M. tuberculosis was 
prepared, which can selectively rank ligands toward the best possible biological activity. The 
4-(3,4-dimethoxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid which was found to be 
very active against the enzyme of the pathogen (Agrawal, Kumar et al.,. 2007) has been 
used throughout the studies to identify the interactions with the residues in the model. Using 
the model over 350 ligands have been screened by docking studies and a library of 
compounds has been generated that fit appropriately within the active site. Ligands which 
are similar to the 3-nitro 5-sulphamoyl benzoic acids have shown the interesting interaction 
and have also scored well in the docking studies. These compounds were clustered as well 
ranked by the model and were selected for further synthesis.  
NH
OHO
S
O
O
NH2
NO2
O
O
 
      Compound 3.1 
Figure 3.1: Structure of 4-(3,4-dimethoxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid (Compound 3.1) 
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Interestingly Compound 3.1 ( 4-(3,4-dimethoxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid) which has diuretic properties (Kansal, Kar et al. 1979) was found to be very active 
against the chorismate mutase from Mycobacterium tuberculosis (Agrawal, Kumar et al.,. 
2007).  Although Kansal et al., reported the diuretic activity of Compound 3.1, they did not 
provide detailed information supporting the synthesis and characterisation of this compound. 
Therefore the work in this thesis has developed the preparation, isolation and 
characterisation of substituted 3-nitro, 5-sulphamoyl benzoic acids and related compounds.  
 
3.3 Substituted 3-sulphamoyl-5-nitro benzoic acid and related compounds:  
The target compounds arising from the in silico screenings are set out in Figure 3.2.   
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Figure 3.2: Target compounds judged to have potential activity against chorismate mutase 
from M. tuberculosis.  
 
 
All the compounds shown in the Figure 3.2 have been clustered into three main analogues of 
the biologically active ligand Type A, Type B and Type C.   
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Figure 3.3:  The three main categories of the compounds used in this investigation.  
 
 
3.4 Screening synthesisable compounds:  
Unfortunately not all the compounds following Figure 3.2 were possible to synthesise. This 
was due to the potential use of starting materials which were classed as restricted drugs 
under Schedule 2 Class A by the UK Home Office. Therefore only the compounds which 
were free of using any controlled drugs in their synthesis were selected for synthesising and 
so in this study the synthesis of Compound 3.22, Compound 3.23, Compound 3.24, 
Compound 3.25 and compound 3.26 has been omitted. The remainder analogues of the 
compounds of Type A (Figure 3.3) were prepared by treating the amines with the 
corresponding acids (Jackman et al., 1962). These compounds were prepared by heating the 
phenethyl amine with the corresponding benzoic acid in presence of DIEA in butanol  at 
reflux as shown in Figure 3.4 (Vlaskina et al., 2004). The final compound was then isolated 
by first converting it into the BOC substituted derivatives (Pope. et al., 1988). It was then 
partitioned between the ammonium chloride and ethylacetate layer. The product was then 
obtained from the organic phase and then BOC was removed by a strong acid such as 
trifluoroacetic acid (England.E, A, et al., 2004) or hydrochloric acid in methanol (Williams. R, 
et al.,. 2003). 
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Figure 3.4:  The general synthesis of the substituted 3-sulphamoyl-5-nitro benzoic acid 
derivatives related to Type A compounds shown in Table 3.1. 
 
 
 
 
 
 
 
Substituted 3-nitro 5-sulphamoyl benzoic acids  2010 
 
P a g e  | 143  
 
 
Compound R R1 R2 R3 R4 Yield (%) 
       
3.2 SO2NH2 OH OH H H 44 
3.3 SO2NH2 OH OH OH H 48 
3.4 SO2NH2 H OH H H 72 
3.5 SO2NH2 H H H H 46 
3.6 SO2NH2 OCH3 H H H 40 
3.7 SO2NH2 OH OH H OH 48 
3.8 NO2 OH OH H H 34 
3.9 NO2 OH OH OH H 32 
3.10 NO2 H OH H H 61 
3.11 NO2 H H H H 59 
3.12 NO2 OCH3 H H H 30 
3.13 NO2 OH OH H OH 10 
 
Table 3.1:  Compounds of Type A.  
 
Similarly the analogues of the compounds from Type B were prepared by adding the acid 
and DIEA mixture in butanol to the hot benzyl-hydrazine solution in butanol and heating at 
reflux overnight (Figure 3.5).  
 
Cl
OHO
NO2R
N
H
NH2
R1
R2
R3
R4
OHO
NH
NH
O2N
R1
R2
R3
R4
R
+
DIEA / Butanol
Reflux under Argon 
 
        Compound B 
 
Figure 3.5:  The general synthesis of the substituted 3-sulphamoyl-5-nitro benzoic acid 
derivatives related to Type B compounds shown in Table 3.1, where R and R1 are the 
substituents within the ring.  
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Compound R R1 R2 R3 R4 
 
     
3.14 SO2NH2 OH OH H H 
3.15 SO2NH2 OCH3 OH H H 
3.16 SO2NH2 OCH3 OCH3 H H 
3.17 NO2 OH OH H H 
3.18 NO2 OCH3 OH H H 
3.19 NO2 OCH3 OCH3 H H 
 
Table 3.2:  Analogues of compounds of Type B.  
 
 
Analogues of compound Type C were also prepared similar to the analogues of Type A and 
Type B, however these reactions requires anhydrous conditions and therefore were carried 
under an argon atmosphere.   
 
 
Cl
OHO
NO2R
N
H
NH2
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        Compound C 
 
 
Figure 3.6:  The general synthesis of the substituted 3-sulphamoyl-5-nitro benzoic acid 
derivatives related to Type C compounds shown in Table 3.1.  
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Compound R R1 R2 R3 R4 
 
3.20 
 
SO2NH2 
 
OCH3 
 
OCH3 
 
H 
 
H 
3.21 NO2 OCH3 OCH3 H H 
 
Table 3.3:  Analogues of compounds of Type C. 
 
3.5 Varying the benzoic acids moiety:  
The benzoic acid part was modified in various positions. The sulphonamide group in 
particular was manipulated to nitro and N-methyl sulphonamide group and these 
modifications have shown some interesting interactions within the active site of the protein 
model.  
 
 
Cl
OHO
S
O
O
NH2
NO2
 
Cl
OHO
NO2O2N
 
Cl
OHO
S
O
O
NO2N
H
CH3
 
Compound 3.27 Compound 3.28 Compound 3.29 
 
Figure 3.7:  The different types of benzoic acids used in this study.  
 
 
Only the 3,5-di-nitro-4-chlorobenzoic acid (Compound 3.28) was commercially available.  
The 3-sulphamoyl-5-nitro-4-chlorobenzoic acid (Compound 3.27) was prepared by the 
chlorosulfonation (Masaki, Mizuno et al.,. 2003) of the 4-chlorobenzoic acid obtained from 
Sigma-Aldrich using chlorosulfonic acid in concentrated  sulphuric acid to prepare the 3-
chlorosulphonyl-4-chloro benzoic acid (Compound 3.30) at 140 oC. It was then set for 
nitration (Palumbo, Napolitano et al.,. 2002) using fuming nitric acid at 90 oC to prepare 
chlorosulphonyl-5-nitro 4-chlorobenzoic acid (Compound 3.31) which was then finally treated 
with concentrated ammonia solution ( Ghadam A, K, et al.,  2005) to give Compound 3.27 
(Kansal, Kar et al.,. 1979).  The final compound was collected by removing the excess 
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ammonia using a high vacuum pump and thereby adjusting the pH to 6. The schematic 
representation of these stages has been illustrated in the Figure 3.8 below.  
 
OHO
S
O
O
NH2
NO2
Cl
Cl
OOH
Cl
OOH
S
O
O
Cl
O2N
Cl
OOH
S
O
O
Cl
Chlorosulphonic acid
Sulphuric acid
140oC
  Conc nitric acid
Sulphuric acid
90oC
Conc NH4OH
Room temp
Compound 3.30 Compound 3.31
Compound 3.27
 
 
 
Figure 3.8:  The stages involved in the synthesis of 3-sulphamoyl-5-nitro 4-chloro benzoic 
acid (Compound 3.27).   
 
Compound 3.31 was used as an intermediate for the synthesis of the analogues of Type A, 
Type B and Type C. Compound 3.29 was prepared by treating 3-chlorosulphamoyl-5-nitro 4-
chloro benzoic with N-methylamine.  
 
Cl
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S
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O
NO2
Cl
NH2
CH3
Cl
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S
O
O
NO2
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H
CH3
+
 
    
 Compound 3.31       Compound 3.29 
 
Figure 3. 9:  The synthesis of 3-(N-methyl sulphonyl)-5-nitro-4-chloro benzoic acid from 3-
chlorosulphamoyl-5-nitro 4-chloro benzoic acid.  
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3.6 Varying the phenylamines:  
All the phenylamines used in this section were commercially obtained from Sigma. The 
phenethylamines used in the experiment are given in Figure 3.10. 
 
NH2
 
NH2
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OHOH
 
NH2
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Pa1 
 
Pa2 
 
Pa3 
 
Pa4 
 
 
NH2
OH
 
 
 
NH2
O
 
  
 
Pa5 
 
Pa6 
  
 
Figure 3.10: The list of various phenylamines used in the study. 
 
 
3.7 Varying the benzylhydrazine moiety:  
All the benzyl-hydrazines used in this experiment have been prepared by slowly adding the 
aldehydes into a mixture of excess hydrazine in ethanol heated at 60 oC with constant stirring 
(Szmant et al., 1959). The resulting hydrazones were hydrogenated using palladium charcoal 
at 110 oC and 10 psi for 24 hours (Daeniker et al, 1973) as shown in Figure 3.5. The benzyl-
hydrazines thus obtained were used in the synthesis of the analogues of Type C and Type D. 
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Figure 3.11:  The stages involved in the synthesis of the benzylidine-hydrazine from the 
aldehyde.  
 
 
The benzyl-hydrazines produced in this study are shown in Figure 3.11.  
 
 
 
O
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NH
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OH
O
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NH2
     
OH
OH
NH
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Compound 3.32  Compound 3.33  Compound 3.34 
 
Figure 3.12: The list of benzyl hydrazines used to prepare the analogues of Type C and Type 
D.  
 
3.8 Reactivity of the substituted benzoic acids: 
The benzoic acids used in this study had a wide range of reactivity. Compound 3.28 and 
Compound 3.27 have similar extent of reactivity. The nitro group and the sulphonamide 
groups are both electronegative in nature although the extent of electro-negativity is more in 
case of nitro and therefore the Cl attached to the acid departs more easily in case of the di-
nitro benzoic acid than in the 5-nitro, 3-sulphamoyl benzoic acid (Figure 3.13).  
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Cl
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Cl
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NO2S
O
O
NH2
 
Compound 3.28 Compound 3.27 
   
Figure 3.13:  The presence of the electronegative groups deactivating the ring pulling the 
electrons thereby making the carbon bearing the Cl atom an easy target for amines.  
 
Apart from using the 3,5-di-nitro benzoic acid and the 5-nitro- 3-sulphamoyl benzoic acid in 
the current research, attempts have been made to synthesise the corresponding analogues 
of the Type A compounds using the 5-nitro-3-(N-methyl)sulphonyl, 4-chloro benzoic acid 
(Compound 3.29). In an attempt to synthesise the compound 3.29 using compound 3.27, the 
corresponding compound was found to be mixture of compound 3.29 (mono addition) and 
compound 3.35 (di-addition) as shown in Figure 3.14 below.  
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   Compound 3.27        Compound 3.29  Compound 3.35 
 
Figure 3.14: Amination of Compound 3.27.  
 
In the synthesis of Compound 3.27 (Figure 3.8), the final compound was obtained by simple 
amination of Compound 3.31 using concentrated ammonia solution. Compound 3.27 was 
collected as pure amorphous solid. Interstingly this reaction was not possible when N-methyl 
amine was used as an amine for the amination in order to prepare Compound 3.29.  
 
In the synthesis of Compound 3.27, 2 M ammonia in methanol was used and the final 
compound was found to contain the starting material as impurities. On using concentrated 
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ammonia (34% ammonia solution) the final compound was obtained pure. However this was 
not the case with the synthesis of Compound 3.28. On reacting with 40% methylamine 
solution the final compound was found to be a di-addition giving 3-(N-methyl)-sulphonyl-4-(N-
methyl) benzoic acid (Compound 3.35 as in Figure 3.13). Using three equivalent of 2M 
methylamine in methanol after 24 hour the corresponding compound was obtained as 
mixture of mono (Compound 3.29) and di-addition (Compound 3.35) of the starting material. 
On reducing the reaction time to 1 hour and maintaining the temperature at 3oC, it was 
observed that the di-addition happens within 1 hour of the reaction as observed under NMR.  
This could be due to the fact that methylamine is more reactive compare to the ammonia and 
therefore acts much faster to give the 3-(N-methyl)sulphonyl-4-(N-methyl) benzoic acid.  
 
Due to the presence of the carboxylic group and the methyl amine group in Compound 3.35, 
this compound behaves like an amino acid and the presence of these properties had made 
difficulties in isolating the compound from aqueous solvent. Too much acidification made the 
compound soluble in the aqueous layer and therefore the pH was carefully maintained at 6 to 
precipitate the compound. 
 
3.9 Reactivity of the phenylamines:  
The phenethylamines used in the experiment have wide range of reactivity. Apart from the 
Pa1, Pa5 and Pa6 as shown in Figure 3.10 all the phenethylamines requires anhydrous 
condition. It was observed that on reaction with the acids in presence of the DIEA, the 
reaction mixture was converted into a black sticky mass, the NMR and TLC suggest plenty of 
impurities which were difficult to remove. Pa3 and Pa4 are very unstable in presence of 
oxygen and get converted into black sticky mass immediately on exposure to oxygen. It in 
fact reacts readily with the oxygen present within the apparatus. Hence Compound 3.2 was 
obtained as solid yellow mass on synthesis, on storage this compound get converted first 
into a sticky brown mass and then into a semi solid mass. Compound 3.3 on the other hand 
when prepared was obtained as solid which immediately converts into semi solid mass over 
48 hours and on storage it converts into a black residue. This may be due to the presence of 
the adjacent OH groups which triggers oxidation of the moiety which is often observed with 
the ascorbic acids. The phenylamine Pa2 had two adjacent OH groups and is relatively 
stable toward oxidation when compared with the amine Pa3 and Pa4 (three OH groups), 
however the final product has been found to absorb moisture and convert into a sticky brown 
mass.  
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3.10 Reactivity of the benzylhydrazines:  
 The benzyl hydrazines Compound 3.32, Compound 3.33 and Compound 3.34 used in this 
work were obtained in two steps. The first step includes the action of the aldehyde on the 
hydrazine; then this was hydrogenated using palladium on charcoal (Figure 3.5). The 
reaction was successful to prepare the corresponding benzyl hydrazines Compound 3.32 
and Compound 3.33, however synthesising the benzyl hydrazine Compound 3.34 was 
unsuccessful.  Compound 3.32 and Compound 3.33 were more reactive due to the presence 
of the electron donating methoxy group. Compound 3.32 is more reactive when compared 
with Compound 3.33 due to the presence of two electron donating methoxy groups. 
Compound 3.34 was the least reactive of all the benzyl hydrazines and perhaps that was the 
reason why the aldehydes although successfully reacted with the hydrazine in the first step 
to form the benzylidine hydrazine however failed in the next step to reduce the imide. Instead 
the reaction gave plenty of impurities which were difficult to remove.  
 
The benzyl hydrazines were thought to react similarly to the phenyl amines used earlier in 
this study. Interestingly when these benzyl hydrazines Compound 3.32 and Compound 3.33 
when treated with Compound 3.27 and Compound 3.28 (Figure 3.5) the final compounds 
were found to contain plenty of impurities which were difficult to separate. The phenylamines 
required higher reaction temperature and perhaps this reaction condition was too high for 
benzyl hydrazines. Therefore when the reaction temperatures were reduced the reaction 
contents were found to be the mixture of the starting materials. To further investigate the 
reactivity of the hydrazinyl moiety of Compound 3.32 and Compound 3.33, each of them was 
set for qualitative investigation by treating with 4-methyl benzaldehyde in boiling ethanol. The 
corresponding imides were confirmed by NMR and a single spot on a TLC plate. Therefore 
this suggests that Compound 3.32 and Compound 3.33 are reactive but when reacted with 
Compound 3.27  and Compound 3.28 the final compounds were found to contain impurities 
which were difficult to remove.  
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Figure 3. 15: The reaction between the benzyl hydrazine and the aldehyde yielding 
corresponding imides. 
 
The impurities which were observed following the reaction between Compound 3.32 and 
Compound 3.33 and the Compound 3.27 and Compound 3.28 were perhaps due to the 
presence of two reactive nitrogens in the benzyl hydrazines which contributes to the complex 
mixture.  
 
3.11 Reactivity of the benzoyl hydrazide:  
In this study the benzoyl hydrazides were found to be relatively less reactive when compared 
with the benzyl hydrazines used in this investigation. All the benzoyl hydrazides used in this 
investigation was obtained commercially. 
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Figure 3.16:  The various benzoyl hydrazides used in this investigation.  
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When Compound 3.37 reacted with the aryl chlorides Compound 3.27 and Compound 3.28 
under the similar condition to that with the phenylamines (Figure 3.6), the final compound 
was found to contain many impurities when judged with TLC. On reaction of the Compound 
3.38 with the acids the resultant products were found to be a mixture of two starting 
materials. The presence of the electron withdrawing carboxyl group appears to render 
compound 3.37 and Compound 3.37 insufficiently reactive to be able to react with 
Compound 3.27 and Compound 3.28.  
 
3.12 Microbiological studies:  
 
Of the 14 compounds which were synthesised, 8 were sent to the TAACF for screening 
against the pathogenic organism. The screening was conducted in two designed stages. The 
primary screening involves the determination of the 90% inhibitory concentration (IC90). The 
following screening or the secondary screening involves the determination of the mammalian 
cell cytotoxicity (CC50).  
 
3.12.1 Dose Response screening: 
The dose response screen was conducted against Mycobacterium tuberculosis H37Rv 
(ATCC 27294) in BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA). 
(Collins, L.A et al. 1997) Compounds were tested in ten 2-fold dilutions, typically from 
100µg/mL to 0.19µg/mL. The IC90 is defined as the concentration effecting a reduction in 
fluorescence of 90% relative to controls. This value was determined from the dose-response 
curve using a curve-fitting program. Any IC90 value of <100µg/mL was considered “Weakly 
Active" for antitubercular activity and values with >100µg/mL were considered ‘Inactive’.  
 
Compound Assay Activity IC50 (µg/mL) IC90 (µg/mL) 
3.11 MABA Weakly Active 65.600 97.120 
3.2 MABA Inactive >100 >100 
3.3 MABA Inactive >100 >100 
3.4 MABA Inactive >100 >100 
3.5 MABA Inactive >100 >100 
3.8 MABA Inactive >100 >100 
3.10 MABA Inactive >100 >100 
3.12 MABA Inactive >100 >100 
 
Table 3.4:  The biological activity of the compounds against M .tuberculosis.   
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3.13 Discussion:  
 
In an attempt to synthesise the substituted sulphamoyl benzoic acids, the 4-chloro-3- 
sulphamoyl benzoic acid (Compound 3.27) was treated directly with the amines (Figure 3.18) 
(Kanasal, et al. 1979)  
 
 
Cl
OHO
SO2NH2 NO2
NH2
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R2
R3
R4
OHO
NH
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R3
R4
SO2NH2
+
 
 
Figure 3.17:  Synthesis of the substituted sulphamoyl benzoic acids 
 
 
Although Kansal et al., in the earlier research have successfully synthesised Compound 3.1 
they did not illustrate the steps involved in the synthesis, isolation or purification of the 
compound. In this investigation the work has laid out steps to synthesise and isolate the 
substituted sulphamoyl benzoic acid derivatives Compound 3.2 to Compound 3.13 (Figure 
3.2). The benzoic acid moiety was not very reactive reactive due to the presence of the 
sulphonamide and the nitro group and therefore in an attempt to substitute the chlorine with 
the amine Compound 3.27 was treated with the amine at reflux in toluene (high boiling point 
solvent) in presence of pyridine (Barlow et al., 1951 and Louis et al., 1984); the resultant 
product was found to contain a mixture of the starting materials. Although 3-nitro-4-chloro-
benzoic acid ethyl ester successfully reacted with the propylamine in presence of high boiling 
point liquid dimethylformamide giving up the corresponding 3-nitro-4-propylamino-benzoic 
acid ethyl ester (Özden et al, 2005) it was not possible in this case to synthesise Compound 
3.2 under the similar condition. Using a solvent with further higher boiling point such as 
dimethylformamide (Özden. et al, 2005), propanol or butanol delivered the target compound 
but in an impure form. Also the resultant compound had turned into a black sticky mass; this 
Compound 3.27 
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could possibly due to the pyridine (bp 115oC) which is susceptible under such conditions. 
Pyridine was not an effective solvent and n-butanol was found to be relatively better solvent 
under such reaction conditions (Ramage et al., 1952). Incorporating DIEA (N,N-
diisopropylethylamine) in place of pyridine the reaction was found successful (Ka Young et 
al, 2004).   
Cl
OHO
NO2NH2SO2
NH2
R1
R2
R3
R4
OO
NH
SO2NH2O2N
R1
R2
R3
R4
+
DIEA
Butanol
DIEA+
 
Scheme 3.1:  Synthesis of the DIEA salt of the substituted sulphamoyl benzoic acids 
 
 
The analogues of compound type A thus obtained were found difficult to isolate from the 
impurities. It was observed that the products were equally soluble into both the organic and 
the aqueous layer and therefore the yield of the final product was found to be very low. This 
could be due to the fact that the final compounds are amino acids. The basic amino group 
was therefore blocked with a BOC group as shown in the scheme 3.2 below using BOC 
anhydride (Barry. et al., 1988).   
NH
NO2
R1
R2
R3
R4
R
COO
N
COOH
NO2
R1
R2
R3
R4
R
NH4Cl (aq)
BOC anhydride / MeCN
BOC
-
DIEA+
 
Scheme 3.2: The synthesis of the BOC-substitute of compound A.  
Compound 3.27 
Substituted 3-nitro 5-sulphamoyl benzoic acids  2010 
 
P a g e  | 156  
 
 
Incorporating the BOC group increases the liphophilicity of the compound and therefore it 
was easily extracted from the aqueous phase into the organic solvent when partitioned 
between ethyl acetate and NH4Cl solution. The final compound was then generated by 
removing the BOC group in presence of strong acid.  
H2N
NO2
R1
R2
R3
R4
NH2SO2
COOH
N
COOH
NO2
R1
R2
R3
R4
NH2SO2
CF3COOBOC
TFA
DMF
-
+
 
Scheme 3.3:  Showing the synthesis of substituted benzoic acid derivatives.  
 
Following the incomplete details in the literature it was not possible to prepare and isolate the 
target compounds. In this study the isolation was only possible via the BOC derivative. The 
BOC group was then removed by treating with strong acids (Shendage. D, et al., 2004) to 
collect the title compound.   
 
3.13.1 Attempted synthesis of Compound 3.25 and other related compounds:  
In an attempt to synthesise Compound 3.25, Compound 3.32 was first obtained by treating 
the aldehyde with a large excess of hydrazine; the resultant compound was then reduced 
using palladium catalyst as shown in Figure 3.11.  
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N
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DIEA + Impurities
Compound 3.32  Compound 3.28   Compound 3.25 
Scheme 3.4:  Synthesis of the Compound 3.25.  
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The benzylhydrazine was then heated at reflux with Compound 3.28 in presence of Hunig’s 
base in butanol. The 1H NMR spectrum of the amide product and the TLC indicated a 
complex mixture. Recrystallisation of the final product was not possible. The reaction was 
also carried out in reduced boiling point solvents such as toluene and ethanol and also at 
room temperature, but this gave no improvement. Again the presence of two potentially 
reactive nitrogens in the benzyl hydrazines and the derivative products (Compound 3.32, 
3.33 and 3.34) might have been the source of some of the observed impurities.  
 
3.13.2 Attempted synthesis of Compound 3.20 and related compounds:  
 
In an attempt to prepare the Compound 3.20, Compound 3.38 was heated at reflux with the 
Compound 3.28 in Hunig’s base dissolved in butanol. It was observed that the resultant 
compounds were the mixture of two starting materials.  
 
OHO
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Compound 3.38   Compound 3.28        
 
Scheme 3. 5:  Showing the synthesis of Compound 3.20. 
 
It appears that the benzoyl hydrazide is not sufficiently nucleophilic under these conditions.  
 
3.13.3 Attempted synthesis of 3-methoxy-2-hydroxy benzyl amine Compound 3.40: 
 
The 3-methoxy substitution on the benzyl ring of Compound 3.1 has been observed to make 
good interaction within the active site model and therefore an attempt has been made to 
synthesise the 3-methoxy-2-hydroxy benzyl substituted analogue of the compound Type A 
as in Figure 3.3. The aldehyde was first treated with a mixture of methylamine in methanol 
and Na2CO3 and then with another mixture of nitromethane in methanol (Ma, Wu et al. 2004). 
The corresponding compound was then reduced using palladium (Daeniker, et al., 1973) a 
shown in Figure 3.26.  
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Scheme 3.6: Attempted synthesis of 3-methoxy-2-hydroxy benzyl amine. 
 
The TLC and 1H-NMR analysis indicatesd the presence of a complex mixture.  
 
3.13.4 Attempted synthesis of Compound 3.29:  
 
The methyl group attached to the sulphonamide has shown some good interaction within the 
active site. Therefore in an attempt to synthesise Compound 3.29, Compound 3.31 was 
treated with 40% methylamine in water. The resultant compound was found to contain the 
double addition product of the methylamine as shown in Scheme 3.7. 
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Scheme 3. 7:  Showing synthesis of compound 3.35.  
 
It was observed that on reaction of the Compound 3.31 with 2M methylamine in methanol 
solution, the corresponding product is a mixture of single and double addition product of the 
amine. On further analysis of the rate and duration of the reaction within 1st, 2nd and 24 
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hours, it was observed that the double addition starts immediately within 1st hour on adding 
the amine. This reaction was however found successful with the concentrated ammonia 
solution giving only the mono addition product.  This could possibly due to the fact that the 
methylamines are more reactive than ammonia. The presence of the electron donating 
methyl group pumps electrons into the amino group making the amino groups more reactive. 
Interestingly the amino group within the phenethylamines also carries the similar properties; 
these amines however required high temperature (120oC) to react with Compound 3.31.  
 
3.13.5 Structural Activity Relationship studies: 
Out of the 14 compounds synthesised, 8 compounds have been tested for biological 
activities against the pathogen organism. Only one compound (Compound 3.11) has shown 
activity against the organism M. tuberculosis. The IC50 value of this compound was found to 
be 65.6 µg/mL and the IC90 value of 97.12 µg/mL; all other compounds were found inactive 
showing IC50 values more than 100 µg/mL. In the earlier research carried out by Agrawal et 
al., compound 3.1 was found to be very active (Agrawal et al., 2007) with Ki value of 5.7±1.2. 
In this investigation the active and the inactive compounds from the studies carried out by 
Agrawal et al., were employed and a protein model was designed that ranks the compounds 
toward their possible antibacterial activity. The compound 3.2, which was one of the closest 
analogues of the most potent Compound 3.1 was expected to show biological activity 
according to the chorismate mutase model designed in chapter 2 (Figure 3.19). Interestingly 
both the compounds have the nitro, carboxylic and the sulphonamide substituents which 
have shown similar interaction within the model. This compound only lacks the methoxy 
groups which were replaced with the hydroxyl groups. The hydrogen bondings which were 
however observed with compound 3.1 were also observed with the compound 3.2, however 
it lacks efficacy within the organism, perhaps because of its pharmaceutical properties.  
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Compound 3.1 
 
Figure 3.18:  Showing the interaction of the compound 3.1 within the active site.  
 
 
The methoxy groups of the Compound 3.1 have shown some key interaction (Figure 3.19) 
with the residues in the active site of the model. These interactions were improved by 
substituting the methoxy groups of Compound 3.1 with the hydroxyl groups as in Compound 
3.2, Compound 3.3 and Compound 3.4. Unfortunately all these compounds lack efficacy 
when tested for biological activity. Interestingly all these compounds were the analogues of 
Compound 3.1 containg the same subtituents, except the methoxy groups.  
 
 
Compound IC50 (µg/mL) Mol weight Calc LogP Hydrogen bond acceptor 
Hydrogen 
bond donor 
      
3.11 65.600 331 3.28 9 2 
3.2 >100 397 1.25 11 6 
3.3 >100 413 0.98 12 7 
3.4 >100 381 1.54 10 5 
3.5 >100 365 2.01 9 4 
3.8 >100 363 2.31 11 4 
3.10 >100 347 2.80 10 3 
3.12 >100 361 3.31 10 2 
 
Table 3.5: The lipinski’s calculation of the molecular properties. LogP was calculated 
using Fijitsu CAChe 6.1 
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All the compounds in this chapter of the thesis were isolated as TFA salts. This gives an 
additional weight of 114 to all the compounds shown in table 3.5. The Compound 3.1 had 11 
hydrogen bond acceptors and 4 hydrogen bond donors and perhaps was isolated as a free 
molecule and thus falls within Lipinski’s rule of 5 (Lipinski et al., 2001). Interestingly 
Compound 3.2, Compound 3.3 and Compound 3.4 all have more than 5 hydrogen bond 
donors and molecular weight more than 500 (as TFA salts form) therefore do not obey 
Lipinski’s rule of 5. Although the lack of efficacy of these compounds particularly Compound 
3.2 and Compound 3.3 can be supported at this stage by Lipinski’s rule, however this 
requires attention when considering these compounds for further development.  Compound 
3.11 on the other hand stays well within the Lipinski’s rule.   
 
The Compound 3.12 in particular had the 3-methoxy substitution on the phenylamine moiety 
and successfully showed good interactions with the active site residues in the protein model 
of the enzyme, however showed no biological activity when tested in the organism.  The 
Compound 3.11 on the other hand was found to be active with IC50 value of 65.6 µg/mL.  
This compound had a nitro substitution instead of sulphonamide and was also devoid of any 
substitution on the phenethylamine moiety. Interestingly this compound had 2 hydrogen bond 
donors and obeys the Lipinski’s rule. The nitro substitution however carries almost smiliar 
electronic effect to the sulphonamide as in Compound 3.1. 
 
NH
OHO
NO2O2N
 
NH
OHO
S
O
O
NH2
NO2
O
O
 
Compound 3.11 
IC50 65.6 µg/mL 
Compound 3.1 
Ki value of 5.7±1.2 nM 
 
Scheme 3.8:  Showing structural similarity between compound 3.11 and compound 3.1  
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These di-nitro substituted benzoic acid derivatives also have shown good interaction within 
the chorismate mutase model and these compounds were ranked well in the model. The 3,4-
dimethoxy substituted phenylamines, 3-methoxy- 4-hydroxyphenylamine and the 4-methoxy-
3-hydroxy substituted phenylamines have shown interesting  interactions within the model 
but these compounds were not possible to synthesise due to the restriction of laboratory use 
of these compounds (www.homeoffice.gov.uk/documents/cdlist.pdf) .  
 
The protein model prepared in the previous chapter (Chapter 2) was based on the potential 
interactions between the active site residues and the Compound 3.1 whch has shown 
significant activity against mycobacterial chorismate mutase (Aggarwal et al., 2007). 
Compounds 3.2 to 3.7 of figure 3.2 have the same structure with only modification on the 
methoxy groups and according to the model these compounds were expected to show good 
activity in the organism (T.B). Unfortunately none of these compounds have shown biological 
activity when tested against the organism. Compound 3.11 was only biologically active and 
this compound was different to compound 3.1 with the substitutions on both the rings. Thus 
Compound 3.1 together with Compound 3.11 left an interesting area of further research to 
discovery of chorismate mutase inhibitor from Mycobacterim tuberculosis.  
 
Due to the limitation on the structural information in the database of the compounds 
(Aggarwal et al., 2007), the selection of the biologically active and inactive compounds 
became very small. Only 3 active compounds were available to extract the structural 
information of the ligand within the active site. All of these 3 compounds were also 
structurally very different from each other. Despite this limited information it was still possible 
to prepare a model which has ranked these ligands according to their biological activity. 
Although a library of 23 compounds was designed and was attempted for synthesis, it was 
only possible to prepare 12 compounds. This is due to the restriction in the use of the various 
phenylamines and thus the library prepared was small. The information on the synthesis of 
the Compound 3.1 was also not outlined by the authors in the previous research and in this 
work much emphasis was given to establish the steps involved in the preparation and 
isolation of all the analogues of Compound 3.1.  The work in this thesis revealed another 
active compound (Compound 3.11) and some inactive compounds which along with the 
other library (Aggarwal et al., 2007) opened a vast area to carry out further research to 
discover inhibitors of chorismate mutase from Mycobacterium tuberculosis.  
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3.14 Conclusion:  
 
A library of the substituted sulphamoyl benzoic acid derivatives which were ranked well in the 
model was prepared. All these compounds have been successfully isolated, purified and 
characterised. These compounds have been screened for biological activity against the 
pathogenic organism Mycobacterium tuberculosis. Only one compound has shown activity 
against the pathogenic organism and all the rest were found inactive.  
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CHAPTER 4 
MATERIALS AND METHODS 
 
 
 
4.1. Chemicals: 
All chemicals and solvents were used as supplied. 4-chlorobenzoic acid, fuming nitric acid, 
chlorosulphonic aicd, ammonia solution, phenethylamines, hydrazine monohydrate and all 
the aldehydes were purchased from Sigma-Aldrich. Organic solvents were purchased from 
Fisher Chemicals. Thin layer chromatography plates on aluminium sheets (20 X 20) of silica 
gel F254 were obtained from Merck.  
 
4.2. Instrumentation:  
Proton NMR spectra were obtained on a Bruker AC 250 instrument operating at 250 MHz as 
solution in d6-DMSO and referenced from δDMSO = 2.50 ppm unless otherwise stated. 
Infrared spectra were recorded as KBr disc on a Mattson 3000 FTIR spectrophotometer. 
(APCI-MS) was carried out on a Hewlett-Packard 5989B quadrupole instrument connected to 
an electrospray 59987A unit with an APCI accessory and automatic injecting using a 
Hewlett-Packard 1100 series autosampler. Accurate MS was carried out on TOF mass 
spectra (ESI mode) measured on a Waters LCT Premier Mass Spectrometer.  
  
4.3.1.1 Preparation of 4-chloro-3-chlorosulfonylbenzoic acid: Compound 3.30.  
S
O
OOH
O ClCl
 
11ml or 0.165 mol of chlorosulfonic acid was taken in a three neck flask. The temperature 
inside the flask was maintained at 15oC.  5g or 0.0319 mol of 4-chlorobenzoic acid was 
added gradually with constant stirring. The temperature within the flask was then maintained 
at 125oC and was left to react for 24 hours. The reaction mixture was then cooled and added 
dropwise into 100ml of ice water with constant stirring. The white product precipitated out 
which was then filtered and freeze dried for 48 hours to obtain white amorphous powder.  
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Yield was 6.06g, 24.047 mmol, 75%.     
1H NMR (250 MHz d6-DMSO): 8.42 (d, 1H, J= 1.896 Hz, Benzyl-6H); 7.85 (dd, 1H, J= 1.896, 
8.214 Hz, Benzyl-2H); 7.5 (d, 1H, J= 8.214 Hz, Benzyl-2H); 8.47 (s, 1H, OH) ppm. 
MS (APCI -) m/z = found 201, 215, 235, 237, 249, 251, (M - H) +.  
IR (KBr) ν= 3404-3087, 2900 (-COOH), 2645, 2500, 2198, 1928, 1833, 1735, 1598, 1478, 
1410 (SO2Cl), 1307 cm-1 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.75 (single spot).  
4.3.1.2 Preparation of 4-chloro-3-chlorosulfonyl-5-nitrobenzoic acid: Compound 3.31.  
S
O
OOH
NO2
O ClCl
 
6.06g or 0.0237 mol of 4-chloro-3-sulfonylbenzoic acid was dissolved in 98% concentrated 
sulphuric acid was taken in a three neck flask. The temperature was maintained within -15oC 
to -10oC. 33ml of nitrating mixture prepared from 9ml of fuming nitric acid in 24ml of 
concentrated sulphuric acid was added drop wise into the flask with continuous stirring. The 
temperature was then raised slowly to 105oC when the suspension dissolves to a solution 
and was left to react overnight. The reaction mixture was cooled and added drop wise into 
300ml of ice water, it was then filtered, washed and collected as white amorphous powder.  
 
Yield = 7.07g, 23.64mmol, 98.6 %. 
Mp: 153.3-156.6 oC 
1H NMR (250 MHz d6-DMSO): 8.61 (d, 1H, J= 1.896 Hz, Benzyl-6H); 8.4 (d, 1H, J= 2.527 
HZ, Benzyl-2H); 4.5 (bs, 1H, OH) ppm. 
MS (APCI +) m/z = found 202, 204 (M – SO2Cl) -, 246 (M – OH, Cl) - , 298 (M - H) -.  
IR (KBr) ν= 3384-3087, 2894 (-COOH), 2645, 2500, 2198, 1958, 1847, 1698, 1598, 1544 (-
NO2), 1420- 1150 (SO2Cl and NO2),   cm-1 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.187 (single spot).  
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4.3.1.3 Preparation of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid: Compound 3.27.  
S
O
NH2
OOH
NO2
O Cl
 
7g or 23.300 mmol of 4-chloro-3-chlorosulfonyl-5-nitro-benzoic acid was dissolved in 80ml of 
2M concentrated ammonia in methanol solution. The suspension slowly turns yellow and the 
reaction mixture was left was left to react for 24 hours. The reaction mixture was then 
transferred dropwise into acidified water and the pH was adjusted to just below 6. The 
product was then extracted in ethyl acetate, evaporated, dried and collected as yellow 
amorphous powder.     
 
Yield: 3.78g or 13.404mmol, 58% 
Mp: 121.6-125.7 0C 
1H NMR (250 MHz d6-DMSO): 8.69 (d, 1H, J= 1.86 Hz, Ph-6H); 8.55 (d, 1H, J= 1.86 Hz, Ph-
2H); 8.00 (bs, 1H, OH); 7.55 (bs, 2H, NH2) ppm. 
MS (APCI -) m/z = found 201 (M – SO2 NH2)-, 235 (M – NO2)-, 245 (M – Cl)-, 279 (M - H) -.  
IR (KBr) ν= 3575, 3300-2790, 2315, 2295, 2100, 1890, 1810, 1665, 1610, 1550 (-NO2), 
1475, 1335 (-SO2NH2) cm-1 
MS (-ES) = 278.95 (M - H)- and 280.95 (M - H)-  
Accurate MS (-ES) = Calculated 278.9479 (m-H)- and 280.9451 (m-H)- found 278.9478 (m-
H)- and 280.9453 (m-H)-,  0.4 ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.58 (single spot tailing).  
Material and Methods  2010 
 
P a g e  | 167  
 
4.4.1 Preparation of 4-(3,4-dihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid : Compound 3.2.  
S
NH
O
NH2
OOH
NO2
O
OH
OH
 
4.4.1.1. Preparation of DIEA salt of 4-(3,4-dihydroxyphenethylamino)-3-sulphamoyl-5-
nitro benzoic acid:  
0.159g or 0.567 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in 10ml of 
butanol and 0.35g of diisopropylethylamine was added. 0.1g or 0.529 mmol of dopamine was 
then added into the reaction mixture and left reacted under reflux for 24 hours under argon. 
The solvent was then evaporated to obtain thick yellow oil.  
 
Yield = 0.17g or 0.426 mmol, 75% 
1H NMR (250 MHz d6-DMSO): 9.8 (s, 1H, OH); 9.65 (s, 1H, OH); 8.55 (d, 1H, J= 1.86 Hz, Ph-
2H); 8.35 (d, 1H, J= 1.86 Hz, Ph-6H); 7.9 (bs, 2H, NH2); 7.00 (s, 1H, NH); 6.8 (d, 1H, J= 
8.214 Hz, Ph-2H); 6.8 (d, 1H, J= 1.896 Hz, Ph-5H); 6.65 (dd, 1H, J= 1.896, 8.214 Hz, Ph-
6H); 3.15 (dd, J= Hz, 2H, CH2); 2.78 (dd, J= Hz, 2H, CH2) ppm.  
TLC carried out in ethyl acetate: methanol (4:1) shows long tailing from baseline.  
4.4.1.2 Preparation of BOC substituted 4-(3,4-dihydroxyphenethylamino)-3-sulphamoyl-5-
nitro benzoic acid :  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549 mmol of BOC 
anhydride was added and left reacted for 48 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.14g  
1H NMR (250 MHz d6-DMSO): 9.8 (s, 1H, OH); 9.65 (s, 1H, OH); 8.55 (d, 1H, J= 1.86 Hz, Ph-
2H); 8.35 (d, 1H, J= 1.86 Hz, Ph-6H); 8.00 (bs, 2H, NH2); 7.00 (s, 1H, NH); 6.7 (d, 1H, J= 
8.214 Hz, Ph-2H); 6.7 (d, 1H, J= 1.896 Hz, Ph-5H); 6.5 (dd, 1H, J= 1.896, 8.214 Hz, Ph-6H); 
3.15 (dd, J= Hz, 2H, CH2); 2.78 (dd, J= Hz, 2H, CH2); 1.5 (s, 9H, BOC) ppm.  
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TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.72 (tailing). 
4.4 1.3. Preparation of 4-(3,4-dihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid : 
The BOC substituted product was then dissolved in 5ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 4 hours. The final product was obtained by 
evaporating the reaction mixture to obtain the dark yellow colour product.  
 
Yield: 0.1g, 0.251 mmol, 44% 
Mp: 63.2 – 68.1 0C. 
1H NMR (250 MHz d6-DMSO): 8.8 (bs, 2H, Phenyl-OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 
8.32 (d, 1H, J= 1.896 Hz, Ph-2H); 794 (s, 2H, NH2); 7.05 (t, 1H, NH); 6.62 (d, 1H, J= 8.214 
Hz, Ph-2H); 6.6 (d, 1H, J= 1.896 Hz, Ph-5H); 6.45 (dd, 1H, J= 1.896, 8.214 Hz, Ph-6H); 
3.064 (m, 2H, CH2); 2.72 (m, 2H, CH2) ppm. 
IR (KBr) ν= 3357, 3202, 3090, 2931, 2855, 2637, 2366, 1856, 1657, 1614, 1575 (-NO2), 1410 
(-OH), 1325(-SO2NH2) cm-1 
MS (ES -) m/z = found 396.05 (M - H) -.  
Accurate MS (-ES) = Calculated 396.0502 (m-H)- found 396.0505 (m-H)- 0.8 ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.44 (single spot small tailing). 
 
4.5.1. Preparation of 4-(phenethylamino)-3-sulphamoyl-5-nitro benzoic acid: 
Compound 3.5.  
S
NH
O
NH2
OOH
NO2
O
 
4.5.1.1 Preparation of DIEA salt of 4-(phenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
0.15g or 0.567 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in n-10ml of 
butanol and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.075g or 0.619 mmol 
of phenethylamine was then added into the reaction mixture and left reacted under reflux for 
16 hours. The solvent was then evaporated to obtain thick yellow oil.  
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Yield = 0.2g 0.549 mmol, 96% 
1H NMR (250 MHz d6-DMSO): 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 1H, J= 1.896 Hz, 
Ph-2H); 8.00 (bs, 2H, NH2); 7.2 (m, 5H, Ph-H); 4.4 (s, 1H, NH); 3.1 (m, 2H, CH2); 2.8 (dd, J= 
2.52, 8.84 Hz, 2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.75 (single spot). 
4.5.1.2 Preparation of BOC substituted 4-(phenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid:  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 48 hours. The solvent was then evaporated and the 
product was dissolved in ammonium chloride solution and then extracted into ethyl acetate to 
obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.338g, 
1H NMR (250 MHz d6-DMSO): 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 1H, J= 1.896 Hz, 
Ph-2H); 7.8 (bs, 2H, NH2); 7.2 (m, 5H, Ph-H); 7.1 (s, 1H, NH); 6.9 (t, 1H, NH); 3.15 (dd, J= 
1.89, 8.21 Hz, 2H, CH2); 2.6 (dd, J= 2.52, 8.84 Hz, 2H, CH2); 1.5 (s, 9H, BOC) ppm.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.73 (single spot). 
4.5.1.3.  Preparation of 4-(phenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
The BOC substituted product was then dissolved in 5ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 4 hours. The final product was obtained by 
evaporating the reaction mixture to obtain the yellow colour product (yield = 0.24g or 
0.657mmol), which was recrystallised from dichloromethane to give bright yellow product. 
 
Yield = 0.09g or 0.246 mmol or 46% 
Mp: 157.2 – 163.0 0C 
1H NMR (250 MHz d6-DMSO): 13.15 (bs, 1H, OH); 8.46 (d, 1H, J= 1.896 Hz, Ph-6H); 8.33 (d, 
1H, J= 1.896 Hz, Ph-2H); 7.9 (s, 2H, NH2); 7.28 (m, 5H, Ph-H); 7.1 (s, 1H, NH); 3.16 (m, 2H, 
CH2); 2.8 (dd, J= 2.52, 8.84 Hz, 2H, CH2); ppm.  
IR (KBr) ν= 3378, 3347, 3272, 3083, 3025, 2958, 2658, 2624, 2529, 2282, 1955, 1688, 1610, 
1550 (-NO2), 1407, 1320 (-SO2NH2)  cm-1 
MS (ES -) m/z = found 364 (M - H) -.  
Accurate MS (-ES) = Calculated 364.0603 (m-H)- found 364.0601 (m-H)- 0.5 ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.62 (single spot). 
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4.6.1. Preparation of 4-(4-hydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid: 
Compound 3.4.  
S
NH
O
NH2
OOH
NO2
O
OH
 
4.6.1.1 Preparation of DIEA salt of 4-(4-hydroxyphenethylamino)-3-sulphamoyl-5-nitro 
benzoic acid:  
0.151g or 0.567 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in 10ml of 
butanol and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.1g or 0.578 mmol of 
4-hydroxyphenethylamine was then added into the reaction mixture and left reacted under 
reflux for 16 hours. The solvent was then evaporated to obtain a thick mass.  
 
Yield = 0.19g 0.490mmol, 86% 
1H NMR (250 MHz d6-DMSO): 9.45 (s, 1H, OH); 8.48 (d, 1H, J= 1.896 Hz, Ph-6H); 8.29 (d, 
1H, J= 1.896 Hz, Ph-2H); 8.00 (bs, 2H, NH2); 7.06 (dd, 2H, J= 8.214, 1.896 Hz, Ph-H); 6.9 (s, 
1H, OH); 6.67 (dd, 2H, J= 1.896, 8.214 Hz, Ph-H); 4.4 (s, 1H, NH); 3.064 (m, 2H, CH2); 2.72 
(m, 2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.66 (long tailing) 
4.6.1.2 Preparation of BOC substituted 4-(4-hydroxyphenethylamino)-3-sulphamoyl-5-nitro 
benzoic acid:  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 48 hours. The solvent was then evaporated and the 
product was dissolved and ammonium chloride solution and then extracted into ethyl acetate 
to obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.121g or 0.244mmol 
1H NMR (250 MHz d6-DMSO): 9.3 (bs, 1H, OH); 9.2 (bs, 1H, OH); 8.48 (d, 1H, J= 1.896 Hz, 
Ph-6H); 8.29 (d, 1H, J= 1.896 Hz, Ph-2H); 8.00 (s, 2H, NH2); 7.06 (dd, 2H, J= 8.214, 1.896 
Hz, Ph-H); 6.9 (s, 1H, OH); 6.67 (dd, 2H, J= 1.896, 8.214 Hz, Ph-H); 3.064 (m, 2H, CH2); 
2.72 (m,  2H, CH2); 1.5 (s, 9H, BOC) ppm. 
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TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.49 (single spot). 
4.6.1.3 Preparation of 4-(4-hydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
0.121g or 0.244mmol of the BOC substituted product was then dissolved in 5ml 
dichloromethane and 5ml trifluoroacetic acid was added and left reacted for 4 hours. The 
final product was obtained by evaporating the reaction mixture to obtain the brown colour 
product, which was then recrystallised from dichloromethane.  
 
Yield = 0.147g or 0.385 mmol or 72% 
Mp: 160.2 – 163.5 0C 
1H NMR (250 MHz d6-DMSO): 13.1 (bs, 1H, NH); 9.3 (s, 1H, OH); 9.2 (s, 1H, OH); 8.46 (d, 
1H, J= 1.896 Hz, Ph-6H); 8.3 (d, 1H, J= 1.896 Hz, Ph-2H); 8.00 (s, 2H, NH2); 7.08 (dd, 2H, 
J= 8.214, 1.896 Hz, Ph-H); 6.67 (dd, 2H, J= 1.896, 8.214 Hz, Ph-H); 3.093 (bd, 2H, CH2); 
2.72 (m, 2H, CH2); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.238 (single spot). 
IR (KBr) ν= 3459, 3366, 3347, 3318, 3200, 3083, 2666, 2537, 1872, 1679, 1610, 1520(-NO2), 
1410 (-OH), 1407, 1330 (-SO2NH2) cm-1 
MS (ES -) m/z = found 380.05 (M - H) -.  
Accurate MS (-ES) = Calculated 380.0552 (m-H)- found 380.0551 (m-H)- 0.3 ppm. 
4.7.1 Preparation of 4-(3,4,5-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid : Compound 3.3.  
S
NH
O
NH2
OOH
NO2
O OH
OH
OH
 
4.7.1.1 Preparation of DIEA salt of 4-(3,4,5-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro 
benzoic acid:  
0.14g or 0.537 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in 15ml of 
butanol and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.095g or 0.463 mmol 
of 3,4,5-trihydroxyphenethylamine was then added into the reaction mixture and left reacted 
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under reflux for 16 hours under argon. The solvent was then evaporated to obtain thick 
yellow oil.  
 
Yield = 0.2g, 0.485mmol, 90.4% 
1H NMR (250 MHz d6-DMSO): 9.5 (bs, 2H, OH); 8.8 (bs, 1H, OH); 8.44 (d, 1H, J= 2.527 Hz, 
Ph-6H); 8.32 (d, 1H, J= 2.527 Hz, Ph-2H); 7.9 (bs, 2H, NH2); 6.9 (bs, 1H, OH); 6.13 (s, 2H, 
Ph-H); 4.4 (bs, 1H, NH); 3.064 (m, 2H, CH2); 2.62 (m,  2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.25 (tailing). 
4.7.1.2 Preparation of BOC substituted 4-(3,4,5-trihydroxyphenethylamino)-3-sulphamoyl-5-
nitro benzoic acid:  
The product was then dissolved in 25ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 24 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the yellowish brown BOC substituted product.  
 
Yield = 0.133g. 
1H NMR (250 MHz d6-DMSO): 8.8 (s, 3H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 2.527 Hz, Ph-2H); 7.9 (bs, 2H, NH2); 6.9 (bs, 1H, OH); 6.12 (s, 2H, Ph-H); 4.4 (t, 1H, 
NH); 3.034 (m, 2H, CH2); 2.62 (m, 2H, CH2); 1.5 (s, 9H, BOC); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.125 (tailing). 
4.7.1.3 Preparation of  4-(3,4,5-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours under argon. The final product 
was obtained by evaporating the reaction mixture to obtain the yellowish brown colour 
product.  
 
Yield = 0.1g, 0.234 mmol or 48% 
1H NMR (250 MHz d6-DMSO): 8.8 (s, 1H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 2.527 Hz, Ph-2H); 7.9 (s, 2H, NH2); 7.3 (s, 1H, OH); 7.1 (s, 1H, OH); 6.9 (s, 1H, OH); 
6.12 (s, 2H, Ph-H); 4.4 (bs, 1H, NH); 3.034 (m, 2H, CH2); 2.62 (m, 2H, CH2); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.17 (tailing). 
MS (ES -) m/z = found 412.05 (M - H) -  
MS (ES +) m/z = found 414.06 (M + H) +   
Accurate MS (-ES) = Calculated 412.0451 (m-H)- found 412.0449 (m-H)- 0.5 ppm. 
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4.8.1 Preparation of 4-(3,4,6-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic 
acid : Compound 3.7.  
S
NH
O
NH2
OOH
NO2
O OH
OHOH
 
4.8.1.1 Preparation of DIEA salt of 4-(3,4,6-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro 
benzoic acid:  
0.14g or 0.537 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in 15ml of 
butanol and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.1g or 0.487 mmol of 
3,4,5-trihydroxyphenethylamie was then added into the reaction mixture and left reacted 
under reflux for 16 hours under argon. The solvent was then evaporated to obtain thick 
brown oil.  
 
Yield = 0.26g, 0.631mmol 100% 
1H NMR (250 MHz d6-DMSO): 8.8 (s, 1H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 2.527 Hz, Ph-2H); 7.9 (s, 2H, NH2); 7.0 (bs, 3H, OH); 6.12 (s, 1H, Ph-H); 5.9 (s, 1H, 
Ph-H); (4.4 (bs, 1H, NH); 3.034 (bt, 2H, CH2); 2.62 (dd, J=8.214 Hz, 2H, CH2); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.25 (tailing). 
4.8.1.2 Preparation of BOC substituted 4-(3,4,6-trihydroxyphenethylamino)-3-sulphamoyl-5-
nitro benzoic acid:  
The product was then dissolved in 25ml acetonitrile and 0.125g or 0.571mmol of BOC 
anhydride was added and left reacted for 24 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the yellowish brown BOC substituted product.  
 
Yield = 0.12g 
1H NMR (250 MHz d6-DMSO): 8.8 (s, 1H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 2.527 Hz, Ph-2H); 7.9 (s, 2H, NH2); 7.0 (bs, 3H, OH); 6.12 (s, 1H, Ph-H); 5.9 (s, 1H, 
Ph-H); (4.4 (bs, 1H, NH); 3.034 (bt, 2H, CH2); 2.62 (dd, J=8.214 Hz, 2H, CH2); 1.5 (s, 9H, 
BOC); ppm. 
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TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.25 (tailing). 
4.8.1.3 Preparation of 4-(3,4,6-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours under argon. The final product 
was obtained by evaporating the reaction mixture to obtain the yellowish brown colour 
product.  
 
Yield = 0.101 g or 0.234 mmol or 48% 
1H NMR (250 MHz d6-DMSO): 8.8 (s, 1H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 2.527 Hz, Ph-2H); 7.9 (s, 2H, NH2); 7.0 (bs, 3H, OH); 6.12 (s, 1H, Ph-H); 5.9 (s, 1H, 
Ph-H); (4.4 (bs, 1H, NH); 3.034 (bt, 2H, CH2); 2.62 (dd, J=8.214 Hz, 2H, CH2); ppm. 
MS (ES -) m/z = found 412. (M - H) –  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.47 (tailing). 
4.9.1 Preparation of 4-(3-methoxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid 
: Compound 3.6  
S
NH
O
NH2
OOH
NO2
O O
 
4.9.1.1 Preparation of DIEA salt of 4-(3-methoxyphenethylamino)-3-sulphamoyl-5-nitro 
benzoic acid:  
0.14g or 0.5 mmol of 4-chloro-3-sulphamoyl-5-nitrobenzoic acid was dissolved in 10ml of 
butanol and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.079g or 0.523 mmol 
of 3-methoxyphenethylamine was then added into the reaction mixture and left reacted under 
reflux for 36 hours under argon. The solvent was then evaporated to obtain thick yellow oil.  
 
Yield = 0.16g, 0.405mmol, 81% 
1H NMR (250 MHz d6-DMSO): 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 1H, J= 1.896 Hz, 
Ph-2H); 8.00 (bs, 2H, NH2); 7.2 (dd, 1H, J= 8.214 Hz, Ph-4H); 6.8 (d, 1H, J= 1.896 Hz, Ph-
5H); 6.8 (dd, 2H, J= 1.896, 8.214 Hz, Ph-6H); 4.4 (bs, 1H, NH); 3.064 (m, 2H, CH2); 2.72 (dd, 
J= 2.52, 8.84 Hz, 2H, CH2) ppm. 
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TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.14 (single spot). 
4.9.1.2. Preparation of BOC substituted 4-(3-methoxyphenethylamino)-3-sulphamoyl-
5-nitro benzoic acid:  
The product was then dissolved in 25ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 16 hours under argon. The solvent was then 
evaporated under high vaccum pump and the product was partitioned between ammonium 
hydrochloride solution and ethyl acetate. The organic layer was then evaporated to obtain 
the BOC substituted product as a yellow sticky mass.  
 
Yield = 0.11g 
1H NMR (250 MHz d6-DMSO): 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 1H, J= 1.896 Hz, 
Ph-2H); 8.00 (s, 2H, NH2); 7.2 (dd, 1H, J= 8.214 Hz, Ph-4H); 6.8 (d, 1H, J= 1.896 Hz, Ph-
5H); 6.8 (dd, 2H, J= 1.896, 8.214 Hz, Ph-6H); 3.064 (m, 2H, CH2); 2.72 (dd, J= 2.52, 8.84 Hz, 
2H, CH2); 1.5 (s, 9H, BOC); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.15 (single spot). 
4.9.1.3 Preparation of 4-(3,4,5-trihydroxyphenethylamino)-3-sulphamoyl-5-nitro benzoic acid:  
The BOC substituted product was then dissolved in 10ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours. The final product was obtained 
by evaporating the reaction mixture to obtain the brown colour product. It was then 
recrystallised from dichloromethane and dried.  
 
Yield = 0.08g or 0.202 mmol or 40% 
Mp: 195.1 – 199.8 0C 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.44 (single spot). 
1H NMR (250 MHz d6-DMSO): 13.1 (bs, 1H, OH); 8.44 (d, 1H, J= 1.896 Hz, Ph-6H); 8.32 (d, 
1H, J= 1.896 Hz, Ph-2H); 8.00 (bs, 2H, NH2); 7.2 (dd, 1H, J= 8.214 Hz, Ph-4H); 6.8 (d, 1H, 
J= 1.896 Hz, Ph-5H); 6.8 (dd, 2H, J= 1.896, 8.214 Hz, Ph-6H); 3.064 (m, 2H, CH2); 2.72 (dd, 
J= 2.52, 8.84 Hz, 2H, CH2) ppm. 
IR (KBr) ν= 343351, 3266, 3087, 2957, 2834 (-OCH3), 2622, 2541, 2300, 1938, 1695, 1610, 
1520, 1410 (-NO2), 1407, 1325 (-SO2NH2) cm-1 
MS (ES -) m/z = found 394 (M - H) -.  
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4.10.1. Preparation of 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro benzoic acid: 
Compound 3.8.  
NH
OOH
NO2O2N
OH
OH
 
4.10.1.1 Preparation of DIEA salt of 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
0.25g or 1.016 mmol of 3, 5-dinitro-4-chloro benzoic acid was dissolved in 25ml of butanol 
and 0.33g or 2.557 mmol of di-isopropylethylamine was added. 0.185g or 0.978 mmol of 
dopamine was then added into the reaction mixture and left reacted under reflux for 16 hours 
under argon. The solvent was then evaporated to obtain thick yellow oil.  
 
Yield = 0.14g, 386mmol 
1H NMR (250 MHz d6-DMSO): 8.61 (s, 2H, Ph-H ); 8.45 (t, 1H, NH ); 6.69 (d, 1H, J= 7.58 Hz, 
Ph-2H); 6.62 (d, 1H, J= 1.896 Hz, Ph-5H); 6.45 (dd, 1H, J= 1.896, 7.58 Hz, Ph-6H); 3.13 (m, 
2H, CH2); 2.77 (m, 2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.83 (single spot). 
4.10.1.2 Preparation of BOC substituted 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
The product was then dissolved in 10ml acetonitrile and 0.158g or 0.722mmol of BOC 
anhydride was added and left reacted for 48 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.171g 
1H NMR (250 MHz d6-DMSO): 8.61 (s, 2H, Ph-H ); 8.45 (t, 1H, NH ); 6.69 (d, 1H, J= 7.58 Hz, 
Ph-2H); 6.62 (d, 1H, J= 1.896 Hz, Ph-5H); 6.45 (dd, 1H, J= 1.896, 7.58 Hz, Ph-6H); 3.13 (m, 
2H, CH2); 2.77 (m, 2H, CH2); 1.5 (s, 9H, tert-Butyl, BOC) ppm. 
IR (KBr) ν= 3416, 3316, 3171, 2954, 2282, 1868, 1690, 1621, 1595, 1520, 1410, 1407, 1320 
cm-1 
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TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.44 (tailing). 
4.10.1.3 Preparation of 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours under argon. The final product 
was obtained by evaporating the reaction mixture to obtain the yellowish brown colour 
product. 
 
Yield = 0.12g or 0.330 mmol or 34% 
Mp: 206.8 – 210.1 0C.  
1H NMR (250 MHz d6-DMSO): 8.61 (s, 2H, Ph-H ); 8.45 (t, 1H, NH ); 6.69 (d, 1H, J= 7.58 Hz, 
Ph-2H); 6.62 (d, 1H, J= 1.896 Hz, Ph-5H); 6.45 (dd, 1H, J= 1.896, 7.58 Hz, Ph-6H); 3.13 (m, 
2H, CH2); 2.77 (m, 2H, CH2) ppm. 
MS (ES -) m/z = found 362 (M - H) -.  
IR (KBr) ν= 3418, 3305, 3198, 2965, 2641, 2287, 1872, 1690, 1621, 1595, 1520, 1410, 1407, 
1320 cm-1 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0..75 (long tailing). 
4.11.1 Preparation of 4-(3-methoxyphenethylamino)-3, 5-dinitro benzoic acid: 
Compound 3.12.  
NH
OOH
NO2O2N
O
 
4.11.1.1 Preparation of DIEA salt of 4-(3-methoxyphenethylamino)-3,5-dinitro benzoic 
acid:  
0.25g or 1.016 mmol of 3, 5-dinitro-4-chloro benzoic acid was dissolved in 20ml of butanol 
and 0.33g or 2.557 mmol of di-isopropylethylamine was added. 0.159g or 1.052 mmol of 3-
methoxyphenethylamine was then added into the reaction mixture and left reacted under 
reflux for 18 hours. The solvent was then evaporated to obtain thick yellow oil. 
 
Yield = 0.861g 
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1H NMR (250 MHz d6-DMSO): 8.57 (s, 2H, Ph-H ); 8.33 (t, 1H, NH ); 7.23 (ddd, 1H, J= 1.26, 
7.58, 8.21 Hz Ph-H); 6.79 (overlapping d, 3H, Ph-H); 3.71(s, 3H, methoxy); 3.25 (m, 2H, 
CH2); 2.93 (m, 2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.2 (single spot). 
4.11.1.2 Preparation of BOC substituted 4-(3-methoxyphenethylamino)-3,5-dinitro 
benzoic acid:  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 48 hours. The solvent was then evaporated and the 
product was dissolved in ammonium chloride solution and then extracted into ethyl acetate to 
obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.171g 
1H NMR (250 MHz d6-DMSO): 8.57 (s, 2H, Ph-H ); 8.33 (t, 1H, NH ); 7.23 (ddd, 1H, J= 1.26, 
7.58, 8.21 Hz Ph-H); 6.79 (overlapping d, 3H, Ph-H); 3.71(s, 3H, methoxy); 3.25 (m, 2H, 
CH2); 2.93 (m, 2H, CH2); 1.5 (s, 9H, tert-Butyl, BOC) ppm. 
IR (KBr) ν= 3416, 3316, 3171, 2954, 2282, 1868, 1690, 1621, 1595, 1520, 1410, 1407, 1320 
cm-1 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.2 (single spot). 
4.11.1.3 Preparation of 4-(3-methoxyphenethylamino)-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours. The final product was obtained 
by evaporating the reaction mixture to obtain the yellowish brown colour product which was 
then re-crystallized from ether. 
 
Yield = 0.107 or 0.277 mmol or 30% 
Mp: 142.9 – 144.4 0C.  
1H NMR (250 MHz d6-DMSO): 8.57 (s, 2H, Ph-H); 8.33 (t, 1H, NH); 7.23 (ddd, 1H, J= 1.26, 
7.58, 8.21 Hz Ph-H); 6.79 (overlapping d, 3H, Ph-H); 3.71(s, 3H, methoxy); 3.25 (m, 2H, 
CH2); 2.93 (m, 2H, CH2) ppm. 
MS (ES -) m/z = found 361 (M - H) -.   
Accurate MS (-ES) = Calculated 362.0624 (m-H)- and 362.0626 (m-H)- found  
IR (KBr) ν= 3418, 3305, 3198, 3090, 2965, 2658, 2287, 1872, 1690, 1621, 1595, 1520, 1410, 
1407, 1320 cm-1 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.40 (single spot). 
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4.12.1. Preparation of 4-(4-hydroxyphenethylamino)-3,5-dinitro benzoic acid : 
Compound 3.9.  
NH
OOH
NO2O2N
OH
 
4.12.1.1. Preparation of DIEA salt of 4-(4-hydroxyphenethylamino)-3,5-dinitro benzoic 
acid:  
0.246g or 1.00 mmol of 3,5-dinitro-4-chloro benzoic acid was dissolved in 25ml of butanol 
and 0.33g or 2.881 mmol of di-isopropylethylamine was added. 0.171g or 0.984 mmol of 4-
hydroxyphenethylamine was then added into the reaction mixture and left reacted under 
reflux for 18 hours. The solvent was then evaporated to obtain thick yellow oil. 
 
Yield = 0.37g 
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H ); 8.34 (t, 1H, NH ); 7.02 (d, 
2H, J= 8.214 Hz Ph-H); 6.71 (d, 2H, J= 8.214 Hz Ph-H); 3.25 (m, 2H, CH2); 2.87 (m, 2H, 
CH2) ppm. 
MS (ES -) m/z = found 361 (M - H) -.   
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.52 (tailing). 
4.12.1.2. Preparation of BOC substituted 4-(4-hydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
The product was then dissolved in 25ml acetonitrile and 0.24g or 1.098 mmol of BOC 
anhydride was added and left reacted for 48 hours. The solvent was then evaporated and the 
product was dissolved in ammonium chloride solution and then extracted into ethyl acetate to 
obtain the BOC substituted compound as semisolid product.  
 
Yield = 0.43g  
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H ); 8.34 (t, 1H, NH ); 7.2 (bs, 
2H, NH2); 7.02 (d, 2H, J= 8.214 Hz Ph-H); 6.71 (d, 2H, J= 8.214 Hz Ph-H); 3.25 (m, 2H, 
CH2); 2.81 (m, 2H, CH2); 1.5 (s, 9H, tert-Butyl, BOC) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.54 (single spot). 
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4.12.1.3. Preparation of 4-(4-hydroxyphenethylamino)-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours. The final product was obtained 
by evaporating the reaction mixture to obtain the yellowish brown colour product which was 
then recrystallised from DCM. 
 
Yield = 0.15g or 0.432 mmol or 61% 
Mp: 219.7 – 222.6 0C 
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H); 8.34 (t, 1H, NH ); 7.02 (d, 
2H, J= 8.214 Hz Ph-H); 6.71 (d, 2H, J= 8.214 Hz Ph-H); 3.25 (m, 2H, CH2); 2.87 (m, 2H, 
CH2) ppm. 
IR (KBr) ν= 3490, 3324, 3114, 2923, 2641, 2535, 2350, 2285, 1891, 1789, 1683, 1610, 1520, 
1410, 1407, 1320 cm-1 
MS (ES -) m/z = found 346 (M - H) -.  .  
Accurate MS (-ES) = Calculated 346.0675 (m-H)- and 346.0674 (m-H)- found.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.62 (tailing). 
 
4.13.1. Preparation of 4-phenethylamino-3,5-dinitro benzoic acid : Compound 3.11.  
NH
OOH
NO2O2N
 
4.13.1.1. Preparation of DIEA salt of 4-phenethylamino-3,5-dinitro benzoic acid:  
0.247g or 1.01 mmol of 3, 5-dinitro-4-chloro benzoic acid was dissolved in 25ml of butanol 
and 0.35g or 3.055 mmol of di-isopropylethylamine was added. 0.128g or 1.057 mmol of 
phenethylamine was then added into the reaction mixture and left reacted under reflux for 18 
hours. The solvent was then evaporated to obtain thick yellow oil. 
 
Yield = 0.73g  
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H ); 8.34 (t, 1H, NH ); 7.33 
(m, 5H, Ph-H); 3.22 (m, 2H, CH2); 2.96 (m, 2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.59 (single spot). 
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4.13.1.2. Preparation of BOC substituted 4-phenethylamine-3,5-dinitro benzoic acid:  
The product was then dissolved in 25ml acetonitrile and 0.24g or 1.098 mmol of BOC 
anhydride was added and left reacted for 48 hours. The solvent was then evaporated and the 
product was dissolved in ammonium chloride solution and then extracted into ethyl acetate to 
obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.562g.  
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H ); 8.34 (t, 1H, NH ); 7.33 
(m, 5H, Ph-H); 3.22 (m, 2H, CH2); 2.96 (m, 2H, CH2); 1.5 (s, 9H, tert-Butyl, BOC);  ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.54 (single spot). 
4.13.1.3. Preparation of 4-phenethylamine-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 18 hours. The final product was obtained 
by evaporating the reaction mixture to obtain the yellowish brown colour product which was 
then recrystallised from ether.  
 
Yield = 0.145g or 0.438 mmol or 59% 
M.p: 186.8 – 190.1 0C.   
1H NMR (250 MHz d6-DMSO): 9.3 (s, 1H, OH); 8.58 (s, 2H, Ph-H); 8.34 (t, 1H, NH ); 7.33 (m, 
5H, Ph-H); 3.22 (m, 2H, CH2); 2.96 (m, 2H, CH2); ppm. 
IR (KBr) ν= 3420, 3316, 3104, 2923, 2874, 2628, 2531, 2350, 2296, 1958, 1858, 1677, 1610, 
1520, 1410, 1407, 1320 cm-1 
MS (ES -) m/z = found 330 (M - H) -. 
Accurate MS (-ES) = Calculated 330.0726 (m-H)- and 330.0728 (m-H)- found  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.5 (single spot). 
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4.14.1 Preparation of 4-(3,4,6-trihydroxyphenethylamino)-3,5-dinitro benzoic acid : 
Compound 3.13 
NH
OOH
NO2
OH
OHOH
O2N
 
4.14.1.1. Preparation of DIEA salt of 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
0.155g or 0.629 mmol of 3, 5-dinitro-4-chlorobenzoic acid was dissolved in 10ml of butanol 
and 0.3g or 2.325 mmol of diisopropylethylamine was added. 0.075g or 0.619 mmol of 3,4,6-
trihydroxyphenethylamine was then added into the reaction mixture and left reacted under 
reflux for 16 hours under argon. The solvent was then evaporated to obtain thick brown oil.  
 
Yield = 0.12g 
1H NMR (250 MHz d6-DMSO): 8.9 (bs, 1H, OH); 8.58 (s, 2H, Ph-H); 8.3 (t, 1H, NH); 7.0 (bs, 
3H, OH); 6.12 (s, 1H, Ph-H); 5.9 (s, 1H, Ph-H); 3.034 (bt, 2H, CH2); 2.72 (dd, J=8.214 Hz, 
2H, CH2) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.2 (tailing). 
4.14.1.2. Preparation of BOC substituted 4-(3,4,6-trihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 48 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.05g 
1H NMR (250 MHz d6-DMSO): 8.9 (bs, 1H, OH); 8.58 (s, 2H, Ph-H); 7.0 (bs, 3H, OH); 6.12 
(s, 1H, Ph-H); 5.9 (s, 1H, Ph-H); 3.034 (bt, 2H, CH2); 2.72 (dd, J=8.214 Hz, 2H, CH2); 1.5 (s, 
9H, BOC) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.4 (tailing). 
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14.1.3. Preparation of 4-(3,4,6-trihydroxyphenethylamino)-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours under argon. The final product 
was obtained by evaporating the reaction mixture to obtain the yellowish brown colour 
product. 
 
Yield = 0.02g or 10% 
1H NMR (250 MHz d6-DMSO): 8.9 (bs, 1H, OH); 8.58 (s, 2H, Ph-H); 8.3 (t, 1H, NH); 7.0 (bs, 
3H, OH); 6.12 (s, 1H, Ph-H); 5.9 (s, 1H, Ph-H); 3.034 (m, 2H, CH2); 2.72 (m, J=8.214 Hz, 2H, 
CH2) ppm. 
MS (ES -) m/z = found 378 (M - H) -.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.4 (long tailing). 
 
4.15.1 Preparation of 4-(3,4,5-trihydroxyphenethylamino)-3,5-dinitro benzoic acid : 
Compound 3.9.  
NH
OOH
NO2
OH
OH
O2N
OH
 
4.15.1.1. Preparation of DIEA salt of 4-(3,4,5-trihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
0.13 g or 0.528 mmol of 3, 5-dinitro-4-chlorobenzoic acid was dissolved in 10ml of butanol 
and 0.195g or 1.511 mmol of diisopropylethylamine was added. 0.1g or 0.487 mmol of 5-
hydroxy dopamine was then added into the reaction mixture and left for reflux under argon 
for 16 hours under argon. The solvent was then evaporated to obtain thick yellow oil.  
 
Yield = 0.09 g 
1H NMR (250 MHz d6-DMSO): 9.2 (s, 1H, OH); 8.58 (s, 2H, 2H, Ph-H); 7.1 (bs, 3H, OH); 6.12 
(s, 2H, Ph-H); 4.4 (bs, 1H, NH); 3.034 (m, 2H, CH2); 2.62 (m, 2H, CH2); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.5 (long tailing). 
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4.15.1.2. Preparation of BOC substituted 4-(3,4-dihydroxyphenethylamino)-3,5-dinitro 
benzoic acid:  
The product was then dissolved in 15ml acetonitrile and 0.12g or 0.549mmol of BOC 
anhydride was added and left reacted for 48 hours under argon. The solvent was then 
evaporated and the product was dissolved in ammonium chloride solution and then extracted 
into ethyl acetate to obtain the BOC substituted compound as semisolid product. 
 
Yield = 0.04g 
1H NMR (250 MHz d6-DMSO): 9.2 (s, 1H, OH); 8.58 (s, 2H, 2H, Ph-H); 7.1 (bs, 3H, OH); 6.12 
(s, 2H, Ph-H); 4.4 (bs, 1H, NH); 3.034 (m, 2H, CH2); 2.62 (m, 2H, CH2); 1.5 (s, 9H, tert-Butyl, 
BOC) ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.5 (long tailing). 
4.15.1.3. Preparation of  4-(3,4,5-trihydroxyphenethylamino)-3,5-dinitro benzoic acid:  
The BOC substituted product was then dissolved in 15ml dichloromethane and 5ml 
trifluoroacetic acid was added and left reacted for 12 hours under argon. The final product 
was obtained by evaporating the reaction mixture to obtain the yellowish brown colour 
product. 
 
Yield = 0.065g or 32% 
1H NMR (250 MHz d6-DMSO): 9.2 (s, 1H, OH); 8.58 (s, 2H, 2H, Ph-H); 7.1 (bs, 3H, OH); 6.12 
(s, 2H, Ph-H); 4.4 (bs, 1H, NH); 3.034 (m, 2H, CH2); 2.62 (m, 2H, CH2); ppm. 
MS (ES -) m/z = found 378 (M - H) -.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.5 (long tailing). 
 
4.16.1. Preparation of 3-methoxy-4-hydroxybenzylhydrazine: Compound 3.33.   
OH
O
N
H
NH2
 
4.16.1.1 Preparation of 3-methoxy-4-hydroxybenzylidinehydrazine: 
2g or 0.013 mol of 3-methoxy-4-hydroxybenzaldehyde was added drop wise to 9 ml of 
hydrazine under reflux. The reaction mixture was left reacted for 24 hours and all the solvent 
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was then evaporated and product was collected and recrystallised from dichloromethane. 
The final product was obtained as yellow amorphous powder.  
 
Yield = 1.51 g or 70%. 
1H NMR (250 MHz d6-DMSO): 7.61 (s, 1H, -CH=N-); 7.11 (d, 1H, J= 1.269 Hz, Ph-H); 6.8 
(dd, 1H, J= 1.89, 8.21 Hz, Ph-H); 6.74 (d, 1H, J= 7.58 Hz, Ph-H); 6.43 (bs, 2H, NH2); 3.77 (s, 
6H, Methoxy); ppm. 
MS (ES +) m/z = found 167 (M + H) +.  
TLC carried out in ether (Rf) = 0.9 (single spot).  
4.16.1.2 Preparation of 3-methoxy-4-hydroxybenzylhydrazine:  
1.5g or 9.03 mmol of 3-methoxy-4-hydroxybenzylidinehydrazine was dissolved in 50 ml of 
methanol and 1gm of 10% Palladium charcoal was added under argon and left stirring in a 
hydrogenator at room temperature under 100 psi for 24 hours. The reaction mixture was then 
filtered through a Celite bed and the filtrate was evaporated to obtain the product as bluish 
green colour thick oil.  
 
Yield = 1.18g or 78%.     
1H NMR (250 MHz d6-DMSO): 8.66 (s, 1H, OH); 6.72 (s, 1H, Ph-H); 6.66 (d, J= 7.58 Hz, 1H, 
Ph-H); 6.55 (d, J= 8.21 Hz, 1H, Ph-H); 3.72 (s, 3H, CH3); 2.18 (s, 2H, CH2); 2.08 (s, 2H, 
NH2) ppm. 
MS (ES +) m/z = found 137 (M - NH) +, 169 (M + H) +.  
TLC carried out in ether (Rf) = 0.77 (single spot).  
 
4.17.1. Preparation of 3,4-dimethoxybenzylhydrazine: Compound 3.32.  
 
N
H
O
O
NH2
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4.17.1.1 Preparation of 3,4-dimethoxybenzylidinehydrazine: 
2.01g or 1.20 mmol of 3,4-dimethoxybenzaldehyde was added drop wise to 8 ml of hydrazine 
under reflux. The reaction mixture was left reacted for 24 hours and all the solvent was then 
evaporated and product was collected as pale white amorphous powder.  
 
Yield = 1.45 g or 80%. 
1H NMR (250 MHz d6-DMSO): 8.65 (s, 1H, -CH=N-); 7.49 (d, 1H, J= 1.89 Hz, Ph-H); 7.4 (dd, 
1H, J= 1.89, 8.84 Hz, Ph-H); 7.09 (d, 1H, J= 8.24 Hz, Ph-H); 3.83 (s, 6H, Methoxy); ppm. 
MS (ES +) m/z = found 181 (M + H) +.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.77 (single spot).  
4.17.1.2 Preparation of 3,4-dimethoxybenzylhydrazine:  
1.03g or 5.72 mmol of 3,4-dimethoxy benzylidinehydrazine was dissolved in 50 ml of 
methanol and 1gm of 10% Palladium charcoal was added under argon and left stirring in a 
hydrogenator at room temperature under 100 psi for 24 hours. The reaction mixture was then 
filtered through a Celite bed and the filtrate was evaporated to obtain the product as dark 
yellowish thick oil.  
 
Yield = 0.8g or 65%.     
1H NMR (250 MHz d6-DMSO): 7.29 (d, 1H, J= 1.89 Hz, Ph-H); 7.09 (dd, 1H, J= 1.89, 8.84 
Hz, Ph-H); 7.02 (d, 1H, J= 8.24 Hz, Ph-H); 3.83 (s, 6H, Methoxy); 3.78 (s, 2H, -CH2); ppm. 
MS (ES +) m/z = found 181 (M - H) +, 151 (M - NH) +.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.54 (single spot).  
 
4.18.1. Preparation of 3,4-dihydroxybenzylidinehydrazine: Compound 3.24. 
OH
OH
N NH2
 
4.18.1.1 Preparation of 3,4-dihydroxybenzylidinehydrazine: 
1.05g or 0.131 mmol of 3,4-dihydroxybenzaldehyde was added drop wise to 9 ml of 
hydrazine under reflux. The reaction mixture was left reacted for 24 hours and all the solvent 
was then evaporated and product was collected and recrystallised from dichloromethane. 
The final product was obtained as yellow amorphous powder.  
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Yield = 0.8 g or 0.1925 mmol 68%. 
1H NMR (250 MHz d6-DMSO): 9.1 (bs, 2H, OH); 7.6 (s, 1H, -CH=N-); 7.4 (d, 1H, J= 1.269 
Hz, Ph-H); 7.1 (dd, 1H, J= 1.89, 8.21 Hz, Ph-H); 7.04 (d, 1H, J= 7.58 Hz, Ph-H); 2.13 (bs, 
2H, NH2); ppm. 
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.65 (single spot).  
MS (ES -) m/z = found 151 (M - H) -.  
 
 
4.19.1. Preparation of 2-methoxy-4-((2-(4-methylbenzylidine) hydrazinyl) methyl) 
phenol:  Compound 3.36.  
 
OH
O
N
H
N
 
 
0.15g of 3-methoxy-4-hydroxybenzylidinehydrazine was dissolved in 25ml toluene and 
0.109g of 4-methylbenzaldehyde was added and left reacted under reflux for 18 hours. The 
final product was then isolated by removing the solvent by evaporation followed by re-
crystallisation from ether.   
 
Yield: 0.11g or 76% 
1H NMR (250 MHz d6-DMSO): 8.91 (s, 1H, OH); 7.3 (d, 2H, Ph); 7.22 (s, 1H, HC=NH); 7.12 
(d, 2H, J= 1.2, 1.9 Hz, Ph H); 6.83 (s, 1H, Ph-H); 6.71 (s, 2H, Ph-H); 4.32 (s, 2H, CH2); 3.69 
(s, 3H, CH3); 2.27 (s, 3H, CH3); ppm. 
MS (ES +) m/z = found 271 (M + H) +.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.77 (single spot).  
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4.20.1. Preparation of 4-amino-3-(N-methylsulphamoyl)-5-nitrobenzoic acid: Compound 
3.35. 
S
NH O
O
NH
CH3
O2N
OHO
CH3
 
 
4g of 4-chloro-3-chlorosulfonyl-5-nitrobenzoic acid was added slowly into 60ml of 40% 
methylamine solution at a temperature below 0oC and then slowly increased to room 
temperature and left reacted for 12 hours with continuous stirring. The final product was then 
collected by evaporating all the methylamine thereafter filtering the yellow solid product 
under vacuum. 
 
Yield = 2.2g or 86% 
1H NMR (250 MHz d6-DMSO): 8.35 (d, 1H, J= 2.52 Hz, Ph-H); 8.31 (d, 1H, J= 1.89 Hz, Ph-
H); 8.03 (t, 1H, NH2); 7.06 (t, 1H, NH2); 7.62 (s, 1H, NH); 2.73 (d, 3H, J= 5.68 Hz, methyl), 
2.45 (d, J= 5.05Hz, methyl); ppm. 
IR (KBr) ν= 3528, 3378, 2539 (-NH2), 2350, 2206, 1993, 1876, 1725, 1858, 1677, 1610-1520 
(-NO2), 1477-1085 (-SO2NH2) cm-1 
MS (ES -) m/z = found 288 (M - H) -.  
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.55 (single spot).  
 
. 
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CHAPTER 5 
HETEROARYLCARBOXAMIDRAZONES:                                             
DERIVATIVES AND RELATED CHEMISTRY 
 
5.1 Aim: 
The aim of this work is to generate a library of compounds of the class heteroaryl 
carboxamidrazones and to screen for antimicrobial activity, particularly for anti-tubercular 
activity.   
 
5.2 Background:  
A series of N1–arylidene-pyridine carboxyamidrazone derivatives was prepared and tested 
against for anti-mycobacterial activity. The 4-pyridyl (Mamalo, et al., 1993) and 2-pyridyl 
(Mamalo, et al., 1992) derivatives in particular have shown some interesting results. To 
further investigate the activities of these compounds a library of related 
benzylideneheteroaryl carboxamidrazones was prepared and tested for their antibacterial 
activity against various organisms. One compound in particular, N1–[3, 5-di-(tert-butyl)-2-
hydroxybenzylidine] - pyridine-4-carboxamidrazone (Figure 5.1 Compound 5.1), gave an 
intriguing antimicrobial activity profile. The compound was found to be very active against 
Mycobacterium tuberculosis; the minimum inhibitory concentration (MIC) was found to be 2-4 
µg/mL (Rathbone, et al.. 2006). It has also exhibited strong potency against many gram 
positive organisms. Unfortunately this compound was also found to be very toxic against 
human leucocytes causing 100% cell lysis (Coleman, M., et al., 1999).  
  
 
N
N
NH2
N
OH
  
N
N
NH2
N
H
OHO
 
 
  Compound 5.1    Compound 5.2 
 
Figure 5.1:  Compound 5.1 represents N1–[3, 5-di-(tert-butyl)-2-hydroxybenzylidine] - 
pyridine-4-carboxamidrazone with MIC 2-4 µg/mL. Compound 5.2 is pyridine-2-
carboxamidrazone-N1–[3, 5-di-(tert-butyl)-2-hydroxybenzoyl] amide with MIC <6.25 µg/mL 
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Following the studies done earlier related to compound 5.1, another compound Pyridine-2-
carboxamidrazone N1–[3, 5-di-(tert-butyl)-2-hydroxybenzoyl] amide, (Fig 1 Compound 5.2) 
exhibited potential activity against Mycobacterium tuberculosis. The minimum inhibitory 
concentration (MIC) was found to be <6.25 µg/mL causing a 100% inhibition (Begum N, et 
al., 2007). Hence this heteroaryl carboxamidrazone and related compounds represent a 
useful area in the discovery of new antibacterial agents. 
 
5.3 Structural activity relationship studies:  
The 4-pyridyl group of compound 5.1 was substituted for 2-pyridyl and 3-pyridyl, resulting in 
loss of activity (Tims. K, et al., 2002). Further replacing the 4-pyridyl group with pyrazinyl or 
2-quinolyl abolished the antimicrobial activity (Rathbone, et al., 2006). Moving the hydroxyl 
group from 2-position to 4-position (isomer of Compound 5.1) deactivated the compound 
giving an MIC > 256 µg/mL. The activity was also lost by replacing the OH at the 2 position 
with methyl ether; however modifying the OH into methyl ester preserved antibacterial 
activity MIC 4-8 µg/mL (Rathbone et al. 2006) though the ester may simply be acting as a 
prodrug for the phenol. Reducing the size of the tert-butyl group to methyl group again 
abolished the antimicrobial activity. Interestingly substituting an iodine atom instead of the 
tert-butyl group preserved the antibacterial activity, but four times less potent than 
Compound 5.1 (Tims. et al., 2002). Moderate activity was observed by polyhydroxylated 
compounds  and compounds with a nitro-group para to the hydroxyl group (Rathbone, et al. 
2006). Further investigation was also made at the 3-pyridyl derivatives with N-oxide 
derivatives with no success (Tims. et al., 2002). These suggest that the polar substitution on 
the benzylidine group is perhaps key for its antibacterial activity. On the other hand the 4-
pyridyl moiety of the Compound 5.1 was so far the best group in the class of compounds with 
anti-tubercular activity. In another investigation to replace the benzene ring with a 5-nitro 
furan ring, it was observed that the resultant compound has been found to be very active 
against Mycobacterium fortuitum with MIC 0.1-2 µg/mL (Begum. N, 2007). In the current 
research efforts have been made to modify the linkages between the 4-pyridyl group and the 
benzylidene group so as to design compounds with similar or more potency toward its anti-
tubercular effect and less toxic to human leucocytes.     
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5.4 Optimisation of the lead compound:  
5.4.1 Optimisation of lead compound following Compound 5.1: 
In an attempt to optimise the lead compound (Figure 5.1 i.e, Compound 5.1), the analogues 
of the following compounds shown below (Figure 5.2) were synthesised. Analogues of 
Compound A, Compound B and Compound C were synthesised using the aldehydes shown 
in Figure 5.4.   
 
N
H
N
R1
Pyridyl
 
N
N
R1
Pyridyl
 
Compound A Compound B 
 
N
R1
Pyridyl
 
Compound C 
 
Figure 5.2: Analogues following Compound 5.1, which were designed by modifying the 
benzylidine group, pyridyl group and the junction between benzylidine group and pyridyl 
groups.   
 
 
The analogues of Compound A were prepared by boiling the corresponding 
hydrazinopyridine with the aldehydes in ethanol at reflux (Scheme 5.1). The 4-
hydrazinopyridines used in this study were prepared by boiling 4-chloropyridine with an 
appropriate quantity of hydrazine monohydrate in butanol (Isin, de Jonge et al. 2001) 
(Scheme 5.1). The 2-hydrazinopyridine was obtained from Sigma-Aldrich and was used 
directly in the reaction. 
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NH2
NH2
Ethanol
O
N
N
H
Cl N
H
NH2Pyridyl
Butanol
Reflux
+
Reflux
+
R1
R2
R3
R4
R1
R2
R3
R4
Pyridyl
Pyridyl
 
     Compound A 
 
Scheme 5.1: Synthesis of hydrazinopyridine followed by the condensation with aldehyde.  
 
 
Compound A Pyridyl R1 R2 R3 R4 Yield (%) 
       
5.3 4-pyridyl OH tert-butyl H tert-butyl 53 
5.4 4-pyridyl H tert-butyl OH tert-butyl 69 
5.5 4-pyridyl OH I H I 82 
5.6 4-pyridyl OH Br H Br 63 
5.7 4-pyridyl OH tert-butyl H H 31 
5.8 4-pyridyl OH H H tert-butyl 37 
5.9 4-pyridyl H tert-butyl H tert-butyl 77 
5.10 3-pyridyl OH tert-butyl H tert-butyl 51 
5.11 3-pyridyl H tert-butyl OH tert-butyl 17 
5.12 3-pyridyl OH I H I 63 
5.13 3-pyridyl OH Br H Br 54 
5.14 3-pyridyl OH tert-butyl H H 10 
5.15 3-pyridyl OH H H tert-butyl 29 
5.16 3-pyridyl H tert-butyl H tert-butyl 33 
Table 5.1: The table above shows the list of 4-pyridyl and 2-pyridyl hydrazine substituted 
analogues of Compound 5.1.   
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The analogues of Compound B were prepared by boiling the pyridyl-methylhydrazone with 
aldehydes at reflux (Sandbhor et al., 2003). The 4-pyridyl-methylhydrazone was prepared by 
treating pyridine-4-carboxaldehyde with an excess hydrazine monohydrate in ethanol at 60oC 
as shown in Scheme 5.2 (Szmant, et al.,1959). The 4-pyridyl-methylhydrazone, 3-pyridyl-
methylhydrazone and 2-pyridyl-methylhydrazone were prepared similarly as shown in 
Scheme 5.2.  
NH2
NH2 N
NH2
Ethanol
O R1
R2
R3
R4
N
N
R1
R3
R4
R2
O EthanolPyridyl Pyridyl
Reflux
+
Reflux
+
Pyridyl
 
     Compound B 
 
Scheme 5.2:  The synthesis of pyridyl-methylhydrazone.  
 
 
Compound B Pyridyl R1 R2 R3 R4 Yield (%) 
       
5.17 4-pyridyl OH tert-butyl H tert-butyl 60 
5.18 4-pyridyl H tert-butyl OH tert-butyl 65 
5.19 4-pyridyl OH I H I 78 
5.20 4-pyridyl OH Br H Br 62 
5.21 4-pyridyl OH tert-butyl H H 43 
5.22 4-pyridyl OH H H tert-butyl 65 
5.23 2-pyridyl OH tert-butyl H tert-butyl 42 
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Compound B Pyridyl R1 R2 R3 R4 Yield (%) 
       
5.24 2-pyridyl H tert-butyl OH tert-butyl 44 
5.25 2-pyridyl OH tert-butyl H H 73 
5.26 3-pyridyl OH tert-butyl H tert-butyl 12 
5.27 3-pyridyl OH I H I 27 
5.28 3-pyridyl OH Br H Br 22 
 
Table 5.2: List of 4-pyridyl, 3-pyridyl and 2-pyridyl methylhydrazone substituted analogues of 
Compound 5.1.   
 
The analogues of Compound C were prepared by boiling the aminopyridines with the 
aldehydes as shown in Scheme 5. 3. The 4-aminopyridine and 3-aminopyridine were 
obtained commercially and used directly into the study.  
 
O
R2
R3
R4
R1
R2
Ethanol
Reflux
N
R4
R3
R1
NH2Pyridyl
+
Pyridyl
 
         Compound C 
 
Scheme 5.3: The reaction between aldehydes and the amino pyridine where R-NH2 
represent the 4-aminopyridine and 3-aminopyridine.   
 
Compound C Pyridyl R1 R2 R3 R4 Yield (%) 
       
5.29 4-pyridyl OH tert-butyl H tert-butyl 63 
5.30 4-pyridyl H tert-butyl OH tert-butyl 76 
5.31 4-pyridyl OH I H I 44 
5.32 4-pyridyl OH Br H Br 72 
5.33 3-pyridyl OH tert-butyl H tert-butyl 23 
5.34 3-pyridyl H tert-butyl OH tert-butyl 15 
5.35 3-pyridyl OH I H I 18 
5.36 3-pyridyl OH Br H Br 35 
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Compound C Pyridyl R1 R2 R3 R4 Yield (%) 
       
5.37 3-pyridyl OH H H tert-butyl 13 
5.94 3-pyridyl OH Br H Cl 44 
5.95 3-pyridyl OH Cl H Cl 50 
5.96 3-pyridyl OH H H Cl 73 
5.97 3-pyridyl OH Cl H H 82 
5.98 3-pyridyl OH F H F 32 
5.99 3-pyridyl OH H H I 55 
5.100 3-pyridyl OH Br H H 78 
5.101 3-pyridyl OH H H Br 64 
 
Table 5.3: The list of 4-aminopyridine and 3-aminopyridine substituted analogues of 
Compound 5.1.   
  
5.4.2. Optimisation of the lead compound following Compound 5.2: 
The lead compound pyridine-2-carboxamidrazone N1–[3, 5-di-(tert-butyl)-2-hydroxybenzoyl] 
amide was optimised and the following analogues as shown in Figure 5.3 were synthesised. 
The analogues Compound D, Compound E and Compound F were synthesised by varying 
the acids shown in Figure 5.5. 
 
NH2
N
N
H
O
Pyridyl
R1
 
N
H
N
H
O
R1
Pyridyl
 
Compound D Compound E 
 
N
N
H
O
Pyridyl
R1
 
Compound F 
Figure 5.3:  List of compounds following the analogues of the Compound 5.2.   
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The analogues of compound D were prepared by treating a mixture of the acid and CDI in 
anhydrous THF to give the analogues of Compound D Scheme 5. 4 (Begum N. et al., 2007).  
NH2
N
NH2NH2 NH2
Ethanol
CDI THF
O
OH
NH2
N
N
H
O
N + +
R1
Aryl
Aryl
Pyridyl carboxamidrazone
Pyridyl
Pyridyl
Pyridyl
 
        Compound D 
Scheme 5.4:  General method for the synthesis of pyridyl-carboxamidrazone which is then 
reacted with the acid to give the substituted benzylidine carboxamidrazones. 
 
The pyridyl-4-carboxamidrazone, pyridyl-2-carboxamidrazone and pyridyl-3-
carboxamidrazone were prepared in a similar way by treating the corresponding 
cyanopyridine with hydrazine monohydrate at room temperature with constant stirring as 
shown in Scheme 5. 4 above  (Tanaka, Motoyama et al. 1994).  
 
 
Compound D Pyridyl Aryl Yield (%) 
    
5.38 2-pyridyl 
O
 
59 
5.39 2-pyridyl 
O
 
74 
5.40 2-pyridyl 
O NO2
 
35 
5.41 2-pyridyl 
O Br
 
60 
5.42 2-pyridyl 
O
Br
Br
 
69 
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Compound D Pyridyl Aryl Yield (%) 
5.43 2-pyridyl 
O
 
60 
5.44 2-pyridyl 
O
 
66 
5.45 2-pyridyl 
O
 
64 
5.46 2-pyridyl 
O
 
45 
5.47 2-pyridyl 
O
F
F
F
 
63 
5.48 2-pyridyl 
O
 
69 
5.49 2-pyridyl 
S
 
60 
5.50 4-pyridyl 
S
 
16 
5.51 2-pyridyl 39 
5.52 3-pyridyl 23 
5.53 4-pyridyl 
S
Br
 
48 
5.54 2-pyridyl 19 
5.55 3-pyridyl 20 
5.56 4-pyridyl 
S
Br
 
18 
5.57 2-pyridyl 39 
5.58 3-pyridyl 42 
5.59 4-pyridyl 
S
Cl
 
15 
5.60 2-pyridyl 46 
5.61 3-pyridyl 22 
5.62 4-pyridyl 
Br
 
37 
5.63 2-pyridyl 66 
5.64 3-pyridyl 76 
5.65 4-pyridyl 
O
Br
 
43 
5.66 2-pyridyl 10 
5.67 3-pyridyl 96 
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Compound D Pyridyl Aryl Yield (%) 
5.68 4-pyridyl  
O
F3C
 
16 
5.69 2-pyridyl 66 
5.70 3-pyridyl 74 
5.71 4-pyridyl 
Br
 
14 
 
Table 5.4: List of analogues of the compound D prepared by varying the action of acids 
shown in Figure 5.3b with the pyridine-3-carboxamidrazone, pyridine-2-carboxamidrazone 
and pyridine-4-carboxamidrazone from Figure 5.5. 
 
The analogues of Compound E were prepared on treating the hydrazinopyridine to the 
mixture of CDI and acid as shown in the Scheme 5.5 (Sandbhor et al., 2003).  
 
Pyridyl
N
H
NH2
O
OH
O
N
H
N
H
Pyridyl
+
R1
R2
R3
R4
R1
R2
R3
R4
CDI
THF
 
         Compound E 
Scheme 5.5: The scheme above illustrates synthesis of the analogues of Compound E.  
 
Compound E Pyridyl R1 R2 R3 R4 Yield (%) 
5.72 4-pyridyl OH tert-butyl H tert-butyl 73 
5.73 4-pyridyl OH Br H Br 78 
5.74 4-pyridyl OH I H I 15 
5.75 3-pyridyl OH tert-butyl H tert-butyl 68 
5.76 3-pyridyl H tert-butyl OH tert-butyl 55 
5.92 2-pyridyl OH tert-butyl H tert-butyl 73 
5.93 2-pyridyl H tert-butyl OH tert-butyl 65 
 
Table 5.5:  Showing the list of analogues of Compound E.  
 
Similarly the analogues of compound F were prepared by treating the amines with the 
corresponding acids as shown in Scheme 5.5.  
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N
NH2
Pyridyl
O
OH
O
N
H
NPyridyl
+
R1
R2
R3
R4
R1
R2
R3
R4
CDI
THF
 
         Compound F 
Scheme 5.6:  Synthesis of the analogues of Compound F 
 
Compound F Pyridyl R1 R2 R3 R4 Yield (%) 
5.77 4-pyridyl OH Br H Br 82 
 
Table 5.6: The table above shows the list of the compounds prepared following Compound F 
 
5.5 Varying the aldehyde building blocks in the synthesis of benzylidine 
carboxamidrazones:   
In the earlier research carried out by Rathbone et al., a library of benzylindene heteroaryl 
carboxamidrazones was synthesised and tested for anti-tubercular activity (Rathbone, Parker 
et al. 2006). As a follow-up of the existing research the aldehydes building blocks selected in 
the current research were chosen to modify Compound 5.1 in the hope of increasing the 
biological activity and at the same time to decreasing the toxicity. The figure 5.4 below shows 
the list of all the aldehydes used in optimisation of the Compound 5.1. The tert-butyl groups 
on the 3rd  and 5th position and OH on the 2nd  position on the benzyl ring have successfully 
shown good anti-bacterial activity in the past (Weidner-Wells, et al. 2001) . In the recent 
years the benzylindene heteroaryl carboxamidrazones with such substitutions have shown 
anti-tubercular activity (Rathbone, Parker et al. 2006). The presence of iodine, chlorine or 
bromine at 3rd and 5th position has also shown some anti-tubercular activity (Gershon, et al., 
1962). It is important to note that tert-butyl group is an electron donating group, whereas 
Iodine is a weak electron withdrawing group. Both these groups on the 3rd and 5th position on 
the benzylidene portion of the benzyledene carboxamidrazones have proven good anti-
tubercular activity and thereby leaving a vast area into anti-tubercular drug discovery 
(Rathbone, Parker et al. 2006). Therefore in the current research apart from using the similar 
aldehydes such as aa, ab (isomer of aa) ba and ac attempt has also been made to substitute 
the iodine, a weak electron withdrawing group, with a range of halogens from somewhat 
more electronegative to highly electronegative. Therefore aldehydes with bromine, as in ad, 
chlorine as in ae and fluorine as in ag on the 3rd and 5th positions were used in this study. An 
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attempt was also made to incorporate both bromine and chlorine together in the same moiety 
af. Also the toxicity profile of the di-tert-butyl-2-hydroxy aldehyde derived compounds 
suggests 32% human leukocyte cell death (Coleman, Rathbone et al. 1999);(Coleman, 
Rathbone et al. 2001), hence the di-tert butyl group has also been substituted with mono-tert-
butyl group as in bc and bd. The OH group has also been substituted with H, as in be. Apart 
from using the disubstituted halogens attempt has also been made to incorporate one 
halogen at a time to understand the preference of the halogens in any particular position 
within the aryl moiety and hence the aldehydes bf, bg, bh, bi and bj were used in the current 
investigation.  
OH
O
 
O
OH
 
O
I
I
OH
 
O
Br
Br
OH
 
aa ab ac ad 
O
OH
Cl
Cl
 
O
OH
Br
Cl
 
O
OH
F
F
 
O
O
O
 
ae af ag  ba 
O
OH
 
O
OH
 
O
 
O
OH
Cl
 
bc bd be  bf 
O
OH
Cl
 
O
OH
I
 
O
OH
Br
 
O
OH
Br
 
bg bh bi bj 
Figure 5.4: Aldehydes used in the synthesis of the analogues of Compound 5.1.  
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Most of the aldehydes were commercially available, apart from the ba which was 
synthesised in the laboratory (Rathbone, et al. 2006).  
 
5.6 Varying the aryl acid building blocks in the synthesis of carboxamidrazone 
amides:  
Apart from using various aldehydes, some acids were also used to synthesise analogues of 
Compound D, Compound E and Compound F.   
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Figure 5.5:  Showing the list of acids used to synthesise the analogues of Compound Y.  
 
 
In the earlier research it was observed that pyridine-4-carboxamidrazone N1–[3, 5-di-(tert-
butyl)-2-hydroxybenzoyl] amide was active against M.tuberculosis with a MIC of 6.25 µg/mL 
causing 94% inhibition (Begum. N, et al., 2007). In the current research much interest has 
been gathered on the amide linkage of the moiety and hence synthesising analogues of 
Compound D. The 3, 5-di-(tert-butyl) part of the moiety has shown anti-microbial activity with 
various amidrazone moiety in the previous research (Rathbone, Parker et al. 2006); (Begum. 
N et al., 2007; Tims. K et al., 2002) hence da was used once again in the current research. 
Interestingly presence of iodine on the 3rd and 5th position of the aryl moiety has also shown 
but little activity (Rathbone, et al., 2006) in the organism (Mycobacterium tuberculosis). 
Therefore in this investigation the acids containing iodine dd, and bromine dc in 3rd and 5th 
position of the benzyl moiety were also employed. Bromine being more electronegative than 
iodine  was used to see the effect of stronger electronegative group in the benzyl moiety.  
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5.7 Varying the Pyridyl-amine moiety in the synthesis of analogues of pyridine 
carboxamidrazones:  
In the earlier research, a variety of amidrazones has been used to synthesise a library of 
compounds (Tims. K, et al., 2002). All these amidrazones (Figure 5.4) are prepared by the 
action of hydrazine monohydrate upon the appropriate cyano compounds (Tanaka, 
Motoyama et al. 1994).  
 
 
N
NH2
N
NH2
   
N
NH2
N
NH2
   
N
NH2
N
NH2
 
  
Compound 5.78  Compound 5.79  Compound 5.80 
 
Figure 5.6: The various pyridyl-carboxamidrazones used in the preparation of the analogues 
of Compound 5.2  
 
 
All these carboxamidrazones were selected based on their known antimicrobial activity. For 
example the aldehyde derivatives of compound 5.80 had known antimycobacterial activity 
(Rathbone, et al., 2006). Compound 5.79 and compound 5.78 were also used because of 
their structural similarity to compound 5.80. In particular compound 5.78 had a structural 
similarity to pyrazinamide, a first line anti-tubercular drug. Compound 5.80 derivatives were 
found to have the best anti-tubercular activity. There was no biological activity observed in 
other derivatives of carboxamidrazone, therefore all other derivatives from the previous 
research have been omitted in the current research.  The toxicity profile of the N1–[3, 5-di-
(tert-butyl)-2-hydroxybenzylidine] - pyridine-4-carboxamidrazone, suggests 100% human 
leucocytes cell death. Hence in the current research work the pyridyl moiety within the 
carboxamidrazones has been modified (Figure 5.7) and reacted with the various aldehydes 
and acid derivatives (Figure 5.4 and Figure 5.5).  
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Figure 5.7: The various amino-pyridines and pyridyl carboxamidrazones used to synthesise 
the analogues of Compound 5.1 and Compound 5.2 
 
 
5.8 Reactivity of the pyridyl-amine moiety. 
All the pyridyl amines listed in the Figure 5.7 appear to react with the aldehydes or the acids 
in different ways. The pyridyl-methylhydrazones and the hydrazinopyridines were found to be 
more reactive compared to the aminopyridines. The pyridyl-methylhydrazines and 
hydrazinopyridines reacted successfully with aldehydes (Figure 5.4) when boiled with ethanol 
at reflux, to synthesise the corresponding hydrazones, whereas the amino pyridines failed to 
follow the similar chemistry. In contrast it was necessary to melt a mixture of 4-aminopyridine 
and the acid (da) at 170-210 oC to react with the aldehydes to synthesise the corresponding 
amides (Matyk. J, Waisser. K, et al., 2005; Waisser. K, Kunes. J, et al., 2004). The reactivity 
of compound 5.81 was different from the compound 5.82. In case of 4-aminopyridine the lone 
pair of electrons is shared by the aromatic ring system and the pyridyl nitrogen as shown in 
Figure 5.8.   
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Figure 5.8:  The resonance forms of 4-aminopyridine.  
 
 
It was different in the case of 3-aminopyridine which was found to be more reactive than 4-
aminopyridine. The negative charge of the resonance structures was only on the carbons 
(Figure 5.9). The lone pair on the terminal NH2 is more available and less in the ring in case 
of the 3-amino pyridine and is therefore more reactive than 4-aminopyridine (Alam et al. 
2000).  
 
 
N
NH2
N
NH
N
NH
N
NH
.. + + +
-
-
-
 
a   b    c    d  
 
Figure 5.9:  The various resonance forms of 3-aminopyridine.  
 
 
On the other hand the lone pair of electrons on the terminal NH2 is more easily available in 
case of pyridyl-methylhydrazones and hydrazinopyridines compared to the 2-amino and 3-
amino pyridines as shown in Figure 5.10. In fact the hydrazinopyridines are more reactive 
than the pyridyl-methylhydrazones.    
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N
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N
NH2
      
N
N
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  Compound 5.84   Compound 5.87 
N
N
NH2
N
N
NH2
 
   Resonance forms of Compound 5.87   
 
Figure 5.10: The movement of the lone pair of electrons on the pyridyl-methylhydrazone and 
the hydrazinopyridine.   
 
 
The electron density on the terminal NH2 was found to be more in case of the compound 
5.84, than the compound 5.87. This is because the lone pair of electrons on the NH2 of 
compound 5.87 gives rise to two resonance forms and therefore the electrons were not 
easily available (Figure 5.10). On reaction of the amines with the CDI activated acids da, db, 
dc and dd only the hydrazinopyridines yielded the target amides. The reaction was carried 
out under anhydrous condition in presence of carbonyl-di-imidazole (de Figueiredo. et al. 
2006).  
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Scheme 5.7:  Formation of the imidazole-aryl complex followed by reaction with the amine to 
form the corresponding amide(de Figueiredo. et al. 2006)   
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Although da and dd had electron donating and weak electron withdrawing groups, 
surprisingly 4-pyridyl-methylhydrazine was only successful in synthesising the corresponding 
amide of the acid dc and not da or dd. This is due to the formation of the stable acid 
imidazole intermediate complex with da. The more electron withdrawing are the substituents 
on the acid the more reactive is the acid-imidazole complex. Iodine in dd had weakly electron 
withdrawing property when compared with bromine dc, unfortunately compound 5.87 was 
only successful with dc.  Perhaps compound 5.87 requires strong electron withdrawing 
substituents containing acid-imidazole complex to form the corresponding imide.  
 
 
5.9 Stability of the Pyridyl-amines:  
The pyridyl-amines used within this study have varying stability. Compound 5.82 and 
compound 5.81 are stable towards storage. Compound 5.86, 5.87 and 5.88 were relatively 
unstable when compared with the amino-pyridines. Compound 5.87 was obtained as yellow 
oil which even on storage changes to dark colour oil. This could be due to the presence of a 
highly conjugated system on the moiety. Compound 5.86 and compound 5.88 were relatively 
stable and this is perhaps because they lack such conjugation property. The 
hydrazinopyridines in particular are very unstable and absorb moisture very quickly. 
Compound 5.84 was usually pale white solid which rapidly changes to pink on exposure to 
moisture and progressively converts to dark brown solid and then into semi-solid dark brown 
product. 
 
All the pyridyl-carboxamidrazones have shown various stability parameters. Compound 5.90 
was found to be the most unstable compound when compared with the other pyridyl 
carboxamidrazones (Tims, K., 2005). Compound 5.90 was very sensitive to heat and readily 
decomposed to a brown mass on slight increase in temperature. Compound 5.91 on the 
other hand is more stable compared to the compound 5.90, although it even decomposed to 
a yellow and then brown mass on slight increase in temperature. Compound 5.89 was the 
most stable compound of all the carboxamidrazones used which could again be due to the 
possibility of intra-molecular hydrogen bonding as shown in figure 5.11 (Billington, D et al., 
2000).  
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Figure 5.11:  Showing the stability of the compound 5.89 due to the formation of the intra-
molecular hydrogen bonding.  
 
5.10 Microbiological studies:  
All of these compounds were tested first for biological activity against S.aureus, E.coli and 
M.fortuitum within the Aston University laboratory. S.aureus and E.coli were used as a model 
to study the biological activity of these compounds against other gram positive and gram 
negative organisms. Mycobacterium fortuitum was used to screen the biological activity of 
these compounds against the class of Mycobacterium. These compounds were sent for 
antimicrobial activity against Mycobacterium tuberculosis by the Tuberculosis Antimicrobial 
Acquisition and Coordinating Facility (www.TAACF.org) in U.S.  
 
5.10.1 Initial Biological Screening:  
These compounds were tested for zone of inhibition on agar plate against the 
microorganisms. The test solutions were prepared in DMSO and 20μl of the compounds 
were placed in the wells prepared with a 6mm diameter glass cutter. The zone of inhibition 
was observed and the diameters of the zones were measured in mm (Table 5.7) after 
incubation at 37oC for 72 hours. These compounds were also tested for the minimum 
inhibitory concentration (MIC). 32μg of the compounds were added to 25ml medium broth 
with 100μl inoculums. 1ml of this sample and 3.2μl of stock compound was then added to 
each of the test tubes and left incubating at 37oC for 72 hours. Interestingly the compounds 
with larger zone of inhibition did not necessarily inhibit the organisms and did not even 
produce any inhibition. This suggests that the compounds had different permeability pattern 
which was measured as zone of inhibition.  
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Compound 
Zone of 
inhibition 
S.aureus 
Zone of 
inhibition 
E.coli 
Zone of 
inhibition 
M.fortuitum 
Growth of 
organism 
M.fortuitum 
5.38 - - - + 
5.40 - - - + 
5.44 - - - + 
5.41 10 21 - + 
5.43 - - - + 
5.46 11 - - + 
5.48 - - - + 
5.39 - - - + 
5.47 - - - + 
5.42 12 15 10 + 
5.49 - - - + 
5.45 - - - + 
5.29 - - - + 
5.31 27 15 12 + 
5.17 12 - - + 
5.18 - - - + 
5.19 13 - - + 
5.22 10 - 8 - 
5.21 - - - + 
5.3 16 - 12 - 
5.4 30 - 16 - 
5.5 15 - 9 + 
5.20 9 - - + 
5.6 10 - 10 + 
5.30 - - - + 
5.9 15 - 15 - 
5.32 28 15 14 + 
5.7 18 8 13 - 
5.72 - - 9 - 
5.73 - - 10 + 
5.77 - - - + 
5.8 24 12 17 - 
DMSO - - - + 
 
Table 5.7:  The zone of inhibition of the compounds versus the microorganisms 
(measured in mm as diameter) on a blood agar plate with 6mm diameter wells. The – sign in 
the ‘Zone of Inhibition’ column indicates that the compounds did not show any zone of 
inhibition. The + indicates, growth of the organism and – indicates no growth of the organism 
 
With the help of the biological data further set of compounds were designed and the table 5.8 
below shows the results of the further sets of the compounds.    
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Compounds Zone of inhibition S.aureus 
Zone of inhibition 
E.coli 
5.51 14 20 
5.54 - 16 
5.57 - - 
5.60 - - 
5.71 - - 
5.63 - - 
5.66 6 - 
5.69 - - 
5.52 11 11 
5.55 8 - 
5.58 - - 
5.61 - - 
5.64 - - 
5.67 - - 
5.70 - - 
5.50 - - 
5.53 - - 
5.56 - - 
5.59 - - 
5.62 - - 
5.65 10 - 
5.68 - - 
5.10 - - 
5.11 - - 
5.12 - - 
5.13 7 - 
5.14 5 - 
5.15 7 - 
5.16 - - 
5.23 - - 
5.24 - - 
5.25 - - 
5.26 3 - 
5.27 11 - 
5.28 9 - 
5.33 12 - 
5.34 6 - 
5.35 23 - 
5.36 26 15 
5.37 - - 
5.75 - - 
5.76 - - 
Table 5.8:  The zone of inhibition of the compounds versus the microorganisms 
(measured in mm as diameter) on a blood agar plate with 6mm diameter wells. The (–) sign 
indicates that the compounds did not show any zone of inhibition. 
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5.10.2 TAACF screening:  
All these compounds were sent to TAACF (www.TAACF.org) for screening against the 
pathogenic organism. The screening was conducted in two designed stages. The primary 
screening involves the determination of the 90% inhibitory concentration (IC90). The 
following screening or the secondary screening involves the determination of the mammalian 
cell cytotoxicity (CC50).  
 
 
5.10.2.1 Primary Screen (Dose Response): 
 
The initial screen was conducted against Mycobacterium tuberculosis H37Rv as discussed in 
chapter 3 (Section 3.12.1) and the data are shown in table 5.9 below. Any IC90 value of 
≤10µg/mL is considered "Active" and IC90 value <100µg/mL is considered "Weakly Active" 
for antitubercular activity. 
 
 
5.10.2.2 Secondary Screen:  
The VERO cell cytotoxicity assay was done in parallel with the TB Dose Response assay. 
After 72 hours exposure, viability was assessed using Promega’s Cell Titer Glo Luminescent 
Cell Viability Assay, a homogeneous method of determining the number of viable cells in 
culture based on quantitation of the ATP present. Cytotoxicity was determined from the dose-
response curve as the CC50 using a curve fitting program. Ultimately, the CC50 was divided 
by the IC90 to calculate an SI (Selectivity Index) value.  SI values of ≥ 10 were considered 
for further testing. 
 
Compound Assay Activity IC50 (µg/mL) IC90 (µg/mL) 
     
5.3 MABA Active 0.69 0.81 
5.7 MABA Active 1.38 1.53 
5.9 MABA Active 1.47 1.66 
5.63 MABA Active 1.63 1.86 
5.57 MABA Active 1.83 2.46 
5.66 MABA Active 2.10 2.57 
5.4 MABA Active 2.66 2.94 
5.8 MABA Active 2.90 3.15 
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Compound Assay Activity IC50 (µg/mL) IC90 (µg/mL) 
     
5.60 MABA Active 2.98 3.28 
5.10 MABA Active 3.00 3.32 
5.14 MABA Active 4.56 4.62 
5.69 MABA Active 3.82 5.00 
5.42 MABA Active 2.15 5.25 
5.5 MABA Active 5.54 6.17 
5.47 MABA Weakly Active 5.88 10.44 
5.6 MABA Weakly Active 9.12 11.22 
5.15 MABA Weakly Active 8.99 11.37 
5.13 MABA Weakly Active 6.21 11.81 
5.24 MABA Weakly Active 10.76 11.84 
5.12 MABA Weakly Active 11.22 12.60 
5.72 MABA Weakly Active 11.32 12.85 
5.21 MABA Weakly Active 11.56 13.20 
5.45 MABA Weakly Active 14.91 18.95 
5.41 MABA Weakly Active 6.27 20.54 
5.43 MABA Weakly Active 15.35 21.38 
5.51 MABA Weakly Active 9.70 23.08 
5.25 MABA Weakly Active 22.46 24.13 
5.71 MABA Weakly Active 23.74 26.91 
5.68 MABA Weakly Active 24.20 27.22 
5.33 MABA Weakly Active 26.43 55.72 
5.94 MABA Weakly Active 52.68 60.66 
5.93 MABA Weakly Active 43.60 62.20 
5.35 MABA Weakly Active 56.24 65.22 
5.95 MABA Weakly Active 63.05 68.66 
5.48 MABA Weakly Active 52.02 72.41 
5.31 MABA Weakly Active 59.28 72.80 
5.38 MABA Weakly Active 54.46 75.70 
5.36 MABA Weakly Active 64.32 77.51 
5.32 MABA Weakly Active 60.19 80.95 
5.100 MABA Weakly Active 66.59 88.33 
5.73 MABA Weakly Active 48.91 88.69 
5.22 MABA Weakly Active 75.96 89.51 
5.62 MABA Weakly Active 42.94 89.79 
5.55 MABA Weakly Active 76.69 92.66 
5.28 MABA Weakly Active 99.19 >100 
5.54 MABA Weakly Active 8.04 >100 
5.59 MABA Weakly Active >100 >100 
5.53 MABA Weakly Active >100 >100 
5.58 MABA Weakly Active 91.94 >100 
5.61 MABA Weakly Active 75.27 >100 
5.40 MABA Weakly Active 89.23 >100 
5.44 MABA Weakly Active 72.69 >100 
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Compound Assay Activity IC50 (µg/mL) IC90 (µg/mL) 
     
5.39 MABA Weakly Active 47.15 >100 
5.92 MABA Weakly Active 28.08 >100 
5.99 MABA Weakly Active 95.14 >100 
5.97 MABA Weakly Active 77.38 >100 
5.23 MABA Inactive >100 >100 
5.11 MABA Inactive >100 >100 
5.24 MABA Inactive >100 >100 
5.26 MABA Inactive >100 >100 
5.27 MABA Inactive >100 >100 
5.37 MABA Inactive >100 >100 
5.16 MABA Inactive >100 >100 
5.34 MABA Inactive >100 >100 
5.56 MABA Inactive >100 >100 
5.50 MABA Inactive >100 >100 
5.65 MABA Inactive >100 >100 
5.67 MABA Inactive >100 >100 
5.70 MABA Inactive >100 >100 
5.64 MABA Inactive >100 >100 
5.55 MABA Inactive >100 >100 
5.102 MABA Inactive >100 >100 
5.29 MABA Inactive >100 >100 
5.17 MABA Inactive >100 >100 
5.18 MABA Inactive >100 >100 
5.19 MABA Inactive >100 >100 
5.20 MABA Inactive >100 >100 
5.30 MABA Inactive >100 >100 
5.77 MABA Inactive >100 >100 
5.74 MABA Inactive >100 >100 
5.98 MABA Inactive >100 >100 
5.96 MABA Inactive >100 >100 
5.101 MABA Inactive >100 >100 
     
 
Table 5.9: The IC50 and IC90 values of the compounds when tested against Mycobacterium 
tuberculosis at the TAACF.  
 
 
 
 
 
 
 
Heteroarylcarboxamidrazones   2010 
 
P a g e  | 214  
 
 
Compound 
MABA: H37Rv Data CTG: Vero Cell 
Selectivity Index IC90  
(µg/mL) 
CC50  
(µg/mL) 
    
5.4 2.94 6.58 2.24 
5.3 0.81 1.77 2.19 
5.7 1.53 1.88 1.23 
5.9 1.66 1.84 1.11 
5.5 6.17 6.10 0.99 
5.8 3.15 2.75 0.87 
5.10 3.32 0.80 0.24 
5.63 1.86 0.22 0.12 
5.60 3.28 0.31 0.09 
5.69 5.00 0.45 0.09 
5.57 2.46 0.17 0.07 
5.66 2.57 0.16 0.06 
5.14 4.62 0.24 0.05 
5.42 5.25 0.17 0.03 
 
Table 5.10: The selectivity index of the compounds (CC50/ IC90).  
 
The Selectivity indexes of the compounds were determined as the ratio between the 
concentration of the drug at which it inhibits 50% of the mammalian cells and the 
concentration at which it inhibits 90% of the bacterial cells. SI determines the relative potency 
of the drug to the antimicrobial activity. 
 
 
Graph 5.1:  The graph above showing the distribution of the selectivity index. The lower 
the selectivity index, the more toxic is the product relative to the antimicrobial activity.  
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5.11 Results and Discussion:  
All the analogues of Compound A, Compound B, and Compound C were prepared by the 
reaction of the aldehydes shown in Figure 5.4 with the amino building blocks shown in Figure 
5.7 in presence of ethanol as a solvent. The selection of temperature and duration of the 
reaction were based on the reactivity of the amines. Most of the imines were prepared by 
boiling a mixture of pyridyl-amine and aldehyde in ethanol at reflux. Only the analogues of 
Compound C were obtained by melting the amino-pyridine with the aldehyde and thereafter 
re-crystallizing the compound from appropriate solvent (Matyk. J, Waisser. K, et al., 2005 ; 
Waisser. K, Kunes. J, et al., 2004).  As discussed in section 5.8, that those pyridylamines 
were less reactive when compared with all the amines used in this thesis, and therefore 
Compound C required higher temperature to react with the aldehydes. Interestingly the 
aldehyde ba which was successfully synthesised in laboratory was unsuccessful in preparing 
the final compound when reacted with the pyridyl-amines. The acetate group which was 
incorporated into the aldehyde was absent in the final compound. This could be that the 
acetate is susceptible to hydrolysis by adventitious water or perhaps to amidation by the 
amine used in the amine forming reaction (Figure 5.12).  
 
OHO
H CH3
O
O
CH3
O
OO
H
O CH3
OO
H
O CH3
NH2 R
O
N
O CH3
R
OH
N
R
CH3
O
OH
+
Pyridine
+
Ethanol +
H:OH
+
 
Figure 5.12: Attempted synthesis of compounds containing an acetoxy phenyl substituent.   
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Most of the analogues of Compound D were prepared by treating the pyridyl-amines (Figure 
5.7) to a mixture of carbonyl-di-imidazole in acid shown in Figure 5.5 under anhydrous 
condition at room temperature as shown in Scheme 5. 4 (Begum et al., 2007). Some 
analogues of compound D failed to respond such conditions, for example 4,5-dibromo-2-
furoic acid did not react with CDI and instead it was required to convert the acid to the 
corresponding acid chloride using oxalyl chloride (Adams. R, et al.,. 1920), which was then 
made to react with the amine (Figure 5.13). The presence of an electronegative group made 
the ring highly electron-deficient and therefore the acid become less reactive toward CDI.  
 
 
O Br
Br
O
OH
(COCl)2
DMF O Br
Br
O
Cl
N
NH2
N
NH2
THF
N
NH2
N
N
H
O
O
Br
Br
Compound fc
Compound 5.89
Compound 5.42
 
 
Figure 5.13:  Showing the schematic conversion of dibromo-furoic acid into the 
corresponding acid in presence of oxalyl chloride and subsequent reaction to provide the 
pyridine-2-carboxamidrazone amide.  
 
 
The CDI also was found unsuccessful in the approach to form the acid-imidazole complex 
with some of the benzoic acids containing the OH group in the 2nd position. The presence of 
this OH group perhaps interferes with the formation of the acid-imidazole complex. Perhaps 
this is due to the formation of an intra-molecular hydrogen bonding that stabilizes the acid-
imidazole complex as shown in Figure 5.14.  
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+
 
 Compound ba 
Figure 5.14: Synthesis of the imidazole complex and subsequent intra-molecular hydrogen 
bonding for a 2-hydroxy salicylic acid derivative.   
 
Thus compound 5.81 became unsuccessful on reacting with acid-imidazole complex of the 
acid da, to produce the final compound. The presence of the electron donating di-tertiary 
butyl groups was also the other reason in stabilizing the intermediate complex (Figure 5.14). 
Also converting the acid dd into an acid chloride was also not possible. Hence to further 
investigate the reactivity of compound 5.81, 2-iodo-benzoic acid was used and converted to 
acid chloride. This compound then became successful in giving the final compound.    
 
All the acids used in the study reacted in a similar fashion with the pyridyl 
carboxamidrazones except the 2-bromo benzoic acid ee. Interestingly this reaction was 
successful with 4-bromo benzoic acid, eh. This is probably because of the large size of the 
bromine atom at the 2nd position hindering the attack of the carboxamidrazone (Figure 5.16).  
 
 
Figure 5.15:  Illustrating the large bromine atom causing hindrance to the carboxylic group 
toward the attack of the amine  
Oxygen atoms 
Bromine atom 
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The variation within the reactivity of the acids was mainly observed within the pyridyl amines. 
In terms of the reactivity of the amines used in the study, it was observed that the 4-amino 
pyridine was the most weakly acting amine. Compound 5.81 failed to react with the acids 
catalysed by the CDI and even on converting the acids into more reactive acid chlorides, 
compound 5.81 did not respond to react with the acid chloride. However, in presence of the 
dimethyl amino pyridine (DMAP) and N,N-diisopropylethylamine (Hunig’s base) 
(Konstantinova et al., 2001) the reaction became successful in producing the corresponding 
amide as shown in Figure 5.17.   
 
N
NH2 OOH
I
N
N
H
O I
+
1. oxalyl chloride / THF
2. DIEA / DMAP / THF
 CDI / THF
Compound 5.102
 
Figure 5.16:  The reaction pathway for amide synthesis involving acid chloride.  
 
 The 3-Amino pyridine was relatively more reactive than 4-amino pyridine and successfully 
reacted with most aldehydes on boiling with ethanol at reflux. Thus 4-amino pyridine became 
unsuccessful in the synthesis of the 4 pyridyl analogues of the compound 5.94, 5.95, 5.96, 
5.97, 5.98, 5.99 and 5.100 when boiled in ethanol at reflux with the corresponding aldehydes. 
The final products were observed with two spots on the TLC plate corresponding to the 
starting material. This procedure was however successful in preparing the 3-pyridyl 
analogues. The hydrazino pyridines were more reactive than the amino pyridines used in the 
study. The methyl-hydrazino pyridines are less reactive than the hydrazino pyridines but they 
are relatively more reactive than the amino pyridines. It was observed that the hydrazino 
pyridines reacted with all the aldehydes listed in the Figure 5.4 to give the corresponding 
imides and in this study were the most reactive pyridyl amines.  
 
The aldehyde be was the most weakly acting aldehyde used in the investigation. It is the 
most electron rich aldehyde in the set of aldehydes shown in Figure 5.4. This aldehyde only 
lacks the hydroxyl group at the 2nd position of the aldehyde aa. Interestingly aa was found 
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successful with all the pyridyl carboxamidrazones used in the current investigation and in the 
earlier research carried out by Rathbone et al., whereas be became unsuccessful with most 
amines except the 2-hydrazino pyridine. This could be because of the intra molecular 
hydrogen bonding with the OH to the carbonyl oxygen in da, assists the attack of the amine.  
 
 
The NMR spectra obtained of most of the compounds were fairly simple and were obtained 
in DMSO. Some compounds underwent tautomerism and this was observed on comparing 
the NMR spectrum obtained at room temperature and at high temperature (50oC). One 
compound 5.45 in particular has shown a significant change in NMR spectrum when 
compared at different temperatures.  
 
O N
H
N
O
NH2
O N N
NH2
OH
 
 
Figure 5.17:  Showing the keto-enol form of the compound 5.45.  
 
At room temperature compound 5.45 exists in both forms as shown in Figure 5.18 and 
therefore there is appearance of the OH and the NH as shown in the Figure 5.19. When the 
same spectrum was obtained at 50oC there was the disappearance of the NH peak showing 
the compound in one form.  
 
Figure 5.18: The NMR spectrum of compound 5.45 at room temperature 
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Figure 5.19:  The NMR spectrum of compound 5.45 at 50oC  
 
5.11.1 Microbiological studies: 
An initial set of the compounds was tested against various organisms as shown in Table 5.7. 
It was found that most of the compounds that successfully inhibit the growth of S.aureus 
have also successfully inhibited the growth of the M. fortuitum.  However these compounds 
did not necessarily inhibit the growth of E. coli. This suggests that the compounds had 
specific activity toward certain organisms. Interestingly the compounds which successfully 
inhibit the growth of M. fortuitum in agar medium did not necessarily inhibit the growth of this 
organism in solution. Therefore the differences in the permeability pattern of the compounds 
in agar medium were also an important parameter while considering the zone of inhibition 
values. Only compounds 5.31 and 5.32 exhibited a very good zone of inhibition when tested 
against the organisms; unfortunately they were unable to inhibit the growth of M. fortuitum 
when tested in solution. On the other hand the zone of inhibition was little or none in case 
with the compounds 5.8, 5.72, 5.7, 5.9, 5.4 and 5.22 but these compounds have successfully 
inhibited the growth of M. fortuitum when tested in solution. Therefore the large zones of 
inhibition of the compound 5.31 and 5.32 were perhaps due to the high permeability of these 
compounds in agar plate. Unlike other organisms M. fortuitum behaves badly on agar, 
however is much easier to assay in broth (Tims. K, et al,. 2005). Compound 5.1 was very 
active against Mycobacterium tuberculosis; the di-iodo substituted 4-
pyridylcarboxamidrazone has also shown activity against the MRSA strains of microorganism 
with MIC values 10-20 μg/mL (Rathbone, et al. 2006). Interestingly compound 5.1 had the di-
tert butyl groups which are electron donating, whereas the iodo groups are weakly electron 
withdrawing leaving a wide area of research into drug designing. Therefore compound 5.1 
was further modified by incorporating a wide range of halogens and at the same time the 
pyridyl-amine moiety was also modified in the study (Figure 5.7). Compound 5.35 and 
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compound 5.36 have shown very good inhibitory effect against S.aureus and E.coli in agar 
plate, unfortunately these compounds did not show any inhibition when tested against M. 
tuberculosis. Compounds 5.3, 5.4, 5.5, 5.7, 5.8, 5.9, 5.10, 5.14, 5.42, 5.57, 5.60, 5.63, 5.66 
and 5.69 were found to be very active against M. tuberculosis (Graph 5.2). Compound 5.3 in 
particular has shown the highest potency (in 0.69µg/mL) against M. tuberculosis. None of the 
other compounds have shown similar activity. Compounds 5.4, 5.7, 5.8 and 5.9 were also 
found potent against TB organism (killing 90% of the cells) at a concentration between 0.5-3 
µg/mL. However all these compounds have only exhibited 50% or less potency when 
compared with compound 5.3. All these compounds have also inhibited the growth of gram 
positive organisms M. fortuitum and S. aureus (Table 5.7) but were inactive against the gram 
negative organism E. coli except compound 5.7, which has shown some activity against E. 
coli. Although compounds 5.5 and 5.42 were found active against M.fortuitum in the agar 
medium, they failed to inhibit the growth of the organism when tested in solution.  
 
 
Graph 5.2:  The distribution of the potency of the compounds towards M. tuberculosis in a 
concentration at which compound 5.3 exhibits 100% potency.   
 
Compound 5.57, 5.60, 5.63 and 5.66 (analogues of compound 5.2) were also found active 
with IC50 value less than 3 µg/mL. Interestingly none of these compounds have shown 
activity against any other organisms on the agar plate, except compounds 5.66 and 5.14 
which have shown some activity against S.aureus (Table 5.8). Unfortunately all these 
compounds (Table 5.10) were observed with high toxicity profile representing a selectivity 
index ≤ 1 (Table 5.10). Only compound 5.3 and 5.4 were observed with SI more than 2. But 
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compound 5.3 was reported as the most potent compound isolated in this work showing 
activty at less than 1 µg/mL concentration.   
 
5.11.2 Toxicology:  
All of the 14 compounds (Table 5.9) which have shown activity against the TB organism were 
also studied for their toxicity on mammalian cells (Graph 3). The concentrations at which 
these compounds kill the parent cells were obtained (Table 5.11). Most of these compounds 
have shown high level of toxicity causing almost 90% cell death at a concentration less than 
20 µg/mL.  Particularly compound 5.14, 5.63, 5.57, 5.42 and 5.66 were found extremely toxic 
killing 50% of the parent cells at a concentration as low as 0.16 µg/mL.  
 
 
 Viability of the mammalian cells in concentration (µg/mL) 
Compounds 0.08 0.16 0.31 0.63 1.25 2.50 5.00 10.00 20.00 40.00 
           
5.3 95.42 94.07 90.58 87.64 67.91 37.53 3.15 1.71 1.62 1.58 
5.4 90.29 84.83 86.77 85.51 85.70 78.91 72.15 32.92 10.29 1.58 
5.5 91.52 98.86 85.09 99.10 83.37 93.42 81.49 2.05 2.08 1.58 
5.7 96.54 83.47 86.66 89.78 84.07 24.72 2.69 1.25 0.69 0.68 
5.8 101.90 89.74 92.04 84.49 76.40 70.41 7.36 2.96 1.62 2.26 
5.9 95.31 91.79 81.39 75.62 84.53 30.50 4.20 1.94 1.74 1.36 
5.10 95.09 86.89 82.96 44.38 30.23 29.02 19.73 13.21 4.05 3.62 
5.14 91.18 50.40 31.95 28.54 19.77 14.85 13.89 11.62 11.10 7.36 
5.42 89.51 35.80 25.00 25.62 11.16 10.20 10.04 5.69 1.27 0.91 
5.57 88.39 31.13 32.96 24.49 8.26 9.64 8.76 3.53 1.74 1.92 
5.60 87.50 76.05 34.30 28.09 23.37 15.19 10.97 8.77 7.06 7.02 
5.63 90.18 50.51 29.26 32.02 15.81 8.96 8.76 6.83 7.06 6.23 
5.66 82.92 39.68 29.48 18.88 7.79 7.26 9.46 7.52 2.89 1.47 
5.69 89.84 92.70 66.03 28.09 20.12 11.79 8.64 6.83 3.01 1.92 
           
 
Table 5.11: Showing the percentage viability of the mammalian cells at various 
concentrations.  
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Graph 5.3: The graph above showing the distribution of the percentage of cell viability of the 
mammalian cells versus the concentration of the compound.  
 
The toxicological study of these compounds shows that the 4-hydrazino pyridine analogues 
of compound A were less toxic compared to any other compounds. Compounds 5.4 and 5.5 
which were highly active against the gram positive organism (TB), had least toxicity profile 
killing less than 30% of the mammalian cells at a concentration as high as 5 µg/mL. This 
concentration was found to be extremely toxic in all other compounds killing as high as 97% 
of the mammalian cells. The compound 5.5 however has IC90 value of 6.17 µg/mL, and 
compound 5.4 has 2.9 µg/mL. This suggests that the compound 5.5 is relatively toxic to 
mammalian cells in the concentration at which it produces anti-bacterial activity. Compound 
5.4 on the other hand was relatively toxic against the organism causing 90% death at a 
concentration which only kills about 25% of the mammalian cells.  
 
5.11.3 Structural activity relationship studies:  
Out of the 102 compounds prepared only 14 compounds have shown activity and another 42 
have shown weak activity against the pathogenic Mycobacterium tuberculosis (Table 5.9). Of 
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these 14 compounds, 8 compounds were the analogues of Compound A, and 5 of the rest 
were the analogues of compound D. 
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Figure 5.20: Showing the analogue of Compound A and Compound D 
 
 
Of these 8 compounds which have shown potential activities against M.tuberculosis, 6 
compounds were the 4-hydrazino pyridine derivative of Compound A. Compounds 5.3, 5.4, 
5.9 and 5.10 had the tertiary-butyl substitution on the R2 and R3 position and were 
particularly active against gram positive organisms and inactive against gram negative 
organisms. Removing a tertiary butyl group either from R2 or R3 position, makes the 
compounds active against gram negative organisms as well. These suggest that the di-tert-
butyl substitution is essential to make the compound specifically active against gram positive 
organisms. 7 out of the 8 compounds had the OH on the R1, except Compound 5.4. 
Replacing the OH from the R1 to R3 (Scheme 5.1) as in Compound 5.4 the activity goes 
down by three fold. Compound 5.3 was the most potent compound reported in this 
investigation; changing the 4-pyridyl with the 3-pyridyl moiety as in compound 5.10 the 
activity drops by 5 fold.  Although the tertiary butyl group is essential on both R2 and R4, it 
was observed that substitution on the R2 was more important than the R4 for its anti-
tubercular activity. Thus compound 5.7 was observed as the next most potent compound in 
this study. Interestingly the 3-pyridyl analogue of compound 5.7 has also shown activity 
within the organism. This suggests that the presence of the OH on the R1 and tert-butyl on 
the R2 is essential within the active site. The presence of 4-pyridyl is more favourable than 
the 3-pyridyl within the active site. Iodine has shown some activity in the earlier studies and 
hence in this study a wide range of aldehydes containing halogen substitutions at R2 and R4 
was used, but none of the halogen containing derivatives has shown any biological activity 
except iodine, compound 5.5.  
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Compound D has also shown some interesting activity in the organism; these compounds 
were the analogues of the Compound 5.2 (Begum. et al., 2007). Of these 6 compounds 
which have shown potential activity within the organism, 5 were the analogues of 2-pyridyl 
carboxamidrazone. This suggests that the presence of 2-pyridyl carboxamidrazone moiety 
was essential for the activity. The presence of the halogen on the 2nd position of the aryl ring 
of compound 5.89 has shown some interesting results in the active site (Mamalo, et al.,. 
1992). All these 6 compounds had electro-negative halogen substitution suggesting the 
presence of the electronegative substitution is favourable within the active site. Unfortunately 
all these compounds were found to be highly toxic with the selectivity index less than 1.  
 
Compounds A, B, C, D, E and F were designed as analogues of compounds 5.1 and 
Compound 5.2. This was essentially with the idea to change the various substitutions 
throughout the moiety to reduce the toxicity and increase the potency of Compound 5.1, 
compound 5.2. All the analogues of Compound D were reported cytotoxic (Graph 5.2 and 
Graph 5.3).  Interestingly all these compounds had the common pyridyl carboxamidrazone 
moiety. In the current research the pyridyl carboxamidrazone moiety was observed as the 
toxicity reason of the compound and was also observed with compound 5.2 in the earlier 
research. This is perhaps that the pyridyl carboxamidrazone derivatives were metabolised 
into pyridyl derivatives in the bacteria (Tims. et al., 2005). This aromatic ring of pyridine may 
as well act as an oxidising agent for the nicotinamide adenosine dinuleotide phosphate in the 
amino-oxidative metabolism in the bacteria (Ignatenko. et al., 1978). The di-tert-butyl aryl 
moiety in Compound 5.1 was probably important to produce the biological activity. Although 
compounds 5.3, 5.7 and 5.9 were found active, they had a small selectivity index just over 1. 
This was found among most of the ant-TB drugs used as second line treatment. While 
considering these two compounds as a possible anti-tubercular agent, the risk-benefit 
analysis must be considered. Thus any of these compounds could be used as an anti-
tubercular agent if the beneficial effect of these compounds exceeds the possible risk 
associated with them.  Another interesting feature about these agents was that they were 
specifically active against all the gram positive bacteria, but not gram negative.  Thus these 
agents may also be considered as a useful compound in screening gram positive bacteria.        
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5.12 Conclusion:  
 A library of 102 compounds have been generated following the lead compounds N1–[3, 5-di-
(tert-butyl)-2-hydroxybenzylidine] - pyridine-4-carboxamidrazone and N1–[3, 5-di-(tert-butyl)-
2-hydroxybenzoyl] amide. All these compounds have been successfully characterised and 
tested against various gram positive and gram negative organisms including Mycobacterium 
tuberculosis. Of only 14 compounds which have shown potential activity against the 
pathogen Mycobacterium tuberculosis, 6 were found less toxic and rest all were found to be 
extremely toxic killing 80% of the mammalian cells at a concentration lower than 5 µg/mL. 
Compound 5.3 was identified as the most potent anti-tubercular agent killing 90% of the 
organisms at concentration 0.6µg/mL.   
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CHAPTER 6 
MATERIALS AND METHODS 
 
 
6.1.  Chemicals: 
All chemicals and solvents were used as supplied. Hydrazine, 2-cyano pyridine, furoyl acrylic 
acid, N,N`-carbonyl di-imidazole, DMSO, 4-amino pyridine, and all the aldehydes were 
purchased from Sigma-Aldrich. Organic solvents were purchased from Fisher Chemicals. 
Thin layer chromatography plates on aluminium sheets (20 X 20) of silica gel F254 were 
obtained from Merck.  
 
6.2.  Instrumentation:  
Proton NMR spectra were obtained on a Bruker AC 250 instrument operating at 250 MHz as 
solution in d6-DMSO and referenced from δDMSO = 2.50 ppm unless otherwise stated. 
Infrared spectra were recorded as KBr disc on a Mattson 3000 FTIR spectrophotometer. 
(APCI-MS) was carried out on a Hewlett-Packard 5989B quadrupole instrument connected to 
an electrospray 59987A unit with an APCI accessory and automatic injecting using a 
Hewlett-Packard 1100 series autosampler. Accurate MS was carried out on TOF mass 
spectra (ESI mode) measured on a Waters LCT Premier Mass Spectrometer.   
 
6.3.1. Preparation of Pyridine-4-methylhydrazone: Compound 5.87 
 
N
N
NH2
 
 
 
An appropriate pyridine-4-carboxaldehyde (11.0287gm or 9.7mL or 90.65mmol) was 
dissolved in ethanol (7mL) and added dropwise through a pressure generated dropping 
funnel into a mixture of hydrazine monohydrate ( 9.5mL or 190mmol) in ethanol (5mL) stirred 
at 60oC for 24 hours. The product was collected by evaporating the excess hydrazine under 
high vacuum pump to give a yellow oil compound.  
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Yield was 10.7234 g or 87.178 mmol or 97%.  
1H NMR (250 MHz d6-DMSO): 7.39 (dd, 2H, J= 1.2, 1.9 Hz, Py-3,5H); 7.45 (s, 2H, NH2); 7.62 
(s, 1H, NH); 8.47 (dd, 2H, J= 1.9, 1.9 Hz, Py-2,6H) ppm. 
MS (APCI +) m/z = found 122 (M + H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.25 (single spot).  
 
6.3.2. Preparation of 4-[3, 5-di-(tert-butyl)-2-OH-benzyl]-1-(4-pyridyl)-2, 3-diaza-1, 3-
butadiene: Compound 5.17 
N
N
N
HO
 
 
3, 5-di(tert-butyl)-2-hydroxybenzaldehyde (3.01gm or 12.844mmol) was dissolved in ethanol 
(5mL). Pyridine-4-carboamidrazone (1.1gm or 9.09 mmol) was added and the reaction was 
stirred at 90 oC for 36 hours. The solvent was removed by filtration under vacuum and the 
title compound was collected as yellow amorphous solid, which was dried under vacuum.  
 
Yield was 1.7229g. or5.082 mmol or  60% 
Melting point: 161-179.5 oC 
1H NMR (250 MHz d6-DMSO): 1.29 (s, 9H, tert-butyl); 1.409 (s, 9H, tert-butyl); 7.43 (d, 1H, 
J= 2.5 Hz, Ph-4H); 7.52 (d, 1H, J= 2.5 Hz, Ph-6H); 7.8 (dd, 2H, J= 1.2, 1.2 Hz, Py-3,5H); 
8.76 (dd, 2H, J= 1.9, 1.9 Hz, Py-2,6H); 8.91 (s, 1H, CH); 9.06 (m, 1H, CH); 12.2 (s, 1H, OH); 
ppm. 
13C NMR (63 MHz d6-DMSO): 29.21 (CMe3); 31.2 (CMe3); 33.93 (CMe3); 34.65 (CMe3); 
116.65 (C1-Ph); 121.95 (C3 and C5 Py), 127.93 (C6 Ph); 135.77 (C4- Ph); 140.41 (C3- Ph), 
140.9 (C5-Ph); 150.54 (C2 and C6 Py); 156.33 (C imide); 160.93 (C- imide); 167.98 (C2- 
Ph); ppm. 
IR (KBr) ν= 3073, 2948, 2869, 1955, 1850, 1796, 1755, 1677, 1420, 1390 (-C=N-), 1433, 
1385 (tert-butyl), 1175 (-OH) cm-1 
MS (APCI +ve) m/z = found 338 (M + H) +.  
Accurate MS (+ES) = Calculated 338.2232(m+H)+ and 339.2263(m+H)+ found 
338.2235(m+H)+ and 339.2275 (m+H)+,  0.9 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.72 (single spot).    
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6.3.3. Preparation of 4-[3, 5-di-(tert-butyl)-4-OH-benzyl]-1-(4-pyridyl)-2, 3-diaza-1, 3-
butadiene: Compound 5.18 
N
N
N
OH
 
 
Yield = 0.38g or 1.127 mmol or 65% 
Melting point: 143.3 – 146.9 oC 
1H NMR (250 MHz d6-DMSO): 1.41 (s, 18H, di-tert-butyl); 7.69 (s, 2H, Ph-H); 7.77 (dd, 2H, 
J= 1.422, 4.423 Hz, Py-3,5H); 8.665 (s, 1H, CH); 8.71 (dd, 2H, J= 1.422, 4.458 Hz, Py-2,6H); 
8.726 (s, 1H, CH); ppm. 
IR (KBr) ν= 3625, 3347, 3081, 2960, 2601, 1940, 1627, 1602, 1420, 1382 (-C=N-), 1433, 
1385 (tert-butyl), 1125 (-OH) cm-1 
MS (APCI -ve) m/z = found 230, 234, 336 (M - H) +.  
Accurate MS (+ES) = Calculated 338.2232(m+H)+, found 338.2233(m+H)+, 0.3 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.78 (single spot).    
 
6.3.4. Preparation of 4-[3, 5-di-iodo-2-OH-benzyl]-1-(4-pyridyl)-2,3-diaza-1,3-butadiene:  
Compound 5.19 
N
N
N
HO
I
I
 
 
Yield = 0.25g or 0.523mmol or 78% 
Melting point: 225.3 – 228.9 oC 
1H NMR (250 MHz d6-DMSO): 7.77 (dd, 2H, J= 1.896, 4.423 Hz, Py-3,5H); 8.05 (d, 1H, J= 
1.896 Hz, Ph-H); 8.17 (d, 1H, J= 2.527 Hz, Ph-H); 8.75 (dd, 2H, J= 1.264, 4.423 Hz, Py-
2,6H); 8.926 (s, 1H, CH); 8.93 (s, 1H, CH); 12.5 (bs, 1H, OH); ppm. 
IR (KBr) ν= 3070, 3011, 1918, 1870, 1729, 1663, 1621, 1450 (-C=N-), 1273, 1182 (-OH) cm-1 
MS (APCI -ve) m/z = found 372, 476 (M - H) +, 477 (M + H) +.  
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Accurate MS (+ES) = Calculated 477.8913(m+H)+, found 477.8921(m+H)+, 1.7 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.62 (single spot).    
 
6.3.5. Preparation of 4- [5-tert-butyl-2-OH-benzyl]-1-(4-pyridyl)-2, 3-diaza-1, 3-
butadiene: Compound 5.22 
N
N
N
OH
 
 
Yield = 0.26g or 0.918 mmol or 65% 
Melting point: 204.3 – 208.9 oC 
1H NMR (250 MHz d6-DMSO): 1.275 (s, 9H, tert-butyl); 6.92 (d, 1H, J=8.214, Ph-H); 7.46 (t, 
1H, J=8.214, 2.527 Hz, Ph-H); 7.74 (d, 1H, J=2.57 Hz, Ph-H); 7.78 (dd, 2H, J= 1.896, 4.423 
Hz, Py-3,5H); 8.73 (dd, 2H, J= 1.264, 4.423 Hz, Py-2,6H); 8.83 (s, 1H, CH); 9.005 (s, 1H, 
CH); 10.92 (bs, 1H, OH); ppm.  
MS (APCI -ve) m/z = found 280 (M - H) +, 281 (M) +, 313 (M +MeO H) +.  
IR (KBr) ν= 3041, 2959, 2869, 1937, 1899, 1760, 1621, 1567(-C=N-), 1492, 1407-1370 (tert-
butyl), 1150 (-OH) cm-1 
Accurate MS (+ES) = Calculated 282.1528 (m+H)+ and 283.1637 (m+H)+ found 282.1613 
(m+H)+, 283.1645 (m+H)+, 2.5 ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.7.    
 
6.3.6. Preparation of 4-[3-tert-butyl-2-OH-benzyl]-1-(4-pyridyl)-2, 3-diaza-1, 3-butadiene 
Compound 5.21 
N
N
N
HO
 
 
Yellow amorphous. 
Yield = 0.45g or 1.590mmol or 43% 
Melting point: 232.2 – 235.6 oC 
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1H NMR (250 MHz d6-DMSO): 1.409 (s, 9H, tert-butyl); 6.95 (t, 1H, J=7.582, 8.214 Hz, Ph-
H); 7.42 (dd, 1H, J=8.214, 1.264 Hz, Ph-H); 7.49 (dd, 1H, J=7.582, 1.264 Hz, Ph-H); 7.8 (dd, 
2H, J= 1.264, 4.423 Hz, Py-3,5H); 8.75 (dd, 2H, J= 1.896, 4.423 Hz, Py-2,6H); 8.92 (s, 1H, 
CH); 9.005 (s, 1H, CH); 9.04 (bs, 1H, OH); 12.370 (s, 1H, CH); ppm. 
IR (KBr) ν= 3041, 2959, 2869, 1937, 1899, 1760, 1692, 1621, 1567 (-C=N-), 1490, 1412-
1350 (tert-butyl), 1175 (-OH) cm-1 
MS (APCI -ve) m/z = found 280 (M - H) +, 281 (M) +, 351.  
Accurate MS (+ES) = Calculated 282.1606 (m+H)+ found 282.1609 (m+H)+, 1.1 ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.65 (single spot).    
 
6.3.7. Preparation of 4-[3, 5-di-bromo-2-OH-benzyl]-1-(4-pyridyl)-2, 3-diaza-1, 3-
butadiene: Compound 5.20 
N
N
N
Br
Br
HO
 
 
Yellow amorphous.  
Yield = 0.57g or 2.072 mmol or 62% 
Melting point: 179.1 – 183.6 oC 
1H NMR (250 MHz d6-DMSO): 7.8 (dd, 2H, J= 1.896, 4.423 Hz, Py-3,5H); 7.95 (d, 1H, 
J=2.527, Ph-H); 7.98 (d, 1H, J=1.896 Hz, Ph-H); 8.76 (dd, 2H, J= 1.896, 4.423 Hz, Py-2,6H); 
8.946 (s, 1H, CH); 9.015 (s, 1H, CH); 12.3 (bs, 1H, OH); ppm.  
IR (KBr) ν= 3424, 3046, 2987, 2869, 2358, 1939, 1627(-C=N-), 1480, 1432, 1175 (-OH) 697 
(-C-Br) cm-1 
MS (APCI -ve) m/z = found 276, 324, 382 (M - H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.5 (single spot).    
 
6.4. 1. Preparation of 4-hydrazino pyridine:  Compound 5.84.  
N
N
H
NH2
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4-chloropyridine (4.93g or 43.628 mmol) was added to a mixture of hydrazine (33ml or 20eq) 
and n-butanol (18ml). The reaction mixture was refluxed at 100oC for 24 hours with constant 
stirring. The excess hydrazine was removed under high vacuum evaporation and the white 
solid residue was dissolved in 1 M NaOH. The final product was then obtained by extracting 
with ethyl acetate from the NaOH solution and then evaporating the ethyl acetate under 
vacuum. The final product is a white solid which on exposure to air changes to violet colour.  
Yield = 3.5g or 31.531mmol or 72.27% 
Melting point: 241.3 – 243.7oC 
1H NMR (250 MHz d6-DMSO): 7.39 (dd, 2H, J= 1.2, 1.9 Hz, Py-3,5H); 7.45 (s, 2H, NH2); 7.62 
(s, 1H, NH); 8.47 (dd, 2H, J= 1.9, 1.9 Hz, Py-2,6H) ppm. 
MS (APCI -ve) m/z = found 120 (M - H) +.  
Accurate MS (ES +ve) m/z = found 110 (M + H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.57. 
 
6.4.2. Preparation of 3,5-di-tert butyl 2-OH benzylidine 4-hydrazinopyridine  
Compound 5.03 
N
N
OH
N
 
 
4-hydrazinopyridine (0.3g) and 3,5 di-tert butyl 2-OH benzaldehyde (0.69g) was dissolved in 
7ml ethanol and was refluxed for 18 hours with constant stirring. The final product was then 
filtered washed and then recrystallised from ethanol to give a yellow amorphous compound.  
 
Yield 0.32g. 0.984 mmol or 36% 
Melting point: 191.1 – 193.9 oC 
1H NMR (250 MHz d6-DMSO): 1.29 (s, 9H, tert-butyl); 1.409 (s, 9H, tert-butyl); 4.49 (s, 1H, 
NH); 6.96 (dd, 2H, J=5.05, 1.896 Hz, Py-H); 7.25 (d, 2H, J=4.423 Hz, Ph-H); 8.22 (s, 1H, 
CH); 8.3 (dd, 1H, J=5.05, 1.896 Hz, Py-H); 11.01 (s, 1H, OH); 11.3 (s, 1H, OH); ppm. 
IR (KBr) ν= 3619 (-NH), 3418, 3156, 2954, 2873, 2491, 1914, 1596 (-C=N-), 1520, 1350 
(tert-butyl), 1300, 1140 (-OH) cm-1 
MS (APCI -ve) m/z = found 232, 233, 296, 324 (M - H) +.  
Accurate MS (ES -ve) m/z = Calculated 325.2154, found 324.2108 (M - H) +. PPM=9.9  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.55 tailing.     
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6.4.3. Preparation of 3,5-di-tert butyl 4-OH benzylidine 4-hydrazinopyridine. 
Compound 5.04 
N
N
N
OH
 
 
Pale yellow amorphous.  
Yield = 0.73g 2.274 mmol or 69% 
Melting point: 208.3 – 210.7 oC 
1H NMR (250 MHz d6-DMSO): 1.476 (s, 18H, di-tert-butyl); 4.39 (s, 1H, NH); 6.8 (dd, 2H, 
J=5.05, 1.896 Hz, Py-H); 7.5 (s, 2H, Ph-H); 7.93 (s, 1H, CH); 8.25 (dd, 2H, J=5.05, 1.896 Hz, 
Py-H); 10.652 (s, 1H, OH); ppm. 
IR (KBr) ν= 3627 (-NH), 3313, 2952, 2875, 2481, 1920, 1600 (-C=N-), 1530, 1360 (tert-butyl), 
1300, 1120 (-OH) cm-1 
MS (APCI -ve) m/z = found 230, 323 (M - 2H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.63 (single spot).    
 
6.4.4. Preparation of 3,5-di-iodo 2-OH benzylidine 4-hydrazinopyridine Compound 
5.05 
N
N
I
N
I
OH
 
 
Yellow amorphous.  
Yield = 0.782g or 1.558mmol or 82% 
Melting point: 222.1 -215.3 oC 
1H NMR (250 MHz d6-DMSO): 6.86 (dd, 2H, J=5.05, 1.896 Hz, Py-H); 7.87 (dd, 1H, J=1.896, 
2.527, 4.423 Hz, Ph-H); 7.97 (dd, 1H, J=2.527, 1.896 Hz, Ph-H);  8.1 (s, 1H, CH); 8.26 (dd, 
2H, J=1.896, 5.05 Hz, Py-H); ppm. 
IR (KBr) ν= 3600 (-NH), 3245, 3041, 2491, 2366, 2080, 1632 (-C=N-), 1586, 1430, 1187 (-
OH) cm-1 
MS (APCI +ve) m/z = found 466 (M + H) +.  
Accurate MS (ES+ve) m/z = Calculated 464.8835, found 465.8904(M + H) +, 1.9 ppm 
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TLC: ethyl acetate: methanol (4:1) (Rf) = 0.67 (single spot).    
6.4.5. Preparation of 3,5-di-bromo 2-OH benzylidine 4-hydrazinopyridine Compound 
5.06.  
N
H
N
Br
Br
HO
N
 
 
Bright yellow powder.  
Yield = 0.63g or 1.7073 mmol or 62.6% 
Melting point: 239.3 – 242.7 oC 
1H NMR (250 MHz d6-DMSO): 6.88 (d, 2H, J=6.318 Hz, Py-H); 7.73 (d, 1H, J=2.527 Hz, Ph-
H); 7.8 (d, 1H, J=2.527 Hz, Ph-H); 8.1 (s, 1H, CH); 8.24 (d, 2H, J=6.318 Hz, Py-H); ppm. 
IR (KBr) ν= 3436 (-NH), 3199, 3085, 2965, 2084, 1976, 1637 (-C=N-), 1520, 1495, 1430, 
1235, 1220, 1150 (-OH) 710 (C-Br) cm-1 
MS (APCI -ve) m/z = found 277, 278, 292, 324, 370 (M - H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.55 (single spot).    
 
6.4.6. Preparation of 3,5-di-tert-butyl benzylidine 4-hydrazinopyridine: Compound 
5.09. 
N
H
N
N
 
White solid.  
Yield = 0.3g or 0.964mmol or 77% 
Melting point: 167.1 – 169.5 oC 
1H NMR (250 MHz d6-DMSO): 1.307 (s, 18H, di-tert-butyl); 6.94 (d, 2H, J=6.318 Hz, Py-H); 
7.388 (t, 1H, J=1.896, 1.246 Hz, Ph-H); 7.5 (d, 2H, J=1.896 Hz, Ph-H); 7.95 (s, 1H, CH); 8.2 
(d, 2H, J=6.318 Hz, Py-H); 10.847 (s, 1H); ppm. 
IR (KBr) ν= 3438 (-NH), 3210, 3149, 2950, 2867, 2495, 1922, 1596 (-C=N-), 1495, 1375 
(tert-butyl), 1220, 1110 cm-1 
MS (APCI +ve) m/z = found 213, 241, 310 (M + H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.82 (tailing).  
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6.4.7. Preparation of 3-tert-butyl 2-OH benzylidine 4-hydrazinopyridine: Compound 
5.07 
N
H
N
HO
N
 
 
Pale white solid.  
Yield = 0.2g 0.743mmol or 31% 
Melting point: 176.1 – 178.2 oC 
1H NMR (250 MHz d6-DMSO): 1.407 (s, 9H, tert-butyl); 6.8 (d, 2H, J=6.318 Hz, Py-H); 6.88 
(t, 1H, J=7.582 Hz, Ph-H); 7.2 (ms, 2H, Ph-H);  8.19 (s, 1H, CH); 8.27 (d, 2H, J=6.318 Hz, 
Py-H); 11.1 (bs, 1H, OH); 11.46 (s, 1H, OH); ppm. 
IR (KBr) ν= 3212, 3154, 2998, 2501, 1920, 1859, 1586 (-C=N-), 1500, 1425, 1367 (tert-
butyl), 1300, 1200, 1135 (-OH) cm-1 
MS (APCI -ve) m/z = found 176, 268 (M - H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.68 tailing.    
 
6.4.8. Preparation of 5-tert-butyl 2-OH benzylidine 4-hydrazinopyridine Compound 
5.08 
 
N
N
N
OH
 
 
Pale brown 
Yield = 0.27g or 1.003 mmol or 37% 
Melting point: 174.2 – 177.1 oC 
1H NMR (250 MHz d6-DMSO): 1.28 (s, 9H, tert-butyl); 6.83 (d, 1H, J=8.214 Hz, Ph-H); 6.88 
(d, 2H, J=6.318 Hz, Py-H); 7.25 (dd, 1H, J=2.527, 8.214 Hz, Ph-H); 7.65 (d, 2H, J=2.527 Hz 
Ph-H); 8.22 (d, 2H, J=6.318 Hz, Py-H); 8.268 (s, 1H, CH); 10.91 (s, 1H, OH); ppm. 
IR (KBr) ν= 3434 (-NH), 3230, 3139, 2967, 2869, 1922, 1602 (-C=N-), 1495, 1367 (tert-butyl), 
1220, 1135 (-OH) cm-1 
MS (APCI -ve) m/z = found 220,268 (M - H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.72 (short tailing).    
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6.5.1. Preparation of 4-[3,5-di-(tert-butyl)-2-OH-benzylidine]-amino-pyridine: 
Compound 5.29.   
 
N
N
HO
 
 
 
Red crytraline  
Yield = 0.51g or 1.645mmol or 63% 
Melting point: 118.2 – 120.6 oC 
1H NMR (250 MHz d6-DMSO): 1.29 (s, 9H, Ph); 1.41 (s, 9H, Ph); 7.42 (dd, 2H, J= 1.264, 
4.423 Hz, Py-3H,5H); 7.45 (d, 1H, J= 2.527 Hz, Ph-6H); 7.53 (d, 2H, J= 1.896 Hz, Ph-4H); 
8.61 (dd, 2H, J= 1.264, 4.423 Hz, Py-2,6H); 9.05 (s, 1H, CH); 13.466 (s, 1H, OH); ppm. 
IR (KBr) ν= 3438, 3077, 2964, 2908, 1926, 1801, 1619, 1575 (-C=N-), 1440, 1385, 1375 
(tert-butyl), 1210, 1175 (-OH) cm-1 
MS (APCI -ve) m/z = found 309 (M - H) +.  
MS (APCI +ve) m/z = found 311 (M + H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.65.    
 
6.5.2. Preparation of 4-[3,5-di-iodo-2-OH-benzylidine]-amino-pyridine: Compound 5.31 
N
N
HO
I
I
 
 
 
 
Yellow solid 
Yield = 0.2g or 0.444mmol or 44% 
Melting point: 179.1 – 182.6 oC 
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1H NMR (250 MHz d6-DMSO): 7.42 (dd, 2H, J= 1.264, 4.423 Hz, Py-3,5H); 8.02 (d, 1H, J= 
2.527 Hz, Ph-6H); 8.201 (d, 2H, J= 2.527 Hz, Ph-4H); 8.64 (dd, 2H, J= 1.264, 4.423 Hz, Py-
2,6H); 8.94 (s, 1H, CH); 13.88 (bs, 1H, OH); ppm. 
IR (KBr) ν= 3432, 3016, 2959, 2815, 2599, 1920, 1870, 1735, 1614, 1581 (-C=N-), 1482, 
1436, 1160 (-OH) cm-1 
MS (APCI -ve) m/z = found 373, 419, 449 (M - H) +and 450 (M) +,   
TLC carried out in ethyl acetate: methanol (4:1) (Rf) = 0.68.    
 
6.5.3. Preparation of 4-[3,5-di-(tert-butyl)-4-OH-benzylidine]-amino-pyridine: 
Compound 5.30 
 
N
N
OH
 
 
 
Pale yellow solid.  
Yield = 0.5g or 1.612mmol or 76% 
Melting point: 141.1 – 143.3 0C 
1H NMR (250 MHz d6-DMSO): 1.315 (s, 18H, di-tert Ph); 7.3 (bd, 2H, J= 3.791 Hz, Py-3,5H); 
7.7 (bs, 1H, J= 2.527 Hz, Ph-6H); 8.15 (s, 2H, J= 1.896 Hz, Ph-4H); 8.45 (dd, 2H, J= 1.264, 
5.05 Hz, Py-2,6H); 10.4 (s, 1H, HC=N); ppm. 
IR (KBr) ν= 3627, 3286, 3071, 2955, 2869, 2599, 1924, 1824, 1735, 1631, 1575 (-C=N-), 
1420, 1360, 1310 (tert-butyl), 1250, 1175 (-OH) cm-1 
MS (APCI -ve) m/z = found 233, 279, 309 (M - H) +, 341 and 367.   
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.71.    
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6.5.4. Preparation of 4-[3, 5-di-bromo-2-OH-benzylidine]-amino-pyridine: Compound 
5.32 
 
N
N
HO
Br
Br
 
 
State = Red amorphous.  
Yield = 0.212g or 0.595mmol or 72% 
Melting point: 167.3 – 170.7 0C 
1H NMR (250 MHz d6-DMSO): 7.43 (dd, 1H, J= 1.896, 5.05 Hz, Py-3,5H); 7.92 (d, 1H, J= 
2.527 Hz, Ph-6H); 8.01 (d, 2H, J= 2.527 Hz, Ph-4H); 8.65 (dd, 2H, J= 1.896, 5.05 Hz, Py-
2,6H); 9.027 (s, 1H, HC=NH); ppm.  
IR (KBr) ν= 3441, 3274, 3090, 2971, 2830, 1766, 1634, 1577 (-C=N-), 1450, 1190 (-OH), 700 
(Br) cm-1 
MS (APCI -ve) m/z = found 355 (M - H) +.  
MS (APCI +ve) m/z = found 357 (M + H) +.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.78.    
 
6.6.1. Preparation of 3,5-di-tert-butyl 2-OH benzylidine 2-hydrazinopyridine.  
Compound 5.10  
 
N N
H
N
HO
 
 
 
2-hydrazinopyridine (0.1g or 0.916 mmol) and 3,5 di-tert butyl 2-OH benzaldehyde (0.239g or 
1.02 mmol) was dissolved in 5ml ethanol and was refluxed for 18 hours with constant stirring. 
The final product was then filtered washed and then recrystallised from ethanol to give a 
yellow amorphous compound.  
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Yield is 0.153 g or 0.47mmol or 51 % 
Mp: 178.0-182.8 0C and 187.2-189.6 0C 
1H NMR (250 MHz d6-DMSO): 1.29 (s, 9H, CMe3); 1.42 (s, 9H, CMe3); 7.16 (d, 1H, J= 2.5 
Hz, Ph-H4); 6.81-6.88 (overlapping m, 2H, Py-H5 and H3); 7.24 (d, 1H, J= 2.5 Hz, Ph-6H); 
7.72 (ddd, 1H, J= 7.58, 5.05, 1.89 Hz, Py-H4); 8.20 (dd, 1H, J= 5.05, 1.26 Hz, Py-H6); 8.24 
(s, 1H, N=CH); 11.07 (s, 1H, NH); 11.73 (s, 1H, OH); ppm 
IR (KBr) ν= 3463 (OH), 3213 (NH), 3069, 2957, 2865, 1593, 1541, 1458, 1396, 1366, 1317, 
1291, 1241 cm-1 
MS (+ES) m/z= 325 (M+), 326 (M+H)+, 327 (M+2H)+,349 (M+H+Na)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.53 
 
 
6.6.2. Preparation of 3,5-di-tert-butyl-4-OH benzylidine-4-hydrazinopyridine: 
Compound 5.11.  
N
N
N
OH
 
 
Yield: 0.021g or 0.065mmol or 7 % 
Mp: 207.8-213.9 0C. 
1H NMR (250 MHz d6-DMSO): 1.43 (s, 18H, di- tert-butyl ); 6.7 (overlapping m, H, Py-H5); 
7.16 (dd, 1H, J= 8.21, 1.26 Hz, Py-H3); 7.4 (s, 2H, Ph-6H and Ph-H4); 10.55 (s, 1H, OH); 
7.63 (overlapping, m, 1H, Py-H4); 7.95 (s, 1H, N=CH); 8.08 (dd, 1H, J= 5.05, 1.26 Hz, Py-
H6); ppm 
1H NMR (CDCl3; δCHCl3= 7.29 ppm): 1.48 (s, 18H, C Me3 C3’ and C Me3  C5’), 6.77 (m, 1H, 
H3), 7.38 (d, 1H, J= 8.2 Hz, H5), 7.53 (s, 2H, H2’ and H6’), 7.65 (m, 1H, H4), 7.76 (s, 1H, 
N=CH), 8.12 (m, 1H, H2), 8.44 (s,1H, NH or OH) ppm 
IR (KBr) ν= 3623, 3435, 3187 (NH), 3063, 2953, 1601, 1542, 1463, 1443, 1320, 1233 cm-1 
MS (+ES) m/z= 326 (M+H)+, 327 (M+2H)+, 391 (M+2H+2 CH3OH)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.72 
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6.6.3. Preparation of 3,5-diiodo-2-OH benzylidine-4-hydrazinopyridine Compound 
5.12.  
 
N
N
IN
I
OH
 
 
Yield: 0.272 g, 0.58mmol, 63 % 
Mp: 211.1-212.3 0C 
1H NMR (250 MHz d6-DMSO): 6.92-6.84 (overlapping m, 2H, Py-H5 and Py-H3); 7.70 
(overlapping, m, 1H, Py-H4);  7.78 (d, 1H, J= 1.89 Hz, Ph-H6); 7.95 (d, 1H, J= 1.89 Hz, Ph-
H4);  8.10 (s, 1H, N=CH); 8.22 (m, 1H, Py-H6); 11.3 (s, 1H, NH); 12.38 (s, 1H, OH); ppm 
IR (KBr) ν= 3437 (OH), 3168 (NH), 3063, 1602, 1596, 1545, 1449, 1313, 1227, 1147 cm-1 
MS (+ES) m/z= 466 (M+H)+, 467 (M+2H)+, 536 (M+2H+3Na)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.65 
 
6.6.4. Preparation of 3,5-dibromo-2-OH benzylidine-2-hydrazinopyridine: Compound 
5. 13.  
N
N
BrN
Br
OH
 
 
Yield: 0.093 g, 0.2 5mmol, 54 % 
Melting point: 242.8-245.8 0C 
1H NMR (250 MHz d6-DMSO): 12.04 (bs, 1H, OH); 11.3 (s, 1H, NH); 8.21-8.22 (overlapping, 
m, 1H, Py-H6); 8.20 (s, 1H, N=CH); 7.70 – 7.74 (overlapping, m, 2H, Ph-H4 and Py-H4); 7.67 
(d, 1H, J= 1.89 Hz, Ph-H6); 6.96 (d, J=8.2 Hz, 1H, Py-H3); 6.88 (overlapping m,1H, Py-H5); 
ppm 
IR (KBr) ν= 3463 (OH), 3180 (NH), 3069, 1596, 1544, 1439, 1343, 1314, 1248, 1149 cm-1 
MS (+ES) m/z= 370/372/374 (M+H)+ (Isotopes) 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.58 
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6.6.5. Preparation of 3-tert-butyl-2-OH benzylidine-2-hydrazinopyridine: Compound 
5.14.  
N N
H
N
HO
 
Yield: 0.002 g, 0.007 mmol, 
Mp: 170.3-174 0C  
1H NMR: 1.42 (s, 9H, tert-butyl), 6.81-6.90 (overlapping m, 3H, H5,H3 and H5’), 7.18-7.24 
(overlapping m, 2H, H4’ and H6’), 7.72 (m, 1H , H4), 8.2 (m, 1H, H6), 8.25 (s, 1H, N=CH), 
11.03 (s, 1H, NH), 11.89 (s, 1H, OH) ppm 
IR (KBr) ν= 3440 (OH), 3193 (NH), 3067, 2955, 1599, 1582, 1538, 1496, 1483, 1439, 1317 
cm-1 
MS (+ES) m/z= 270 (M+H)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.64 
 
6.6.6. Preparation of 5-tert-butyl-2-OH benzylidine-2-hydrazinopyridine: Compound 
5.15.  
N N
H
N
HO
 
Yield: 0.068 g, 0.25 mmol, 29 % 
Mp: 173.2-176.7 0C 
1H NMR (d6- DMSO): 1.29 (s, 9H, tert-butyl), 6.75-6.84 (overlapping m, 2H, H3 and H5), 7.02 
(d, 1H, J= 8.8 Hz, H3’), 7.24 (dd, 1H, J= 8.2, 2.5 Hz, H4’), 7.54 (d, 1H, J= 2.5 Hz, H6’), 7.67 
(m, 1H, H4), 8.14 (dd, 1H, J= 5.1, 1.3 Hz, H6), 8.29 (s, 1H, N=CH), 10.89 (s, 1H, NH) ppm 
1H NMR (CDCl3; δCHCl3= 7.26 ppm): 1.31 (s, 9H, C Me3), 6.84 (m, 1H, H3), 6.94 (d, 1H, J= 
8.2 Hz, H5), 7.07 (d, 1H, J= 8.8 Hz, H3’), 7.17 (d, 1H, J= 2.5 Hz, H4’), 7.65 (m,1H, H4), 7.94 
( s, 1H, N=CH), 8.18 (dd, 1H, J= 1.3, 5.0 Hz, H2), 8.38 (s, 1H, NH or OH), 10.48 (br s, 1H, 
NH or OH) ppm 
IR (KBr) ν= 3457 (OH), 3193 (NH), 3109, 2957, 1597, 1534, 1494, 1442, 1366, 1307, 1255 
cm-1 
MS (+ES) m/z= 270 (M+H)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.68. 
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6.6.7. Preparation of 3,5-di-tert-butyl-benzylidene-2-hydrazinopyridine: Compound 
5.16.  
N N
H
N
 
 
Yield: 0.047 g, 0.15 mmol, 33 % 
Mp: 165.8-168.5 0C 
1H NMR (d6- DMSO): 1.33 (s, 18H, di- tert-butyl ); 6.76 (m, 1H, H5), 7.23 (d, 1H, J= 8.2 Hz, 
H3), 7.39 (m,1H, Ph-H4); 7.48 (d, 2H, J= 1.89 Hz, Ph-H2 and Ph-H6); 7.66 (m, 1H, Py-H4); 
8.03 (s, 1H, N=CH); 8.11 (dd, 1H, J= 5.05, 1.3 Hz, H6); 10.79 (s, 1H, NH) ppm 
IR (KBr) ν= 3193 (NH), 3061, 2954, 1602, 1585, 1538, 1462, 1442, 1363, 1316 cm-1 
MS (+ES) m/z= 310 (M+H)+, 311 (M+2H)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.75. 
 
6.7.1. Preparation of Pyridine-2-methylhydrazone: Compound 5.88.  
 
N
N
NH2
 
 
 
An appropriate pyridine-2-carboxaldehyde (5ml) was dissolved in ethanol (5mL) and added 
dropwise through a pressure generated dropping funnel into a mixture of hydrazine 
monohydrate (9mL) in ethanol (5mL) stirred at 60oC for 24 hours. The product was collected 
by evaporating the excess hydrazine under high vacuum pump to give a yellow oil 
compound.  
 
Yield was 10.7234 g, 98.37 mmol.  
Melting point:    
1H NMR (250 MHz d6-DMSO): 7.1 (ddd, 1H, J= 5.05, 3.2, 1.26 Hz, Py-H5), 7.4 (s, 2H, NH2); 
7.6 (dd, 1H, J= 1.89, 7.58 Hz, Py-H4), 7.8 (d, 1H, J= 7.58 Hz, Py-H3), 7.9 (s, 1H, Py-CH=N), 
8.50 (dd, 1H, J= 1.26, 5.05 Hz, Py-H6) ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.48.  
Materials and Methods 2010 
 
P a g e  | 243  
 
 
6.7.2. Preparation of 4-[3,5-di-(tert-butyl)-2-OH-benzyl]-1-(2-pyridyl)-2, 3-diaza-1, 3-
butadiene: Compound 5.23.  
 
N
N
N
OH
 
 
3, 5-Di-(tert-butyl)-2-hydroxybenzaldehyde (0.24gm or 1.02mmol) was dissolved in ethanol 
(5mL). Pyridine-2-carboxamidrazone (0.125gm or 1.03mmol) was added and the reaction 
was stirred at reflux for 18 hours. It was then cooled and the solvent was removed by 
filtration under vacuum. The title compound was collected as yellow amorphous solid, which 
was dried under vacuum.  
 
Yield: 0.124 g, 0.37 mmol, 42 % 
Melting point: 131.2-132.9 0C  
1H NMR (d6- DMSO): 1.31 (s, 9H, tert-butyl); 1.44 (s, 9H, tert-butyl); 7.43-7.58 (overlapping 
m, 3H, Py-H5, Ph-H4 and Ph-H6); 8.03 (dd, 1H, J= 7.6, 1.89 Hz, Py-H4); 8.12 (d, 1H, J= 7.6 
Hz, Py-H3); 8.74-8.77 (overlapping m, 2H, Ph-CH=N and Py-H6); 9.08 (d, 1H, J= 13.9 Hz, 
Py-CH=N); 12.12 (br s, 1H, OH) ppm 
IR (KBr) ν= 3432 (OH), 2954, 1625, 1600, 1592, 1562, 1473, 1443, 1390, 1363 cm-1 
MS (+ES) m/z= 338 (M+H)+, 339 (M+2H)+, 392 (M+H+3NH3)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.75 
 
6.7.3. Preparation of 4-[3,5-di-(tert-butyl)-4-OH-benzyl]-1-(2-pyridyl)-2,3-diaza-1,3-
butadiene.  Compound 5.24.  
 
N
N
N
OH
 
Yield: 0.096 g, 0.28 mmol, 44 % 
Melting point: 114.6-116.7 0C 
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1H NMR (d6- DMSO): 1.43 (s, 18H, di- tert-butyl); Ph-C3 and Ph-C5); 7.50 (ddd, 1H, J= 5.1, 
3.2, 1.26 Hz, Py-H5); 7.70 (s, 2H, Ph-H2 and Ph-H6); 7.94 (dd, 1H, J= 7.58, 1.7 Hz, Py-H4); 
8.08 (d, 1H, J= 8.2 Hz, Py-H3); 8.56 (s, 1H, Ph-CH=N); 8.65 (s, 1H, Py-CH=N); 8.70 (m, 1H, 
H6) ppm 
IR (KBr) ν= 3492 (OH), 3067, 2941, 2862, 1625, 1592, 1555, 1475, 1439, 1412, 1367, 1300 
cm-1 
MS (+ES) m/z= 338 (M+H)+, 339 (M+2H)+, 401 (M+2CH3OH)+, 402 (M+H+2CH3OH)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.76 
 
6.7.4. Preparation of 4-[3-(tert-butyl)-2-OH-benzyl]-1-(2-pyridyl)-2,3-diaza-1,3-
butadiene: Compound 5.25.  
 
N
N
N
OH
 
 
Yield: 0.027g, 0.096mmol, 12% 
Melting point: 264.1-269.9 0C 
1H NMR: 1.43 (s, 9H, tert-butyl), 6.96 (t, 1H, J= 7.6 Hz, H5’), 7.41-7.58 (overlapping m, 3H, 
H5,H4’ and H6’), 7.84 (td, 1H, J= 7.2, 1.5 Hz, H4), 8.12 (d, 1H, J= 7.6 Hz, H3), 8.75 (m, 1H, 
H6), 8.79 (s, 1H, Ar-CH=N), 9.05 (s, 1H, Py-CH=N), 12.29 (s, 1H, OH) ppm 
IR (KBr) ν= 3454 (OH), 3059, 2958, 2866, 1611, 1489, 1462, 1429, 1396, 1197 cm-1 
MS (+ES) m/z= 282 (M+H)+, 283 (M+2H)+, 353 (M+H+3Na)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.83 
 
6.8. 1. Preparation of Pyridine-3-methylhydrazone: Compound 5.86.  
 
N N
NH2
 
 
An appropriate pyridine-3-carboxaldehyde (3.54g or 32.477 mmol) was dissolved in ethanol 
(10mL) and added dropwise through a pressure generated dropping funnel into a mixture of 
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hydrazine monohydrate (9.5 mL) in ethanol (5mL) stirred at 70oC for 24 hours. The product 
was collected by evaporating the excess hydrazine under high vacuum pump to give a yellow 
oil compound.  
 
Yield was 4.01g, 32.338mmol or 99.5% 
1H NMR (250 MHz d6-DMSO): 7.1 (s, 2H, NH2); 7.3 (overlapping m, 1H, Py-H); 7.7 (s, 1H, 
Py-CH=N); 7.8 (dd, J= 1.89, 7.58 Hz Py-H); 8.4 (dd, 1H, J= 1.89, 5.05 Hz, Py-H); 8.7 (dd, 1H, 
J= 1.89 Hz, Py-H); ppm 
 
6.8.2. Preparation of 4-[3,5-di-(tert-butyl)-2-OH-benzyl]-1-(3-pyridyl)-2, 3-diaza-1, 3-
butadiene.  Compound 5.26 
 
N N
N
OH
 
 
 
Yield: 0.074 g, 0.22 mmol, 27 % 
Melting point: 141.8-147.1 0C 
1H NMR: 1.31 (s, 9H, tert-butyl), 1.44 (s, 9H, tert-butyl), 7.42-7.51 (overlapping m, 2H, H4’ 
and H6’), 7.58 (dd, 1H, J= 8.2, 5.1 Hz, H5), 8.29 (m, 1H, H4), 8.73 (dd, 1H, J= 5.1, 1.9 Hz, 
H6), 8.95 (s, 1H, Ar-CH=N), 9.03 (m, 1H, Py-CH=N), 9.10 (s, 1H, H2), 12.24 (s, 1H, OH) ppm 
IR (KBr) ν= 3426 (OH), 2954, 2875, 1625, 1595, 1578, 1552, 1466, 1439, 1416, 1393, 1317 
cm-1 
MS (+ES) m/z= 338 (M+H)+, 339 (M+2H)+, 379 (M+H+CH3CN)+ 
T TLC: ethyl acetate: methanol (4:1) (Rf) = 0.72 
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6.8.3. Preparation of 4-[3,5-di-iodo-2-OH-benzyl]-1-(3-pyridyl)-2,3-diaza-1, 3-butadiene:  
Compound 5.27  
 
N N
N
I
OH
I
 
Yield: 0.041 g, 0.087 mmol, 22 % 
Melting point: 215.8-218.5 0C 
1H NMR: 7.58 (dd, 1H, J= 4.8, 7.9 Hz, H5), 8.04 (d, 1H, J= 2.5 Hz, H6’), 8.17 (d, 1H, J= 1.9 
Hz, H4’), 8.27 (m, 1H, H4), 8.74 (dd, 1H, J= 1.6, 4.8 Hz, H6), 8.92 (s, 1H, Ar-CH=N), 8.99-
9.02 (overlapping m, 2H, Py-CH=N and H2), 12.62 (br s, 1H, OH) ppm 
IR (KBr) ν= 3439 (OH), 3034, 1625, 1578, 1476, 1416, 1370, 1310, 1270 cm-1 
MS (+ES) m/z= 478 (M+H)+, 519 (M+H+CH3CN)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.65 
 
6.8.4. Preparation of 4-[3,5-di-bromo-2-OH-benzyl]-1-(3-pyridyl)-2,3-diaza-1,3-
butadiene:  Compound 5.28.  
N N
N
Br
OH
Br
 
 
Yield: 0.069 g, 0.18 mmol, 42 % 
Melting point: 178.8-181.1 0C 
1H NMR: 7.58 (dd, 1H, J=7.9, 4.7Hz, H5), 7.94-7.98 (overlapping m, 2H, H4’ and H6’), 8.28 
(m, 1H, H4), 8.75 (dd, 1H, J= 4.8, 1.6 Hz, H6), 8.99-9.03 (overlapping m, 2H, Ar-CH=N and 
H2), 9.07 (s, 1H, Py-CH=N), 12.32 (br s, 1H, OH) ppm 
IR (KBr) ν= 3431 (OH), 3068, 1625, 1592, 1562, 1443, 1376, 1310 cm-1 
MS (+ES) m/z= 382/384/386 (M+H)+, 423/425/427 (M+H+CH3CN)+ (Isotopes) 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.58. 
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6.9.1. Preparation of 3,5-diiodo-2-OH benzylidine-3-aminopyridine: Compound 5.35.  
N
N
HO
I
I
 
Yield: 0.085 g, 0.19 mmol, 18 % 
Melting point: 175.7-177.4 0C 
1H NMR: 7.54 (dd, 1H, J= 5.1, 8.2 Hz, H5), 7.93 (ddd, 1H, J= 1.3, 2.5, 5.7 Hz, H4), 8.02 (d, 
1H, J= 1.9 Hz, H6’), 8.20 (d, 1H, J= 1.9 Hz, H4’), 8.56 (dd, 1H, J= 1.6, 5.1 Hz, H6), 8.72 (d, 
1H, J= 2.5 Hz, H2), 8.98 (s, 1H, N=CH), 14.14 (br s, 1H, OH) ppm 
IR (KBr) ν= 3439 (OH), 3054, 1611, 1572, 1429, 1270, 1157 cm-1 
MS (+ES) m/z= 451 (M+H)+, 492 (M+H+CH3CN)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.66 
 
6.9.2.  Preparation of 3,5-di-(tert-Butyl)-2-OH benzylidine-3-aminopyridine: Compound 
5.33.  
N
N
HO
 
 
Yield: 0.079 g, 0.25 mmol, 23% 
Melting point: 114.6-116.7 0C 
1H NMR: 1.31 (s, 9H, tert-butyl), 1.43 (s, 9H, tert-butyl), 7.44 -7.54 (overlapping m, 3H, 
H6’,H4’ and H5), 7.92 (ddd, 1H, J= 1.3, 2.5, 5.7 Hz, H4), 8.52 (dd, 1H, J= 1.6, 5.1 Hz, H6), 
8.68 (d, 1H, J= 2.5 Hz, H2), 9.07 (s, 1H, N=CH), 13.61 (s, 1H, OH) ppm 
IR (KBr) ν= 3431 (OH), 3026, 2953, 2861, 1616, 1569, 1475, 1436, 1363, 1204 cm-1 
MS (+ES) m/z= 311 (M+H)+, 353 (M+2H+ CH3CN)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.66. 
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6.9.3.  Preparation of 3,5-dibromo-2-OH benzylidine-3-aminopyridine: Compound 5.36.  
N
N
HO
Br
Br
 
 
Yield: 0.066 g, 0.19 mmol, 35 % 
Melting point: 163.3-164.8 0C 
1H NMR: 7.55 (dd, 1H, J= 5.7, 8.2 Hz, H5), 7.91-8.00 (overlapping m, 3H, H4, H4’ and H6’), 
8.57 (dd, 1H, J= 1.6, 4.7 Hz, H6), 8.72 (d, 1H, J= 2.5 Hz, H2), 9.07 (s, 1H, N=CH), 14.00 (br 
s, 1H, OH) ppm 
IR (KBr) ν= 3445 (OH), 3061, 1612, 1579, 1555, 1483, 1449, 1364 cm-1 
MS (+ES) m/z= 355/357/359 (M+H)+, 396/398/400 (M+H+CH3CN)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.61 
 
 
6.9.4.  Preparation of 5-(tert-Butyl)-2-OH benzylidine-3-aminopyridine: Compound 5.37.  
N
N
HO
 
 
Yield: 0.032 g, 0.13 mmol, 13 % 
Melting point: 119.8-120.9 0C 
1H NMR: 1.31 (s, 9H, tert-butyl), 6.94 (d, 1H, J= 8.2 Hz, H3’), 7.48-7.54 (overlapping m, 2H, 
H4’ and H5), 7.71 (d, 1H, J= 2.5 Hz, H6’), 7.86 (ddd, 1H, J= 1.3, 2.5, 5.7 Hz, H4), 8.51 (dd, 
1H, J= 1.6, 4.8 Hz, H6), 8.63 (d, 1H, J= 2.5 Hz, H2), 9.03 (s, 1H, N=CH), 12.41 (br s, 1H, 
OH) ppm 
IR (KBr) ν= 3432 (OH), 3034, 2961, 2868, 1618, 1562, 1485, 1388, 1360, 1346 cm-1 
MS (+ES) m/z= 255 (M+H)+, 296 (M+H+CH3CN)+, 297(M+2H+ CH3CN)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.57 
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6.9.5.  Preparation of 3,5-di-(tert-Butyl)-4-OH benzylidine-3-aminopyridine: Compound 
5.34.  
N
N
OH
 
Yield: 0.024 g, 0.08 mmol, 15 % 
Melting point: 135.8-138.7 0C 
1H NMR: 1.39 (s, 18H, di-tert-butyl),
 
7.42 (dd, 1H, J= 8.2, 4.7 Hz, H5), 7.70 (br overlapping 
m, 3H, H2’,H6’ and H4), 8.37 (d, 1H, J= 4.4 Hz, H2), 8.53 (br overlapping s, 2H, H6 and 
N=CH) ppm 
IR (KBr) ν= 3379 (OH), 3034, 2961, 2868, 1625, 1565, 1479, 1433, 1396, 1360, 1300 cm-1 
MS (+ES) m/z= 311 (M+H)+, 312 (M+2H)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.69. 
 
 
6.9.6. Preparation of 3-bromo-5-chloro-2-hydroxy benzylidine-3-aminopyridine: 
Compound 5.94.   
N
N
OH
Br
Cl
 
Yield: 0.43 g, 1.38 mmol, 45 % 
Melting point: 135.2-137.5 0C 
1H NMR: 14.0 (bs, 1H, OH); 9.07 (s, 1H, CH=NH), 8.73 (d, 1H, J= 2.52 Hz Py-2H); 8.57 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.95 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.91 (d, 1H, J= 
2.57 Hz Ph-4H); 7.79 (d, 1H, J= 2.57 Hz Ph-6H);  7.55 (dd, 1H, J= 8.21, 4.42 Hz Py-5H) ppm 
IR (KBr) ν= 3440 (OH), 3067, 3046, 2896, 2830, 1930, 1787, 1611 (-CH=N-), 1565, 1479, 
1433, 1396, 1360, 1300 cm-1 
MS (+ES) m/z= 311 (M+H)+, 312 (M+2H)+ 
TLC: ethyl acetate: methanol (4:1) (Rf) =  0.71. 
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6.9.7.  Preparation of 3,5-dichloro-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.95. 
N
N
OH
Cl
Cl
 
Yield: 0.426 g, 1.59 mmol, 45 % 
Melting point: 144.7-148.3 0C 
1H NMR: 14.0 (bs, 1H, OH); 9.07 (s, 1H, CH=NH), 8.73 (d, 1H, J= 2.52 Hz Py-2H); 8.57 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.95 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.80 (d, 1H, J= 
2.57 Hz Ph-4H); 7.76 (d, 1H, J= 2.57 Hz Ph-6H);  7.55 (dd, 1H, J= 8.21, 4.42 Hz Py-5H) ppm 
IR (KBr) ν= 3447 (OH), 3077, 3054, 2840, 2830, 1932, 1741, 1615 (-CH=N-), 1563, 1479, 
1433, 1396, 1360, 1300 cm-1 
MS (+ES) m/z= 267 (M+H)+, 269 (M+2H)+ 
Accurate MS (ES +ve) m/z: Calculated 267.0092, found 267.0105 (M + H) +; 4.9 ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.7. 
 
6.9.8. Preparation of 3,5-di-fluoro-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.98. 
N
N
OH
F
F
 
Yield: 0.115 g, 0.491 mmol, 45 % 
Melting point: 121.2-125.1 0C 
1H NMR: 12.7 (bs, 1H, OH); 9.03 (s, 1H, CH=NH), 8.67 (d, 1H, J= 2.52 Hz Py-2H); 8.52 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.90 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.57 (d, 1H, J= 
2.57 Hz Ph-4H); 7.52 (d, 1H, J= 2.57 Hz Ph-6H);  7.42 (dd, 1H, J= 8.21, 4.42 Hz Py-5H) ppm 
IR (KBr) ν= 3413 (OH), 3063, 2734, 2350, 1698, 1619 (-CH=N-), 1598, 1476, 1433, 1396, 
1360, 1300 cm-1 
MS (+ES) m/z= 235 (M+H)+, 236 (M+2H)+ 
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Accurate MS (ES +ve) m/z: Calculated 235.0694, found 235.0690 (M + H) +; 3 ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.6. 
 
6.9.9. Preparation of 5-Iodo-2-hydroxy benzylidine-3-aminopyridine: Compound 5.99. 
 
N
N
OH
I
 
 
Yield: 0.174 g, 0.537 mmol, 45 % 
Melting point: 158.2-160.5 0C 
1H NMR: 12.7 (bs, 1H, OH); 8.95 (s, 1H, CH=NH), 8.63 (d, 1H, J= 2.52 Hz Py-2H); 8.52 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 8.05 (d, 1H, J= 2.52 Hz Ph-H); 7.86 (ddd, 1H, J= 1.89, 4.42, 
8.21 Hz Py-4H); 7.73 (dd, 1H, J= 8.84, 1.89 Hz Ph-H); 7.52 (dd, 1H, J= 8.21, 4.42 Hz Py-
5H); 6.85 (d, 1H, J= 8.21 Hz Ph-H); ppm 
IR (KBr) ν= 3424 (OH), 3060, 2963, 2348, 1958, 1766, 1675, 1612 (-CH=N-), 1554, 1479, 
1433, 1396, 1360, 1300 cm-1 
MS (+ES) m/z= 324 (M+H)+, 325 (M+2H)+ 
Accurate MS (ES +ve) m/z: Calculated 324.9838, found 324.9832 (M + H) + 1.8 ppm.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.5. 
 
6.9.10. Preparation of 3-chloro-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.97. 
 
N
N
OH
Cl
 
 
Yield: 0.207 g, 0.892 mmol, 45 % 
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Melting point: 54.2-58.5 0C 
1H NMR: 13.85 (s, 1H, OH); 9.12 (s, 1H, CH=NH), 8.72 (d, 1H, J= 2.52 Hz Py-2H); 8.55 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.96 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.73 (dd, 1H, J= 
8.84, 1.89 Hz Ph-H); 7.68-7.62 (m, 2H, Ph-H); 7.52 (dd, 1H, J= 8.21, 4.42 Hz Py-5H); 7.04 (t, 
1H, J= 7.58, 8.21 Hz Ph-H); ppm 
IR (KBr) ν= 3426 (OH), 3052, 3025, 2855, 2572, 2350, 2281, 1912, 1685, 1607 (-CH=N-), 
1554, 1479, 1433, 1396, 1360, 1300 cm-1 
MS (+ES) m/z= 233 (M+H)+, 334 (M+2H)+ 
Accurate MS (ES +ve) m/z: Calculated 233.0482, found 233.0480 (M + H) + 0.9 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.75. 
 
6.9.11. Preparation of 2-bromo-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.100. 
 
N
N
OH
Br
 
 
Yield: 0.201 g, 0.725 mmol, 45 % 
Melting point: 67.6-73.2 0C 
1H NMR: 13.97 (s, 1H, OH); 9.09 (s, 1H, CH=NH), 8.73 (d, 1H, J= 2.52 Hz Py-2H); 8.56 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.98 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.76 (dd, 1H, J= 
8.21, 1.26 Hz Ph-H); 7.75 (d, 1H, J= 1.89, 7.58 Ph-H); 7.56 (dd, 1H, J= 8.21, 4.42 Hz Py-5H); 
6.99 (t, 1H, J= 7.58, 8.21 Hz Ph-H); ppm 
IR (KBr) ν= 3426 (OH), 3058, 2854, 2439, 1965, 1918, 1612 (-CH=N-), 1554, 1479, 1433, 
1396, 1360, 1300 cm-1 
MS (+ES) m/z= 276 (M+H)+, 277 (M+2H)+ 
Accurate MS (ES +ve) m/z: Calculated 276.9976, found 276.9974 (M + H) + 0.7 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.71. 
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6.9.12. Preparation of 5-chloro-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.96. 
 
N
N
OH
Cl
 
Yield: 0.115 g, 0.495 mmol, 45 % 
Melting point: 130.2-131.8 0C 
1H NMR: 12.7 (bs, 1H, OH); 8.91 (s, 1H, CH=NH), 8.63 (d, 1H, J= 2.52 Hz Py-2H); 8.52 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.86 (ddd, 1H, J= 1.89, 4.42, 8.21 Hz Py-4H); 7.78 (d, 1H, J= 
2.52 Hz Ph-H); 7.53-7.45 (m, 2H, Py-5H, Ph-H); 6.85 (d, 1H, J= 8.84 Hz Ph-H); ppm 
IR (KBr) ν= 3447 (OH), 3068, 2622, 1965, 1899, 1756, 1613 (-CH=N-), 1554, 1479, 1396, 
1360, 1300 cm-1 
MS (+ES) m/z= 233 (M+H)+, 235 (M+2H)+ 
Accurate MS (ES +ve) m/z: Calculated 233.0482, found 233.0481 (M + H) + 0.4 ppm. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.7. 
 
6.9.13. Preparation of 5-bromo-2-hydroxy benzylidine-3-aminopyridine: Compound 
5.101. 
 
N
N
OH
Br
 
Yield: 0.5 g, 1.805 mmol, 45 % 
Melting point: 128.6-132.1 0C 
1H NMR: 12.5 (bs, 1H, OH); 8.95 (s, 1H, CH=NH), 8.63 (d, 1H, J= 2.52 Hz Py-2H); 8.52 (dd, 
1H, J= 1.89, 4.42 Hz Py-6H); 7.91 (d, 1H, J= 3.159 Hz Ph-H); 7.86 (ddd, 1H, J= 1.89, 4.42, 
8.21 Hz Py-4H); 7.61 (dd, 1H, J= 8.84, 2.52 Hz Ph-H); 7.52 (dd, 1H, J= 8.21, 4.42 Hz Py-
5H); 6.9 (d, 1H, J= 8.84 Hz Ph-H); ppm 
IR (KBr) ν= 3472 (OH), 3058, 2854, 2394, 1958, 1926, 1760, 1613 (-CH=N-), 1554, 1479, 
1433, 1396, 1360, 1300 cm-1 
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MS (+ES) m/z= 278 (M+H)+  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.68. 
 
6.10.1. Preparation of pyridine-2-carboxamidrazone:  Compound 5.89.  
 
N
N
NH2
NH2
 
2- cyanopyridine (30.103g, 288.4mmol) was suspended in ethanol (90mL) and treated with 
hydrazine monohydrate (60mL) and stirred at ambient temperature for two days. The 
resulting precipitate was collected by filtration under vacuum and washed with petroleum 
ether (40-60oC) to give a white crystalline compound.  
 
Yield was 31.664g or 234mmol or 83%.  
Melting point:    
1H NMR (250 MHz d6-DMSO): 5.24(bs, 2H, NH2); 5.71 (s, 2H, NH2); 7.31 (td, 1H, J=4.9, 1.2 
Hz, Pyr-H4); 7.74 (td, 1H, J=6.92, 1.8 Hz, Pyr-H5); 7.91 (m, 1H, Pyr-H3); 8.48 (m, 1H, Pyr-
H6) ppm.  
MS (APCI +ve) m/z = 137 (m+H)+.  
TLC, carried out in ethyl acetate: methanol (2:1) (Rf) = 0.1 (single spot). 
      
6.10.2. Preparation of N1-(2-furoylacryl)-pyridine-2-carboxamidrazone:  Compound 
5.38.  
N
NH2
N
N
O
O
 
 
Anhydrous tetrahydrofuran (8mL) was added into a mixture of furoylacrylic acid (1.078g or 
1.054 mmol) and carbonyl di-imidazole (1.30gm or 1.065mmol). The mixture was stirred at 
room temperature for 1 hr and then pyridine 2-carboxamidrazone (0.9824g or 7.2 mmol) 
dissolved in dry tetrahydrofuran (10mL) was added and the reaction was stirred at room 
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temperature for 18 hrs. The reaction mixture was poured dropwise into saturated sodium 
bicarbonate solution (75ml). The resulting precipitate was filtered dried and recrystallised 
from ethanol to give a brownish yellow amorphous solid.  
 
Yield was 0.275g 1.074 mmol or 15% 
Melting Point: 162.3 – 168.6 oC.  
1H NMR (250 MHz d6-DMSO): 6.57 (d, 2H, J= 15.796 Hz, NH2); 6.6 (dd, 1H, furyl-H); 6.7 (s, 
1H, NH); 6.8 (d, 1H, J=3.478 Hz, furyl-H); 7.35 (d, 1H, J= 15.638 Hz, CH); 7.44 (d, 1H, furyl-
H); 7.5 (ddd, 1H, Py-5H); 7.9 (ddd, 1H, Py-4H); 8.1 (d, 1H, J= 8.056 Hz, Py-3H); 8.6 (d, 1H, 
J= 4.42 Hz, Py-6H); 10.2 (s, 1H, NH) ppm. 
MS (+ electro spray): 257 (M + H) +; 279 (M+ Na) +  
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC, carried out in ethyl acetate: methanol (4:1) (Rf) = 0.55 (single spot). 
 
6.10.3. Preparation of N1-2-(5-bromofuroyl)-pyridine-2-carboxamidrazone: Compound 
5.41.  
N
NH2
N
N
H
O
Br
O
 
Yield = 0.52g or 1.68mmol or 40%  
Melting Point: 207.1 – 209.3 oC  
1H NMR (250 MHz d6-DMSO): 6.8 (d, 1H, furyl-H); 7.0 (s, 2H, NH2); 7.3 (d, 1H, J=3.478 Hz, 
furyl-H); 7.5 (ddd, 1H, Py-5H); 7.9 (ddd, 1H, Py-4H); 8.1 (d, 1H, J= 8.056 Hz, Py-3H); 8.6 (d, 
1H, J= 4.42 Hz, Py-6H); 10.2 (s, 1H, NH) ppm. 
MS (+APCI): 309, 311 (M + H) +; 292 (M- NH2) +  
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC, carried out in ethyl acetate: methanol (4:1) (Rf) = 0.55 (single spot). 
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6.10.4. Preparation of N1-2-(4,5-dibromofuroyl)-pyridine-2-carboxamidrazone: 
Compound 5.42.   
N
NH2
N
N
H
O
Br
O
Br
 
Yield = 0.201g or .515mmol or 35% 
Melting Point: 237.3 – 239 oC.   
1H NMR (250 MHz d6-DMSO): 6.85 (bs, 2H, NH2); 7.45 (s, 1H, furyl-H); 7.5 (ddd, 1H, Py-5H); 
7.9 (ddd, 1H, Py-4H); 8.1 (d, 1H, J= 8.056 Hz, Py-3H); 8.6 (d, 1H, J= 4.42 Hz, Py-6H); 10.2 
(bs, 1H, NH) ppm. 
MS (+ APCI): 387, 389, 391 (M + H) +; 
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC, carried out in ethyl acetate: methanol (4:1) (Rf) = 0.73 (single spot). 
 
6.10.5. Preparation of N1-2-[3-(2-furoyl)-propyl]-pyridine-2-carboxamidrazone: 
Compound 5.44.  
N
NH2
N
N
H
O
O
 
Yield = .426g or 1.77mmol or 65.5% 
Melting Point: 177.8 – 179.7 oC.   
1H NMR (250 MHz d6-DMSO): 2.5 (d, 2H, CH2); 2.9 (d, 2H, CH2); 6.18 (d, 1H, J= 15.796 Hz, 
furyl-H); 6.3 (dd, 1H, furyl-H); 6.7 (ss, 2H, NH2); 7.5 (ddd, 1H, Py-5H); 7.55 (d, 1H, furyl-H); 
7.9 (ddd, 1H, Py-4H); 8.1 (dd, 1H, J= 8.056 Hz, Py-3H); 8.6 (dd, 1H, J= 4.42 Hz, Py-6H); 
10.2 (s, 1H, NH) ppm. 
MS (+ APCI): 259 (M + H) +; 241  
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC, carried out in ethyl acetate: methanol (4:1) (Rf) = 0.62 (single spot). 
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6.10.6. Preparation of N1-3-(2,5-dimethylfuroyl)-pyridine-2-carboxamidrazone: 
Compound 5.43.  
 
N
NH2
N
N
H
O
O
 
 
Yield = 1.2g or 4.651mmol or 60% 
Melting Point: 242.3 – 246.8 oC.  
1H NMR (250 MHz d6-DMSO): 2.2 (s, 3H, CH3); 2.4 (s, 3H, CH3); 6.6 (s, 2H, NH2); 6.9 (s, 1H, 
furyl-H); 7.5 (ddd, 1H, Py-5H); 7.9 (ddd, 1H, Py-4H); 8.1 (d, 1H, J= 8.056 Hz, Py-3H); 8.6 (d, 
1H, J= 4.42 Hz, Py-6H); 10.2 (s, 1H, NH) ppm. 
MS (+APCI): 259 (M + H) +; 241 (M- NH2) +  
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC, carried out in ethyl acetate: methanol (4:1) (Rf) = 0.33 (single spot). 
 
 
6.10.7. Preparation of N1-3-furoyl-pyridine-2-carboxamidrazone: Compound 5.39.  
 
N
NH2
N
N
H
O
O
 
Yield = 0.975g or 4.239mmol or 64% 
Melting Point: 185.3 – 187.8 oC.  
1H NMR (250 MHz d6-DMSO): 6.8 (s, 2H, NH2); 6.9 (d, 1H, J=3.478 Hz, furyl-H); 7.5 (ddd, 
1H, Py-5H); 7.8 (d, 1H, furyl-H);  7.9 (ddd, 1H, Py-4H); 8.1 (d, 1H, J= 8.056 Hz, Py-3H); 8.3 
(d, 1H, furyl-H); 8.6 (d, 1H, J= 4.42 Hz, Py-6H); 10.2 (s, H, NH) ppm. 
MS (+ APCI): 213, 214 (M- NH2), 231 (M + H) +;  
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
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6.10.8. Preparation of N1-2-benzofuroyl-pyridine-2-carboxamidrazone: Compound 5.45.  
 
N
NH2
N
N
H
O
O
 
Yield = .136g or 4.857mmol or 63.47% 
Melting Point: 215.6 - 220.3oC. 
1H NMR (250 MHz d6-DMSO): 7.1 (s, 2H, NH2); 6.6 (dd, 1H, furyl-H); 7.4 (dd, 1H, Ph-H); 7.5 
(ddd, 1H, Ph-H); 7.5 (ddd, 1H, Py-5H); 7.7 (s, 1H, furyl-H); 7.7 (d, 1H, Ph-H); 7.8 (d, 1H, Ph-
H); 7.9 (ddd, 1H, Py-4H); 8.2 (d, 1H, J= 8.056 Hz, Py-3H); 8.6 (d, 1H, J= 4.42 Hz, Py-6H); 
10.2 (s, 2H, NH2) ppm. 
MS (+ electro spray): 281 (M + H) +;  
Accurate MS (+ES): Calculated (M + H) +281.1039; found (M + H) + 281.1007; 11.4 ppm 
IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.58. 
 
 
6.10.9. Preparation of N1-2-[5-(4-Nitrophenyl)furoyl]-pyridine-2-carboxamidrazone: 
Compound 5.40.  
N
NH2
N
N
H
O
O
NO2
 
Yield = 0.111g or 0.318mmol or 20% 
Melting Point: 233.7 – 236.2oC. 
1H NMR (250 MHz d6-DMSO): 7.1 (s, 2H, NH2); 7.4 (d, 1H, furyl-H); 7.5 (d, 1H, Ph-H); 7.5 
(ddd, 1H, Py-5H); 7.9 (ddd, 1H, Py-4H); 8.2 (d, 1H, J= 8.056 Hz, Py-3H); 8.2 (d, 2H, Ph-H); 
8.4 (d, 2H, Ph-H); 8.6 (d, 1H, J= 4.42 Hz, Py-6H); 10.3 (s, 2H, NH) ppm. 
MS (- APCI): 350 (M - H) +;  
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IR (KBr) ν = 3400 (NH2), 3310 (NH2), 3150, 2380 (C=O), 1680, 1620, 1550, 1540, 1500, 
1470, 1440, 1390, 1225 cm-1    
TLC: ethyl acetate: methanol (4:1) (Rf) = tailing on base line. 
 
6.10.10. Preparation of N1-(Thiophen-2-oyl)-pyridine-2-carboxamidrazone: 
Compound 5.51.   
N
NH2
N
N
H
S
O
 
Yield 0.370 g, 1.50 mmol, 39%. 
Melting Point: 214.9 - 217.8 oC  
H1-NMR: 6.87 (bs, 2H, NH2), 7.19 (t, 1H, J=4.2 Hz, thiophenyl – H4), 7.50 (q, 1H, J=5.1 Hz, 
Py – H5), 7.78 - 8.31 (overlapping m, 4H, Py – H3, H4 and thiophenyl – H3, H5), 8.61(d, 1H, 
J=4.4 Hz, Py – H6), 10.33 (bs, 1H, CONH); MS (+ES) m/z = 269 (M + Na) +, 247 (M + H)+, 
230 (M – NH2);  
IR (KBr) υ = 3413 (NH2), 3321(CONH), 3284, 3105, 3072 (Ar-C-H), 3027, 2848, 1654 (CO), 
1617 (C=N), 1544 (Ar-C=C), 1475 cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.38.  
 
 
6.10.11. Preparation of N1-(3-Bromothiophen-2-oyl)-pyridine-2-
carboxamidrazone: Compound 5.54.  
N
NH2
N
N
H
S
O Br
 
Yield 0.230 g, 0.708 mmol, 48%. 
Melting Point: 183.6 – 186.4 oC  
H1-NMR: 6.90 (bs, 2H, NH2), 7.20 (q, 1H, J=5.1 Hz, thiophenyl – H4 or H5), 7.48 (t, 1H, J=5.7 
Hz, Py – H5), 7.75 (d, 1H, J=4.4 Hz, thiophenyl – H4 or H5), 7.90 (t, 1H, J=7.6 Hz, Py – H4), 
8.13 (t, 1H, J=8.2 Hz, Py – H3), 8.60 (d, 1H, J=4.4 Hz, Py – H6), 10.40 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 349 (M + Na) +, 325 & 327 (M + H)+, 310 (M – NH2);  
IR (KBr) υ = 3439 (NH2), 3353 (CONH), 3233, 3169, 3013 (Ar-C-H), 2917, 1668 (CO), 1628 
(C=N), 1585(Ar-C=C), 1566, 1492 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.52.  
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6.10.12. Preparation of N1-(5-Bromothiophen-2-oyl)-pyridine-2-
carboxamidrazone: Compound 5.57.  
N
NH2
N
N
H
S
Br
O
 
Yield 0.091 g, 0.280 mmol, 39%. 
Melting Point: 215.5 – 218.1 oC 
H1-NMR: 6.88 (m, 2H, NH2), 7.33 (d, 1H, J=4.4 Hz, thiophenyl – H4), 7.51 (t, 1H, J=5.1 Hz, 
Py – H5), 7.81 (d, 1H, J=4.4 Hz, thiophenyl – H3) 8.02 (t, 1H, J=7.6 Hz, Py – H4), 8.20 (m, 
1H, Py – H3), 8.63 (d, 1H, J=4.4 Hz, Py – H6), 10.45 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 325 & 327 (M + H)+;  
IR (KBr) υ = 3431 (NH2), 3353 (CONH), 3319, 3254, 3168, 3005 (Ar-C-H), 2906, 1685 (CO), 
1636 (C=N), 1583 (Ar-C=C), 1564, 1488 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.38.  
 
6.10.13. Preparation of N1-(5-Chlorothiophen-2-oyl)-pyridine-2-
carboxamidrazone: Compound 5.60.  
N
NH2
N
N
H
S
O
Cl
 
Yield = 0.198 g, 0.706 mmol, 46%. 
Melting Point: 235.0 – 236.2 oC  
H1-NMR: 6.97 (bs, 2H, NH2), 7.25 (d, 1H, J=4.4 Hz, thiophenyl – H4), 7.51 (t, 1H, J=7.0 Hz, 
Py – H5), 7.86 (d, 1H, J=4.4 Hz, thiophenyl – H3), 8.02 (t, 1H, J=8.2 Hz, Py – H4), 8.21 (d, 
1H, J=7.6 Hz, Py – H3), 8.63 (d, 1H, J=4.4 Hz, Py – H6), 10.50 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 281 & 283 (M + H)+, 231 (M –[NH2 + Cl]);  
IR (KBr) υ = 3419 (NH2), 3382 (CONH), 3213, 3008 (Ar-C-H), 2908, 1688 (CO), 1638 (C=N), 
1565 (Ar-C=C), 1432 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.32.  
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6.10.14. Preparation of N1-(2-bromobenzoyl)-pyridine-2-carboxamidrazone: 
Compound 5.71.  
N
NH2
N
N
H
O
Br
 
Yield 0.070 g, 0.219 mmol, 14%. 
Melting Point: 206.5 – 209.4 oC  
H1-NMR: 6.78 (bs, 2H, NH2), 7.37 – 7.53 (overlapping m, 4H, Ph – H3, H4, H5 and Py – H5), 
7.69 (dd, 1H, J=7.6 Hz, 1.3 Hz), 7.91 (ddd, 1H, J=7.6, 5.7, 1.9 Hz, Py – H4), 8.17 (dd, 1H, 
J=8.2, 1.3 Hz, Py – H3), 8.60 (dd, 1H, J=5.1, 1.9 Hz, Py – H4), 10.38 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 341 & 343 (M + Na) +, 319 & 321 (M + H)+, 302 (M – NH2);  
IR (KBr) υ = 3412 (NH2), 3339 (CONH), 3202, 3005 (Ar-C-H), 2841, 1664 (CO), 1633 (C=N), 
1596 (Ar-C=C), 1577, 1544, 1475 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.42.  
 
 
6.10.15. Preparation of N1-(4-bromobenzoyl)-pyridine-2-carboxamidrazone: 
Compound 5.63.  
N
NH2
N
N
H
O
Br
 
Yield 0.323 g, 1.013 mmol, 66%. 
Melting Point: 209.9 – 212.0 oC;  
H1-NMR: 6.92 (bs, 2H, NH2), 7.50 (t, 1H, J=6.3 Hz), 7.68 (d, 2H, J=8.2 Hz, Ph – H3,H5), 7.80 
– 7.93 (overlapping m, 3H, Ph – H2, H6 and Py – H4), 8.17 (d, 1H, J=8.2 Hz, Py – H3), 8.61 
(d, 1H, J=4.4 Hz, Py – H6), 10.32 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 319 & 321 (M + H)+, 302 (M – NH2), 207 (M – [NH2 + O + Br]);  
IR (KBr) υ = 3425 (NH2), 3328 (CONH), 3307, 3188, 3057 (Ar-C-H), 1659 (CO), 1636 (C=N), 
1583, 1547, 1469 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.21.  
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6.10.16. Preparation of N1-(5-[4-bromophenyl]-furan-2-oyl)-pyridine-2-
carboxamidrazone: Compound 5.66.  
N
NH2
N
N
H
O
O
Br
 
Yield 0.016 g, 0.042 mmol, 10%. 
Melting Point: 209.7 – 212.8 oC;  
H1-NMR: 6.98 (bs, 2H, NH2), 7.19 (d, 1H, J=3.2 Hz, furanyl – H4), 7.28 (d, 1H, J=3.2 Hz, 
furanyl – H3) 7.51(ddd, 1H, J=6.3, 5.7, 1.3 Hz, Py – H5), 7.67 (d, 2H, J=8.2 Hz, phenyl – 
H3,H5), 7.86 – 7.95 (overlapping m, 3H, phenyl – H2,H6 and Py – H4), 8.18 (d, 1H, J=8.2 
Hz, Py – H3), 8.62 (d, 1H, J=4.4 Hz, Py – H6), 10.27 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 407 (M + Na) +, 385 & 387 (M + H)+;  
IR (KBr) υ = 3420 (NH2), 3286 (CONH), 3172, 3044 (Ar-C-H), 2998, 1634 (CO), 1587 (Ar-C-
H), 1560, 1534, 1467 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.26.  
 
6.10.17. Preparation of N1-(5-[2-trifluoromethylphenyl]-furan-2-oyl)-pyridine-2-
carboxamidrazone: Compound 5.69.  
N
NH2
N
N
H
O
O
CF3
 
Yield 0.100 g, 0.267 mmol, 66%. 
Melting Point: 92.2 – 94.4 oC;  
H1-NMR: 6.91 (bs, 2H, NH2), 7.32 (bs, 1H, furanyl – H4), 7.48 (ddd, 1H, J=6.3, 5.1, 1.3 Hz, 
Py – H5), 7.66 (t, 1H, J=7.6 Hz, phenyl – H4), 7.79 – 7.98 (overlapping m, 5H, furanyl – H3, 
phenyl – H3,H4,H6 and Py – H4), 8.17 (d, 1H, J=7.6 Hz, Py – H3), 8.60 (d, 1H, J=4.4 Hz, Py 
– H6), 10.18 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 397 (M + Na) +, 375 (M + H)+;  
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IR (KBr) υ = 3439 (NH2), 3319 (CONH), 3134, 3067 (Ar-C-H), 1635 (CO),  1602 (C=N), 1568 
(Ar-C-H), 1546, 1476 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.22.  
 
6.11.1.   Preparation of pyridine-4-carboxamidrazone:  Compound 5.91.  
N
N
NH2
NH2
 
 
4- cyanopyridine (30.103g, 288.4mmol) was suspended in ethanol (90mL) and treated with 
hydrazine monohydrate (60mL) and stirred at ambient temperature for two days. The 
resulting precipitate was collected by filtration under vacuum and washed with petroleum 
ether (40-60oC) to give a white crystalline compound.  
 
Yield was 33.450g or 244 mmol or 75%   
1H-NMR: 5.33 (bs, 2H, NH2); 5.71 (bs,2H, NH2); 7.63 (d, 2H, J=6.3 Hz, Pyr-H5 and H3); 8.51 
(d, 2H, J=6.3 Hz, Pyr-H2 and H6) ppm. 
MS (APCI +ve) m/z = 137 (M+H)+  
TLC, carried out in ethyl acetate: methanol (2:1) (Rf) = 0.18. 
 
6.11.2.   Preparation of N1-(5-chlorothiophen-2-oyl)-pyridine-4-carboxamidrazone: 
Compound 5.59.  
N
NH2
N
N
H
S
O
Cl
 
5-Chloro-2-thiophenecarboxylic acid (0.283 g, 1.74 mmol) and CDI (0.283 g, 1.75 mmol) 
were mixed in dry THF (6mL) under argon and stirred for 20 minutes at room temperature. A 
solution of pyridine-4-carboxamidrazone (0.208 g, 1.53 mmol) in dry THF (4mL) was added 
dropwise over 5 minutes to the mixture of acid-CDI under argon and stirred for one day at 
room temperature. After 24 hours, the mixture was added dropwise over 10 minutes to 
saturated sodium bicarbonate solution (30 mL) with stirring. The solid material was collected 
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by filtration and washed with very small quantity of distilled water followed by ethyl acetate 
(10 mL). A pale yellow coloured powder was obtained which was recrystallised in hot 
methanol. The final product obtained was yellow coloured powder which was dried under 
vacuum for 24 hours. Yield 0.063 g, 0.225 mmol, 15%. 
 
Melting Point: 216.4 – 218.4 oC;  
H1-NMR: 6.91 (bs, 2H, NH2), 7,21 (d, 1H, J=3.8 Hz, thiophenyl – H4), 7.78 – 7.85 
(overlapping m, 3H, Py – H3, H5 and thiophenyl – H3), 8.71 (d, 2H, J=5.7 Hz, Py – H2, H6), 
10.42 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 303 & 305 (M + Na) +, 281 & 283 (M + H)+, 264 (M – NH2);  
IR (KBr) υ = 3419 (NH2), 3386 (CONH), 3213, 3014 (Ar-C-H), 2928, 1701 (CO), 1648 (C=N), 
1595 (Ar-C=C), 1486 cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.57.  
 
 
6.11.3.   Preparation of N1-(3-bromothiophen-2-oyl)-pyridine-4-carboxamidrazone: 
Compound 5.53.  
N
NH2
N
N
H
S
O Br
 
 
Yield 0.109 g, 0.335 mmol, 23%. 
Melting Point: 162.2 – 164.6 oC;  
H1-NMR: 6.85 (bs, 2H, NH2), 7.18 (s, 1H, thiophenyl – H4 or H5), 7.72 – 7.92 (overlapping m, 
3H, Py – H3, H5 and thiophenyl – H4 or H5), 8.64 (d, 2H, J=5,7 Hz, Py – H2, H6), 10.29 (bs, 
1H, CONH) ppm;  
MS (+ES) m/z = 325 & 327 (M + H)+;  
IR (KBr) υ = 3419 (NH2), 3373 (CONH), 3107, 3028 (Ar-C-H), 2921, 1705 (CO), 1618 (N=C), 
1595 (Ar-C=C),1539, 1493 cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.35.  
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6.11.4.   Preparation of N1-(5-bromothiophen-2-oyl)-pyridine-4-carboxamidrazone: 
Compound 5.56.  
N
NH2
N
N
H
S
O
Br
 
Yield 0.018 g, 0.055 mmol, 8%. 
Melting Point: 205.7 – 208.2 oC  
1H NMR (250 MHz d6-DMSO): 6.8 (s, 2H, NH2), 7.33 (d, 1H, J=4.4 Hz, thiophenyl – H4), 
7.8 (overlapping m, 3H, Py – H3, H5 and thiophenyl – H4 or H5), 8.7 (d, 2H, J=5,7 
Hz, Py – H2, H6), 10.5 (bs, 1H, NH) ppm;  
MS (+ES) m/z = 347 (M + Na) +, 325 & 327 (M + H)+;  
IR (KBr) υ = 3419 (NH2), 3339 (CONH), 3227, 2994(Ar-C-H), 2908, 1705 (CO), 1645 (C=N), 
1599 (Ar-C=C), 1544, 1489 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.45 (single spot).  
 
6.11.5.   Preparation of N1-(4-bromobenzoyl)-pyridine-4-carboxamidrazone: 
Compound 5.62.  
N
NH2
N
N
H
O
Br
 
 
Yield 0.181 g, 0.567 mmol, 37%. 
Melting Point: 269.2 – 270.1 oC;  
H1-NMR: 6.94 (bs, 2H, NH2), 7.67 (d, 2H, J=8.2 Hz, Ph – H3,H5), 7.78 (d, 2H, J=5.7 Hz, Py – 
H3,H5), 7.86 (d, 2H, J=8.2 Hz, Ph – H2,H6), 8.64 (d, 2H, J=6.3 Hz, Py – H2,H6), 10.25 (bs, 
1H, CONH) ppm;  
MS (+ES) m/z = 341 & 343 (M + Na) +, 319 & 321 (M + H)+;  
IR (KBr) υ = 3412 (NH2), 3359 (CONH), 3207, 3040 (Ar-C-H), 2826, 1649 (CO), 1592 (Ar-
C=C), 1536, 1479 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.27.  
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6.11.6.   Preparation of N1-(thiophen-2-oyl)-pyridine-4-carboxamidrazone: 
Compound 5.50.  
N
NH2
N
N
H
S
O
 
 
Yield 0.056 g, 0.228 mmol, 6%. 
Melting Point: 194.8 – 196.9 oC;  
H1-NMR: 6.89 (bs, 2H, NH2), 7.16 (bs, 1H, thiophenyl – H4), 7.75 – 7.87 (overlapping m, 3H, 
Py – H3,H5 and thiophenyl – H5), 8.03 (bs, 1H, thiophenyl – H3), 10.25 (bs, 1H, CONH) 
ppm;  
MS (+ES) m/z = 269 (M + Na) +, 247 (M + H)+;  
IR (KBr) υ = 3346 (NH2), 3160, 3120, 3061 (Ar-C-H), 2994, 2829, 1665 (CO), 1625 (C=N), 
1582 (Ar-C=C), 1536 cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.36.  
 
6.11.7.   Preparation of N1-(5-[4-bromophenyl]-furan-2-oyl)-pyridine-4-
carboxamidrazone: Compound 5.65.  
O
N
NH2
N
N
H
O
Br
 
 
Yield 0.093 g, 0.242 mmol, 43%. 
Melting Point: 206.3 – 208.7 oC;  
H1-NMR: 6.85 (bs, 2H, NH2), 7.15 – 7.21 (overlapping m, furanyl – H3,H4), 7.67 (d, 2H, J=8.2 
Hz, phenyl – H3,H5), 7.80 – 7.86 (overlapping m, 4H, phenyl – H2, H6 and Py – H3,H5), 8.63 
(d, 2H, J=5.7 Hz, Py – H2,H6), 10.26 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 409 (M + Na) +, 385 & 387 (M + H)+;  
IR (KBr) υ = 3372 (NH2), 3228 (CONH), 3123, 3037 (Ar-C-H), 2919, 1672 (CO), 1643 (N=H), 
1580 (Ar-C-H), 1541 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.30.  
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6.11.8.   Preparation of N1-(5-[2-trifluoromethylphenyl]-furan-2-oyl)-pyridine-4-
carboxamidrazone: Compound 5.68.  
O
N
NH2
N
N
H
O
CF3
 
 
Yield 0.025 g, 0.067 mmol, 16%. 
Melting Point: 193.4 – 194.8 oC;  
H1-NMR: 6.91 (bs, 2H, NH2), 7.31 (bs, 1H, furanyl – H4), 7.63 – 7.99 (overlapping m, 7H, 
furanyl – H3, phenyl – H3,H4,H5,H6 and Py – H3,H5), 8.64 (d, 2H, J=5.7 Hz, Py – H2,H6), 
10.18 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 397 (M + Na) +, 375 (M + H)+;  
IR (KBr) υ = 3400 (NH2), 3205 (CONH), 3071, 3024 (Ar-C-H), 1667 (CO), 1631 (C=N), 1600 
(Ar-C-H), 1567, 1544 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.30.  
6.12.1.   Preparation of pyridine-3-carboxamidrazone:  Compound 5.90.  
N N
NH2
NH2
 
3- cyanopyridine (30.103g, 288.4mmol) was suspended in ethanol (90mL) and treated with 
hydrazine monohydrate (60mL) and stirred at ambient temperature for two days. The 
resulting precipitate was collected by filtration under vacuum and washed with petroleum 
ether (40-60oC) to give a white crystalline compound.  
 
Yield was 30.214g or 222.160 mmol or 77%   
1H-NMR: 4.26 (bs, 2H, NH2); 5.73 (bs, 2H, NH2); 7.34 (m, 1H, Pyr-H5); 8.01 (dt, 1H, J= 2.0, 
3.7 Hz, Pyr-H4); 8.48 (d, 1H, J= 4.7Hz, Pyr-H6); 8.86 (d, H, J=2.1 Hz, Pyr-H2) ppm. 
MS (APCI +ve) m/z = 137 (M+H)+  
TLC, carried out in ethyl acetate: methanol (2:1) (Rf) = 0.10 (single spot). 
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6.12.2.   Preparation of N1-(3-bromothiophen-2-oyl)-pyridine-3-carboxamidrazone: 
Compound 5.55.  
 
N
NH2
N
N
H
S
O Br
 
 
3-Bromo-2-thiophenecarboxylic acid (0.345 g, 1.67 mmol) and CDI (0.278 g, 1.72 mmol) 
were mixed in dry THF (6mL) under argon and stirred for 30 minutes at room temperature. A 
solution of pyridine-3-carboxamidrazone (0.208 g, 1.53 mmol) in dry THF (4mL) was added 
dropwise over 5 minutes to the mixture of acid-CDI under argon and stirred for two days at 
room temperature. After 48 hours, the mixture was added dropwise over 10 minutes to 
saturated sodium bicarbonate solution (30 mL) with stirring. The solid material was collected 
by filtration and washed with very small quantity of distilled water followed by ethyl acetate 
(10 mL). A pale yellow coloured powder was obtained which was dried under vacuum for 24 
hours.  
 
Yield 0.099 g, 0.305 mmol, 20%. 
Melting Point: 169.2 – 171.2 oC;  
H1-NMR: 6.85 (bs, 2H, NH2), 7.03 (d, 1H, J=5.1 Hz, thiophenyl – H4 or H5), 7.34 – 7.48 
(overlapping m, 2H, Py – H4 and thiophenyl – H4 or H5), 8.14 (d, 1H, J=7.6 Hz, Py – H6), 
8.55 (d, 1H, J=3.8 Hz, Py – H5), 8.98 (bs, 1H, Py – H2), 10.24 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 347 & 349 (M + Na)+, 325 & 327 (M + H)+ 244 (M – Br)+;  
IR (KBr) υ = 3376 (NH2), 3326 (CONH), 3160, 3045 (Ar-C-H), 2949, 1688 (CO), 1648 (N=C), 
1618, 1580 (Ar-C=C),1539, 1484 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.28.  
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6.12.3.   Preparation of N1-(5-[4-bromophenyl]-furan-2-oyl)-pyridine-3-
carboxamidrazone: Compound 5.67.  
 
Br
NH2
N
N
H
O
O
N
 
 
Yield 0.220 g, 0.571 mmol, 96%. 
Melting Point: >350 oC.  
H1-NMR: 6.91 (bs, 2H, NH2), 7.17 (d, 1H, J=3.2 Hz, furanyl – H4), 7.22 (bs, 1H, furanyl – 
H3), 7.47 (q, 1H, J=7.6 Hz, Py – H4), 7.68 (d, 2H, J=8.2 Hz, phenyl – H3,H5), 7.88 (d, 2H, 
J=8.2 Hz, phenyl – H2,H6), 8.19 (d, 1H, J=7.6 Hz, Py – H6), 8.63 (d, 1H, J=5.1 Hz, Py – H5), 
9.01 (d, 1H, J=1.9 Hz, Py – H2), 10.18 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 407 (M + Na) +, 385 & 387 (M + H)+;  
IR (KBr) υ = 3381 (NH2), 3204 (CONH), 3049 (Ar-C-H), 2912, 1693 (CO), 1657 (N=H), 1606 
(Ar-C-H), 1541 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.23.  
 
6.12.4.   Preparation of N1-(5-[2-trifluoromethylphenyl]-furan-2-oyl)-pyridine-3-
carboxamidrazone: Compound 5.70.  
 
CF
NH2
N
N
H
O
O
N
3
 
 
Yield 0.160 g, 0.428 mmol, 74%. 
Melting Point:  >350 oC;  
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H1-NMR: 6.9 (bs, 2H, NH2), 7.31 (bs, 1H, furanyl – H4), 7.47 (q, 1H, J=7.6 Hz, Py – H4), 7.63 
– 7.99 (overlapping m, 5H, furanyl – H3, phenyl – H3,H4,H5,H6), 8.19 (d, 1H, J=7.6 Hz, Py – 
H6), 8.63 (d, 1H, J=5.1 Hz, Py – H5), 9.01 (d, 1H, J=1.9 Hz, Py – H2), 10.18 (bs, 1H, NH) 
ppm;  
MS (+ES) m/z = 397 (M + Na) +, 375 (M + H)+;  
IR (KBr) υ = 3385 (NH2), 3279 (CONH), 3135, 2924, 1695 (CO), 1652 (C=N), 1603 (Ar-C-H), 
1511, 1456 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.24.  
 
6.12.5.   Preparation of N1-(4-bromobenzoyl)-pyridine-3-carboxamidrazone: 
Compound 5.64.  
 
N
NH2
N
N
H
O
Br
 
 
 
Yield 0.387 g, 1.21 mmol, 76%. 
Melting Point: 198.9 – 201.2 oC;  
H1-NMR: 6.88 (bs, 2H, NH2), 7.47 (q, 1H, J=8.2 Hz, Py – H4), 7.66 (d, 2H, J=8.2 Hz, Ph – 
H3,H5), 7.86 (d, 2H, J=8.2 Hz, Ph – H2,H6), 8.18 (d, 1H, J=7.6 Hz, Py – H6), 8.63 (d, 1H, 
J=5.1 Hz, Py – H5), 9.01 (d, 1H, J=1.9 Hz, Py – H2), 10.24 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 341 & 343 (M + Na) +, 319 & 321 (M + H)+, 302 (M – NH2);  
IR (KBr) υ = 3381 (NH2), 3325 (CONH), 3141, 3040 (Ar-C-H), 2990, 1689 (CO), 1659 (C=N), 
1606 (Ar-C=C), 1544, 1479 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.19.  
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6.12.6.   Preparation of N1-(thiophen-2-oyl)-pyridine-3-carboxamidrazone: 
Compound 5.52.   
N
NH2
N
N
H
S
O
 
 
Yield 0.070 g, 0.285 mmol, 19%. 
Melting Point: 191.5– 194.0oC;  
H1-NMR: 6.85 (bs, 2H, NH2), 7.17 (t, 1H, J=5.1 Hz, thiophenyl – H4), 7.50 (q, 1H, J=7.6 Hz, 
Py – H4), 7.88 (d, 1H, J=3.8 Hz, thiophenyl – H5), 8.01 (d, 1H, J=2.5 Hz, thiophenyl – H3), 
8.20 (d, 1H, J=8.2 Hz, Py – H6), 8.64 (dd, 1H, J=5.1, 4.4 Hz, Py – H5), 9.05 (bs, 1H, Py – 
H2), 10.24 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 269 (M + Na) +, 247 (M + H)+;  
IR (KBr) υ = 3439 (NH2), 3379 (CONH), 3153, 3001 (Ar-C-H), 2822, 1685 (CO), 1652 (C=N), 
1546 (Ar-C=C) cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.27.  
 
6.12.7.   Preparation of N1-(5-bromothiophen-2-oyl)-pyridine-3-carboxamidrazone: 
Compound 5.58.  
N
NH2
N
N
H
S
O
Br
 
 
Yield 0.149 g, 0.458 mmol, 42%. 
Melting Point: 190.7 – 193.4 oC;  
H1-NMR: 6.91 (bs, 2H, NH2), 7.30 (d, 1H, J=4.4 Hz, thiophenyl – H4), 7.48 (q, 1H, J=8.2 Hz, 
Py – H4), 7.78 (d, 1H, J=4.4 Hz, thiophenyl – H3), 8.18 (d, 1H, J=8.2 Hz, Py – H6), 8.66 (dd, 
1H, J=5.1, 4.4 Hz, Py – H5), 9.04 (d, 1H, J=1.9 Hz, Py – H2), 10.45 (bs, 1H, CONH) ppm;  
MS (+ES) m/z = 347 & 349 (M + Na) +, 325 & 327 (M + H)+;  
IR (KBr) υ = 3418 (NH2), 3373 (CONH), 3215, 3031(Ar-C-H), 2926, 1705 (CO), 1636 (C=N), 
1521 (Ar-C=C), 1544, 1478 cm-1. 
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.38  
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6.12.8.   Preparation of N1-(5-chlorothiophen-2-oyl)-pyridine-3-carboxamidrazone: 
Compound 5.61.  
N
NH2
N
N
H
S
O
Cl
 
 
Yield 0.094 g, 0.335 mmol, 22%. 
Melting Point: 190.9 – 193.7 oC;  
H1-NMR: 6.92 (bs, 2H, NH2), 7.21 (d, 1H, J=4.4 Hz, thiophenyl – H4), 7.53 (q, 1H, J=8.2 Hz, 
Py – H4), 7.84 (d, 1H, J=4.4 Hz, thiophenyl – H3), 8.18 (d, 1H, J=7.6 Hz, Py – H6), 8.66 (dd, 
1H, J=5.1, 4.4 Hz, Py – H5), 9.04 (d, 1H, J=1.9 Hz, Py – H2), 10.44 (bs, 1H, CONH) ppm  
MS (+ES) m/z = 303 (M + Na) +, 281 & 283 (M + H)+, 264 (M – NH2);  
IR (KBr) υ = 3421 (NH2), 3386 (CONH), 3227, 2994 (Ar-C-H), 2848, 1691 (CO), 1658 (C=N), 
1625 (Ar-C=C), 1546 cm-1.  
TLC: ethyl acetate: methanol (4:1) (Rf) = 0.45 (single spot).  
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APPENDIX I 
 
 
 
 
 
 
      The grey regions illustrate the steps involved in the development of the targeted protein 
model which was used in the screening of the ligands with possible biological activity.  
 
*  Indicates the particular step which produces the target model.  
 
      The dark regions indicate the additional steps acquired during the model generation 
steps, however were not required to prepare the targeted protein model.   
 
 
Protein X-ray crystal structure (2FP2.pdb) 
(downloaded from the protein data bank)
Remove water molecules, add missing residues and docking study with the 
biologically known active ligands (Table 2.4)
TSA - protein complex 
Phase I (See Chapter 2 Scheme 2.2)
MD study at 1120ps 
* produces the protein model
Docking study with the ligands from table 2.4
Phase II 
study (see 
Chapter 2 
Scheme 2.3)
Phase III 
study (see 
Chapter 2 
scheme 2.4)
Model
Hypothesis
Design and 
screening of 
ligands with 
possible 
biological 
activity
Further 
MD 
study up 
to 12330 
ps
Ligand 1 -
protein 
complex
MD study 
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Docking 
study with 
ligands 
from table 
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Appendix 
II section 
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complex
MD study 
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Docking 
study with 
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from table 
2.4
Appendix 
II section 
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complex
MD study 
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Docking 
study with 
ligands 
from table 
2.4
Appendix 
II section 
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APPENDIX II 
 
1. Table below showing the docking score when the ligands were docked into the 
active site of the protein 2FP2.pdb without performing any MD study 
Ligand 
Docking Score 
Kcal/mol 
Docking Score 
Kcal/mol 
Docking Score 
Kcal/mol 
Avearege Score 
Kcal/mol 
  
   
Ligand 1 
-325.467 -335.467 -312.45 -324.46 
Ligand 2 
-310.43 -330.23 -315.56 -318.74 
Ligand 4 
-294.397 -285.72 -245.55 -275.22 
TSA 
-410.74 -403.74 -412.87 -409.12 
 
 
2. Table below showing the docking score obtained following the MD study over 220ps on 
the docked Ligand1-protein complex obtained from the Scheme 2.2.   
Ligand Score 1 Kcal/mol Score 2 Kcal/mol Score 3 Kcal/mol 
Average docking 
score Kcal/mol 
     Ligand 1 -575.24 -543.27 -575.13 -564.55 
Ligand 2 -246.06 -243.22 -249.37 -246.22 
Ligand 4 -400.30 -236.18 -385.72 -340.73 
Ligand 7 -245.88 -324.68 -241.90 -270.82 
Ligand 8 -592.50 -351.24 -527.20 -490.31 
Ligand 9 -667.56 -635.33 -601.40 -634.76 
Ligand 13 -613.879 -596.421 -639.341 -616.55 
TSA -402.26 -408.49 -406.30 -405.68 
 
 
3. Table below showing the docking score obtained following the MD study over 1120ps on 
the docked Ligand1-protein complex obtained from the Scheme 2.2.   
Ligand 
Docking Score 1 
Kcal/mol 
Docking score 2 
Kcal/mol 
Docking score 3 
Kcal/mol 
Average docking score 
Kcal/mol 
     Ligand 1 -481.15 -496.2 -478.36 -485.24 
Ligand 2 -421.58 -430.79 -421.33 -424.57 
Ligand 4 -340.82 -346.65 -337.82 -341.76 
Ligand 7 -406.17 -407.62 -396.33 -403.37 
Ligand 8 -556.78 -372.47 -477.36 -468.87 
Ligand 9 -646.44 -639.15 -639.25 -641.61 
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4. Table below showing the docking score obtained following the MD study over 1120ps on 
the docked Ligand2-protein complex obtained from the Scheme 2.2.   
Ligand 
Docking Score 1 
Kcal/mol 
Docking score 2 
Kcal/mol 
Docking score 3 
Kcal/mol 
Average docking score 
Kcal/mol 
     Ligand 1 
-326.39 -336.138 -332.26 -331.60 
Ligand 2 
-308.46 -358.504 -413.162 -360.04 
Ligand 4 
-245.1 -241.064 -239.304 -241.82 
Ligand 7 
-265.427 -269.406 -249.752 -261.53 
Ligand 8 
-478.15 -313.195 -305.804 -365.72 
Ligand 9 
-437.063 -302.06 -277.112 -338.75 
Ligand 13 
-411.596 -452.935 -372.057 -412.20 
TSA 
-306.45 -310.49 -303.30 -306.75 
 
 
 
5. Table below showing the docking score obtained following the MD study over 1120ps on 
the docked Ligand4-protein complex obtained from the Scheme 2.2.   
Ligand 
Docking Score 1 
Kcal/mol 
Docking score 2 
Kcal/mol 
Docking score 3 
Kcal/mol 
Average docking score 
Kcal/mol 
     Ligand 1 
-355.43 -346.18 -332.26 -344.62 
Ligand 2 
-320.61 -338.41 -413.162 -357.39 
Ligand 4 
-305.16 -252.04 -279.34 -278.85 
Ligand 7 
-365.47 -269.406 -249.752 -294.88 
Ligand 8 
-518.15 -513.152 -505.41 -512.24 
Ligand 9 
-491.03 -392.07 -485.28 -456.13 
Ligand 13 
-434.26 -462.935 -392.67 -429.96 
TSA 
-341.45 -270.19 -289.53 -300.39 
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